[go: up one dir, main page]

WO2010014257A2 - Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof - Google Patents

Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof Download PDF

Info

Publication number
WO2010014257A2
WO2010014257A2 PCT/US2009/004437 US2009004437W WO2010014257A2 WO 2010014257 A2 WO2010014257 A2 WO 2010014257A2 US 2009004437 W US2009004437 W US 2009004437W WO 2010014257 A2 WO2010014257 A2 WO 2010014257A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
group
hydroxy
carboxylic acid
Prior art date
Application number
PCT/US2009/004437
Other languages
French (fr)
Other versions
WO2010014257A3 (en
Inventor
Hidenori Mikamiyama
Chiyou Ni
Bin Shao
Laykea Tafesse
Original Assignee
Purdue Pharma L.P.
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma L.P., Shionogi & Co., Ltd. filed Critical Purdue Pharma L.P.
Priority to JP2011521130A priority Critical patent/JP5421368B2/en
Priority to US13/056,839 priority patent/US8324249B2/en
Priority to EP09802045.6A priority patent/EP2331522B1/en
Priority to ES09802045.6T priority patent/ES2439767T3/en
Publication of WO2010014257A2 publication Critical patent/WO2010014257A2/en
Publication of WO2010014257A3 publication Critical patent/WO2010014257A3/en
Priority to US13/675,166 priority patent/US20130150377A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Definitions

  • This invention is in the field of medicinal chemistry.
  • the invention relates to novel tetrahydropyridinyl and dihydropyrrolyl compounds and the use of these compounds as blockers of calcium (Ca 2+ ) channels.
  • VGCC Voltage-gated calcium channels
  • Voltage-gated calcium channels are also known as voltage-dependent calcium channels (VDCC) or voltage-sensitive calcium channels (VSCC).
  • Voltage-sensitive calcium channels regulate intracellular calcium concentration, which affects various important neuronal functions such as cellular excitability, neurotransmitter release, hormone secretion, intracellular metabolism, neurosecretory activity and gene expression (Hu et ah, Bioorganic & Medicinal Chemistry 5:1203-1212 (2000)).
  • N-type channels are found mainly in central and peripheral neurons, being primarily located on presynaptic nerve terminals. These channels regulate the calcium flux required for depolarization-evoked release of a transmitter from synaptic endings.
  • the transmission of pain signals from the periphery to the central nervous system (CNS) is mediated by N-type calcium channels located in the spinal cord (Song et al, J. Med. Chem. 43:341 '4-3477 (2000)).
  • N-type calcium channel blockers have usefulness for neuroprotection and analgesia.
  • Ziconotide which is a selective N-type calcium channel blocker, has been found to have analgesic activity in animal models and neuroprotective activity in focal and global ischemia models (Song et al., supra).
  • Examples of known calcium channel blockers include fiunarizine, fluspirilene, cilnipide, PD 157767, SB-201823, SB- 206284, NNC09-0026, and PD 151307 (Hu et al., supra).
  • N-type voltage-gated calcium channels play a major role in the release of synaptic mediators such as glutamate, acetylcholine, dopamine, norepinephrine, gamma- aminobutyric acid (GABA) and calcitonin gene-related peptide (CGRP).
  • the present invention is related to the use of tetrahydropyridinyl and dihydropyrrolyl compounds represented by Formula I, below, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, as blockers of calcium (Ca 2+ ) channels.
  • Compounds of Formula I show selectivity as N-type calcium channel blockers.
  • the invention is also related to treating a disorder responsive to the blockade of calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, as described herein.
  • the invention is related to treating a disorder responsive to the blockade of N-type calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, as described herein.
  • one aspect of the present invention is directed to novel compounds of Formula I, as well as their pharmaceutically acceptable salts, prodrugs and solvates.
  • Another aspect of the present invention is directed to the use of the novel compounds of Formula I, and their pharmaceutically acceptable salts, prodrugs and solvates, as blockers of N-type calcium channels.
  • a further aspect of the present invention is to provide a method for treating pain
  • the present invention provides a method for preemptive or palliative treatment of pain by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a mammal in need of such treatment.
  • a further aspect of the present invention is to provide a method for treating stroke, neuronal damage resulting from head trauma, epilepsy, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, by administering an effective amount of - A -
  • a further aspect of the present invention is to provide a pharmaceutical composition useful for treating a disorder responsive to the blockade of calcium ion channels, especially N-type calcium ion channels, said pharmaceutical composition containing an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in a mixture with one or more pharmaceutically acceptable carriers.
  • an aspect of the invention is to provide a method of modulating calcium channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • a further aspect of the present invention is to provide radiolabeled compounds of Formula I and the use of such compounds, or their pharmaceutically acceptable salts, prodrugs or solvates, as radioligands for their binding site on the calcium channel.
  • a further aspect of the invention is to provide a method for screening a candidate compound for the ability to bind to a binding site on a protein using a radiolabeled compound of Formula I, which includes but is not limited to, a 3 H, 11 C, and 14 C radiolabeled compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • This method comprises a) introducing a fixed concentration of the radiolabeled compound to a soluble or membrane-associated protein or fragment thereof to form a mixture; b) titrating the mixture with a candidate compound; and c) determining the binding of the candidate compound to said binding site.
  • a further aspect of the invention is to provide the use of a compound of
  • Formula I or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating pain in a mammal.
  • the invention provides the use of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for palliative or premptive treatment of pain, such as acute pain, chronic pain, or surgical pain.
  • a further aspect of the invention is to provide the use of a compound of
  • Formula I or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating stroke, neuronal damage resulting from head trauma, epilepsy, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia in a mammal.
  • One aspect of the present invention is based on the use of compounds of
  • Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof as blockers of Ca 2+ channels.
  • compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof are useful for treating disorders responsive to the blockade of calcium ion channels.
  • compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof selectively block N-type calcium ion channels and, thus, are useful for treating disorders responsive to the selective blockade of N-type calcium ion channels.
  • Hy is a 6-membered heteroaromatic ring, a 5-membered heteroaromatic ring, or a 5-membered heterocyclic ring, wherein said Hy has at least one nitrogen atom, and wherein said Hy is attached to the tetrahydropyridinyl or dihydropyrrolyl ring by a carbon atom;
  • W is O or NR 14 , wherein
  • R 14 is hydrogen or alkyl
  • R 3 , R 4 , and R 7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and
  • R 5 and R 6 are hydrogen or alkyl
  • R 2 is selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, nitro, cyano, amino, alkylamino, and dialkylamino;
  • m is 0, 1, 2, or 3;
  • n is O or l
  • R 8 and R 9 are both hydrogen or together form a bridge -(CH 2 ) P -, wherein
  • p is 2, 3, or 4;
  • Z is Z 1 or Z 2 , wherein
  • Z 1 is -SO 2 - R 10 , wherein
  • R 10 is selected from the group consisting of C 3-I2 alkyl, halo(C 3- i 2 )alkyl, C 5-I2 cycloalkyl, (C 3-J2 cycloalkyl)alkyl, C 5-I2 cycloalkenyl, (C 3-12 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and
  • Z 2 is -C(R 1 'R 12 )R 13 , wherein
  • R 11 and R 12 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and
  • R 13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
  • the carbon of Z 2 attached to the tetrahydropyridinyl and dihydropyrrolyl ring can be a chiral center. Accordingly, the configuration at those carbon atoms can be (R) or (S).
  • One group of compounds useful in this aspect of the present invention includes compounds of Formula I as defined above, with the following provisos when X is
  • -CHR 8 - and R 8 is hydrogen: [0044] 1) when R 1 l and R 12 are both hydrogen and R 13 is aryl or arylalkyl, then the aryl portion of R 13 is substituted with at least one of haloalkyl or haloalkoxy; or [0045] 2) when Hy is a pyridin-2-yl ring, then R 1 is other than optionally substituted 2-aminophenylaminocarbonyl or 2-hydroxyphenylaminocarbonyl.
  • compounds useful in the present invention are compounds of Formula I, where n is 1 (tetrahydropyridinyl).
  • compounds useful in the present invention are compounds of Formula I, where n is 0 (dihydropyrrolyl).
  • tetrahydopyridinyl compounds useful in the present invention are compounds of Formula I, where n is 1 , X is -CHR -, and R and R are both hydrogen, having the Formula II:
  • tetrahydropyridinyl compounds useful in the present invention are compounds of Formula I, where n is 1, X is -CHR 8 -, and R 8 and R 9 together form a bridge -(CH 2 ) P -, having the Formula III: and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R 1 , R 2 , Z, m and p are as defined above.
  • compounds useful in the present invention are compounds of Formula III, where p is 2, having the Formula IV:
  • compounds useful in the present invention are compounds of Formula III, where p is 3.
  • compounds useful in the present invention are compounds of Formula III, where p is 4.
  • dihydropyrrolyl compounds useful in the present invention are compounds of Formula I, where n is 0, X is -CHR 8 -, and R 8 and R 9 are both hydrogen, having the Formula VI:
  • dihydropyrrolyl compounds useful in the present invention are compounds of Formula I, where n is 0, X is -CHR 8 -, and R 8 and R 9 together form a bridge -(CH 2 ) P -, having the Formula VII: and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R 1 , R 2 , Z, m and p are as defined above.
  • compounds useful in the present invention are compounds of Formula VII, where p is 2, having the Formula VIII:
  • compounds useful in the present invention are compounds of Formula VII, where p is 3.
  • compounds useful in the present invention are compounds of Formula VII, where p is 4.
  • compounds useful in the present invention are compounds of any of Formulae I-IX, where Hy is a 6-membered heteroaromatic ring having at least one nitrogen atom.
  • compounds useful in the present invention are compounds of any of Formulae I-IX, where Hy is a 5-membered heteroaromatic ring or a 5-membered heterocyclic ring having at least one nitrogen atom.
  • Useful compounds include those where Hy is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, and 1,2,4-oxadiazolyl.
  • Hy is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, imidazol-2- yl, imidazol-4-yl, and oxazol-2-yl. More preferably, Hy is pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, or oxazol-2-yl.
  • the group R 1 takes the place of a hydrogen atom that would otherwise be present in any carbon atom in the Hy ring to which R 1 group is attached.
  • R 1 is attached to a carbon atom adjacent to a nitrogen atom in the Hy ring.
  • the group R 2 takes the place of a hydrogen atom that would otherwise be present in any carbon atom in the Hy ring to which R 2 group is attached.
  • R 1 and R 2 can be attached to the same or different carbon atoms in the Hy ring.
  • compounds useful in the present invention are compounds of any of Formulae I-IX, wherein R 1 is attached to a carbon atom adjacent to a nitrogen atom of the Hy ring.
  • compounds useful in this aspect of the invention include tetrahydropyridinyl compounds having the Formula X:
  • Q 1 , Q 2 , and Q 3 are each CH;
  • X, Z, R 1 , R 2 , R 9 and m are as defined above for Formula I.
  • useful compounds of Formula X include those where one of Q 1 , Q 2 , or Q 3 is N and the remaining two are CH. In another embodiment, useful compounds of Formula X include those where Q 1 , Q 2 , or Q 3 are each CH, having the
  • compounds useful in the present invention, where R 1 is attached to a carbon atom adjacent to a nitrogen atom of the Hy ring are compounds of Formula XII:
  • compounds useful in the present invention are compounds of any one of Formulae X-XII, where X is -CHR 8 - and R 8 and R 9 both are hydrogen.
  • compounds useful in the present invention are compounds of any one of Formulae X-XII, where X is -CHR 8 - and R 8 and R 9 together form a bridge -(CH 2 ) P - and p is 2, 3, or 4.
  • p is 2.
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein W is O and R 3 and R 4 are as defined above for Formula I.
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein W is NR 14 and R 3 , R 4 , and R 14 are as defined above for Formula I.
  • R 14 is hydrogen or Ci -4 alkyl.
  • Useful compounds include those where R 14 is hydrogen.
  • Useful compounds include those where R 4 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and wherein R 4 is preferably selected from the group consisting of Ci
  • R 4 is selected from the group consisting of Ci -6 alkyl, C 2-6 alkenyl, halo(Ci- 6 )alkyl, monohydroxy(C]. 6 )alkyl, dihydroxy(Ci -6 )alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(Cj- 4 )alkyl, C 3-7 cycloalkenyl, C 3-7 cycloalkenyl(Ci- 4 )alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci.
  • Ci -6 alkyl Ci -6 alkoxy, halogen, hydroxy, hydroxy(Ci- 6 )alkyl, cyano, amino, amino(Ci- 6 )alkyl, Ci -6 alkylamino, di(Ci- 6 )alkylamino, and hydroxy(Ci -6 )alkylamino.
  • R 4 is selected from the group consisting of methyl; ethyl; propyl; isopropyl; butyl; tert-butyl; trifluoromethyl; 2,2,2-trifluoroethyl; 3,3,3-trifluoropropyl; 4,4,4-trifluorobutyl; hydroxymethyl; 2- hydroxyethyl; 3-hydroxypropyl; l,3-dihydroxyprop-2-yl; cyclopropyl; cyclopentyl; cyclohexyl; cyclopropylmethyl; phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of Ci -6 alkyl, Ci -6 alkoxy, halogen, halo(C] -6 )alkyl, halo(Cj -6 )alkoxy, hydroxy, hydroxy(Ci -6 )alkyl, cyano, amino, amino(Ci -6 )alkyl, Ci -6
  • Useful compounds include those where R 6 is hydrogen or Ci -6 alkyl, preferably hydrogen or Ci -4 alkyl, and more preferably hydrogen, and R 7 is as defined above for Formula I.
  • Useful compounds include those where R 7 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; preferably selected from the group consisting of Ci -6 alkyl, C 2-6 al
  • R 7 is selected from the group consisting of Ci -6 alkyl, C 2-6 alkenyl, halo(Ci -6 )alkyl, monohydroxy(Ci -6 )alkyl, dihydroxy(Ci -6 )alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(Ci- 4 )alkyl, C 3-7 cycloalkenyl, C 3-7 cycloalkenyl(Ci -4 )alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Cj -6 alkyl, Ci -6 alkoxy, halogen, halo(Ci -6 )alkyl, halo(Ci -6 )alkoxy, hydroxy, hydroxy(Ci -6 )alkyl, cyano, amino
  • R 7 is selected from the group consisting of methyl; ethyl; propyl; isopropyl; butyl; tert-butyl; trifluoromethyl; 2,2,2-trifluoroethyl; 3,3,3-trifluoropropyl; 4,4,4-trifluorobutyl; hydroxymethyl; 2- hydroxyethyl; 3-hydroxypropyl; l,3-dihydroxyprop-2-yl; cyclopropyl; cyclopentyl; cyclohexyl; cyclopropylmethyl; phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of Ci -6 alkyl, Ci -6 alkoxy, halogen, halo(Ci -6 )alkyl, halo(Ci -6 )alkoxy, hydroxy, hydroxy(C 1-6 )alkyl, cyano, amino, amino(C 1-6 )alkyl, Ci -6 alkyl,
  • compounds useful in the present invention are compounds of any of Formulae I-XII where R 1 is cyano.
  • compounds useful in the present invention are compounds of any of Formulae I-XII where R 1 is hydroxyalkyl.
  • Useful compounds include those where R 1 is monohydroxy(Ci- 6 )alkyl or dihydroxy(Ci -6 )alkyl, such as hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, and l,3-dihydroxyprop-2-yl.
  • compounds useful in the present invention are compounds of any of Formulae I-XII where R 1 is a 5-membered, N-containing heteroaryl or a 5- membered, partially unsaturated, N-containing heterocyclo each of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino.
  • Useful compounds are compounds of any of Formulae I-XII where R 1 is selected from the group consisting of oxazolyl; 1,2,4-oxadiazolyl; 1,3,4-oxadiazolyl, and thiazolyl, any of which is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; preferably independently selected from the group consisting Of Ci -6 alkyl, Ci -6 alkoxy, halogen, halo(Ci -6 )alkyl, halo(Ci -6 )alkoxy, hydroxy, hydroxy(C 1-6 )alkyl, cyano, amino, amino(Ci -6 )alkyl, Ci -6 alkylamino, and di(Ci -6 )alkyla
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R 1 is selected from the group consisting of
  • R 101 is selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; preferably selected from the group consisting of Ci -6 alkyl, Ci -6 alkoxy, halogen, halo(Ci -6 )alkyl, hydroxy, hydroxy(Ci.
  • compounds useful in the present invention are compounds of any of Formulae I-XII where m is 0, 1 , or 2, and preferably m is 0 or 1.
  • Useful compounds include those where R 2 is selected from the group consisting of C M alkyl, halo(C 1-4 )alkyl, halogen, hydroxy(Ci- 4 )alkyl, hydroxy, Ci -4 alkoxy, Ci -4 alkoxy(C]. 4)alkyl, halo(Ci ⁇ alkoxy, halo(Ci -4 )alkoxy(Ci -4 )alkyl, nitro, cyano, amino, Ci -4 alkylamino, and di(Ci-4)alkylamino.
  • R 2 is selected from the group consisting of Ci -4 alkyl, halo(Ci -4 )alkyl, halogen, hydroxy(Ci -4 )alkyl, hydroxy, Ci -4 alkoxy, halo(Ci -4 )alkoxy, halo(Ci -4 )alkoxy(Ci -4 )alkyl, nitro, cyano, and amino; preferably selected from the group consisting of Ci -4 alkyl, monohalo(Ci -4 )alkyl, trihalo(C M )alkyl, halogen, monohydroxy(Ci -4 )alkyl, dihydroxy(C i- ⁇ alkyl, hydroxy, C 1- 4 alkoxy, trihalo(Ci -4 )alkoxy, trihalo(Ci -4 )alkoxy(Ci -4 )alkyl, nitro, cyano, and amino; and more preferably selected from the group consisting of methyl, ethyl
  • compounds useful in the present invention are compounds of any of Formulae I-XII where Z is Z 1 , that is -SO 2 -R 10 .
  • Useful compounds include those where R 10 is selected from the group consisting Of C 4-8 alkyl, halo(C 3-6 )alkyl, C 5- i 2 cycloalkyl, (C 3-I2 cycloalkyl)alkyl, C 5-I2 cycloalkenyl, (C 3-I2 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen,
  • R 10 is selected from the group consisting of C 4-6 alkyl, monohalo(C 3-6 )alkyl, dihalo(C 3-6 )alkyl, trihalo(C 3-6 )alkyl, C 5-8 cycloalkyl, C 3-8 cycloalkyl(Ci -2 )alkyl, C 5-8 cycloalkenyl, C 3-8 cycloalkenyl(Ci -2 )alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered heterocyclo(Ci -2 )alkyl, C 6-I4 aryl, C 6- 14 aryl(Ci -2 )alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(Ci.
  • Useful compounds include those where R 10 is selected from the group consisting of C 4-6 alkyl; trifluoro(C 3-6 )alkyl; C 5-8 cycloalkyl; C 3-8 cycloalkyl(C 1-2 )alkyl; C 5-8 cycloalkenyl; C 3-8 cycloalkenyl(Ci -2 )alkyl; heterocyclo selected from the group consisting of pyrrolidinyl, piperidinyl, hexahydropyrimidinyl, oxazolidinyl, and tetrahydrothienyl; heterocyclo(C 1-2 )alkyl selected from the group consisting of pyrrolidinyl(C i -2 )alkyl, piperidinyl(C i -2 )alkyl, hexahydropyrimidinyl(C i -2 )alkyl, oxazolidinyl(C 1-2 )alkyl,
  • heteroaryl selected from the group consisting of pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, and thienyl
  • heteroaryl(C 1-2 )alkyl selected from the group consisting of pyrrolyl(Ci -2 )alkyl, pyridyl(C 1-2 )alkyl, pyrimidyl(C 1-2 )alkyl, isoxazolyl(C 1-2 )alkyl, OXaZoIyI(C 1 -2 )alkyl, and thienyl(C 1-2 )alkyl
  • the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of C 1-4 alkyl, Ci -4 alkoxy, halogen, halo(Ci- 4
  • R 10 is selected from the group consisting of
  • benzyl unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Q -4 alkyl, Ci -4 alkoxy, halogen, halo(Ci- 4 )alkyl, halo(Ci ⁇ )alkoxy, hydroxy, hydroxy ⁇ i ⁇ alkyl, cyano, amino, amino(Ci- 4 )alkyl, C 1-4 alkylamino, and hydroxy(C 1-4 )alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(C 1-4 )alkyl, halo(C 1-4 )alkoxy, and cyano;
  • phenyl ethyl unsubstituted or substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halogen, halo(C 1-4 )alkyl, halo(Ci -4 )alkoxy, hydroxy, hydroxy(C 1-4 )alkyl, cyano, amino, amino(C 1-4 )alkyl, C 1-4 alkylamino, di(C 1-4 )alkylamino, and hydroxy(Ci -4 )alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(C 1-4 )alkyl, halo(Ci ⁇ alkoxy, and cyano;
  • thiophen-2-yl or thiophen-3-yl unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Cj. 4)alkyl, halo(C 1-4 )alkoxy, and cyano;
  • R 10 is a substituted phenyl, benzyl, or phenylethyl, preferably phenyl, and the substituent is at the 2-position of the phenyl portion.
  • the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
  • R 10 is a substituted phenyl, benzyl, or phenylethyl, preferably phenyl, and the substituent is at the 3-position of the phenyl portion.
  • the substituent is halogen, trifluoromethyl, trifluoromethoxy, cyano.
  • R 10 is a substituted phenyl, benzyl, or phenyl ethyl, preferably phenyl, and the substituent is at the 4-position of the phenyl portion.
  • the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
  • R 10 is a substituted phenyl, benzyl, or phenylethyl
  • the substituent is at the 3-position of the phenyl portion.
  • compounds useful in the present invention are compounds of any of Formulae I-XII where Z is Z 2 , that is, -C(R ⁇ R 12 )R 13 .
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R 11 and R 12 are both hydrogen and R 13 is as defined above for Formula I.
  • R 11 and R 12 are both hydrogen and R 13 is as defined above for Formula I.
  • R 13 is aryl or arylalkyl
  • the aryl portion thereof is substituted by at least one of haloalkyl or haloalkoxy, and especially trifluoromethyl or trifluoromethoxy.
  • R 1 is not cyano or a 5-membered, N-containing heteroaryl.
  • R 13 is an aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein the aryl portion is not fluorenyl and consists of a monocyclic or bicyclic ring structure that is optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R 11 is hydrogen, R 12 is selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R 13 is as defined above for Formula I.
  • compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R 11 and R 12 are each independently selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R 13 is as defined above for Formula I.
  • Useful compounds include those where R 11 and R 12 , when other than hydrogen, are each independently selected from the group consisting of C M alkyl, halo(C 1-4 )alkyl, hydroxy(C 1-4 )alkyl, halogen, hydroxy, C 1-4 alkoxy, C 1-4 alkoxy(Ci- 4 )alkyl, halo(Ci.
  • Useful compounds include those where R 13 is selected from the group consisting of C 6- io aryl, C 6-I0 aryl(Ci -2 )alkyl, 5- or 6-membered heteroaryl, and 5- or 6- membered heteroaryl(Ci -2 )alkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and preferably optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci -4 alkyl, Ci -4 alkoxy, halogen, halo(Ci -4 )alkyl, halo(Ci -4 )alkoxy, hydroxy, hydroxy(C
  • R 13 is selected from the group consisting of
  • thiophen-2-yl or thiophen-3-yl unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci- 4)alkyl, halo(C i ⁇ alkoxy, and cyano;
  • oxazol-2-yl, oxazol-4-yl, or oxazol-5-yl unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci -4 )alkyl, halo(Ci ⁇ alkoxy, and cyano; and
  • R 13 is a substituted phenyl, benzyl, or phenyl ethyl, preferably phenyl, and the substituent is at the 4-position of the phenyl portion.
  • the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
  • compounds useful in the present invention are compounds of Formula XI or XII, wherein Z is Z 1 , and X, R 1 , R 2 , R 9 , m, and R 10 are as defined for Formula I.
  • R 10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci -4 alkyl, Ci -4 alkoxy, halogen, halo(Ci- 4 )alkyl, halo(Ci- 4 )alkoxy, hydroxy, hydroxy(Ci -4 )alkyl, cyano, amino, amino(Ci- 4 )alkyl, Ci -4 alkylamino, di(Ci- 4 )alkylamino, and hydroxy(Ci- 4)alkylamino; and preferably substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci -4 )alkyl, halo(Ci ⁇ alkoxy, and cyano; more preferably substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, trifluoromethoxy, and cyano
  • Useful compounds include those where m is 0 or 1, and R 2 is selected from the group consisting of chloro, fluoro and bromo.
  • compounds useful in the present invention are compounds of Formula XI or XII, wherein
  • W is O
  • R 3 is hydrogen
  • R 4 is Ci -6 alkyl, C 2-6 alkenyl, halo(C ]-6 )alkyl, monohydroxy(Ci -6 )alkyl, dihydroxy(Ci -6 )alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(Ci -4 )alkyl, C 3-7 cycloalkenyl, C 3-7 cycloalkenyl(Ci- 4 )alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
  • R 2 is fluoro, chloro or bromo
  • m is O or l
  • X is -CHR 8 -;
  • R 8 and R 9 are both hydrogen or together form a bridge -(CH 2 ) P -, wherein
  • p is 2, 3, or 4;
  • Z is Z 1 ; and R 10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci -4 alkyl, C 1-4 alkoxy, halogen, hydroxy, hydroxy(Ci- 4 )alkyl, cyano, amino, amino(Ci -4 )alkyl, C 1-4 alkylamino, di(Ci . ⁇ alkylamino, and hydroxy(Ci -4 )alkylamino.
  • R and R are both hydrogen.
  • R and R together form a bridge -(CH 2 ) P -.
  • compounds useful in the present invention are compounds of Formula XI or XII, wherein
  • W is O
  • R 3 is hydrogen
  • R 4 is Ci -6 alkyl, C 2-6 alkenyl, halo(C )-6 )alkyl, monohydroxy(Ci -6 )alkyl, dihydroxy(Ci -6 )alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(Ci- 4 )alkyl, C 3-7 cycloalkenyl, C 3-7 cycloalkenyl(Ci -4 )alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
  • R 2 is fluoro, chloro or bromo
  • m is O or l
  • R 9 is hydrogen
  • Z is Z 1 ; and R 10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci -4 alkyl, Ci -4 alkoxy, halogen, halo(Ci -4 )alkyl, halo(Ci- 4 )alkoxy, hydroxy, hydroxy(Ci_ 4 )alkyl, cyano, amino,
  • Optional substituents attached to aryl, phenyl, and heteroaryl rings each take the place of a hydrogen atom that would otherwise be present in any position on the aryl, phenyl or heteroaryl rings.
  • Exemplary preferred compounds useful in the present invention include: 1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ⁇ 2 ⁇ 3 ⁇ 6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2 l ,3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-chlorobenzenesulfonyl)-r,2',3 l ,6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; l'-(2-trifluoromethylbenzenesulfonyl)-r,2 t ,3 l ,6 l -te
  • Useful cycloalkyl groups are selected from C 3-I2 cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Useful cycloalkenyl groups are selected from C 3-12 cycloalkenyl.
  • Typical cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.
  • Useful alkyl groups are selected from straight-chained and branched Ci -10 alkyl groups, more preferably straight chain C ⁇ ⁇ alkyl groups and branched chain C 3- $ alkyl groups, and more preferably straight chain Ci -4 alkyl groups and branched chain C 3-4 alkyl groups.
  • Typical C MO alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, wo-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl and decyl, among others.
  • Useful alkenyl groups are selected from C 2-6 alkenyl groups, preferably C 2 ⁇ alkenyl.
  • Typical C 2-6 alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.
  • Typical C 2-4 alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, and sec-butenyl.
  • Useful alkynyl groups are selected from C 2-6 alkynyl groups, preferably C 2-4 alkynyl.
  • Typical C 2-6 alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
  • Typical C 2-4 alkynyl groups include ethynyl, propynyl, butynyl, and 2-butynyl groups.
  • Useful arylalkyl groups include any of the above-mentioned Ci -I0 alkyl groups substituted by any of the C 6-I4 aryl groups mentioned below.
  • Typical arylalkyl groups include benzyl, phenethyl, and naphthylmethyl.
  • Useful arylalkenyl groups include any of the above-mentioned C 2-6 alkenyl groups substituted by any of the C 6-I4 aryl groups mentioned below.
  • Useful arylalkynyl groups include any of the above-mentioned C 2-6 alkynyl groups substituted by any of the C 6-I4 aryl groups mentioned below.
  • Useful (cycloalkyl)alkyl groups include any of the above-mentioned Ci -I0 alkyl groups substituted by any of the above-mentioned cycloalkyl groups.
  • Useful haloalkyl groups include any of the above-mentioned C MO alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2- difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups).
  • fluorine, chlorine, bromine or iodine atoms e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2- difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,
  • Useful hydroxyalkyl groups include any of the above-mentioned C MO alkyl groups substituted by one or more hydroxy groups, such as monohydroxyalkyl and dihydroxyalkyl groups (e.g., hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, and especially hydroxymethyl, 1 -hydroxyethyl, 2-hydroxyethyl,
  • Useful alkoxy groups include oxygen substituted by one of the C] -1O alkyl groups mentioned above (e.g., methoxy, ethoxy, propoxy, iso-propoxy, butoxy, tert- butoxy, iso-butoxy, sec-butoxy, and pentyloxy).
  • Useful alkoxyalkyl groups include any of the above-mentioned C 1-I0 alkyl groups substituted with any of the above-mentioned alkoxy groups (e.g., methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec- butoxymethyl, and pentyloxymethyl).
  • alkoxy groups e.g., methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxyprop
  • Useful haloalkoxy groups include oxygen substituted by one of the Ci -I0 haloalkyl groups mentioned above (e.g., fluoromethoxy, difiuoromethoxy, trifiuoromethoxy, and 2,2,2-trifluoroethoxy).
  • Useful aryl groups are C 6- I 4 aryl, especially C 6-10 aryl.
  • Typical C 6-I4 aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups, more preferably phenyl, naphthyl, and biphenyl groups.
  • heteroaryl or “heteroaromatic” as employed herein refers to groups having 5 to 14 ring atoms, with 6, 10 or 14 ⁇ electrons shared in a cyclic array, and containing carbon atoms and 1, 2, or 3 oxygen, nitrogen or sulfur heteroatoms, or 4 nitrogen atoms.
  • heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2//-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, ⁇ -carbolinyl, carbazo
  • Preferred heteroaryl groups include thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1 ⁇ - pyrrol-2-yl and l ⁇ -pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4- yl), pyrazolyl (e.g., lH-pyrazol-3-yl, lH-pyrazol-4-yl, and lH-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrimidin-5
  • 6-membered heteroaromatic ring includes any of the above-mentioned heteroaromatic groups that have 6 ring atoms.
  • the term "5-membered heteroaromatic ring” includes any of the above-mentioned heteroaromatic groups that have 5 ring atoms.
  • the term "5-membered, N-containing heteroaryl” includes any of the above-mentioned heteroaryl groups that have 5 ring atoms and at least one nitrogen atom as a ring atom.
  • Useful heteroarylalkyl groups include any of the above-mentioned Ci -I0 alkyl groups substituted by any of the heteroaryl groups mentioned above. Useful values include, for example, pyridin-2-ylmethyl, pyridin-3-ylmethyl, and pyridin-4-ylmethyl.
  • heterocyclic and “heterocyclo” are used herein to mean saturated or wholly or partially unsaturated 3-7 membered monocyclic, or 7-10 membered bicyclic ring system, which consist of carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and wherein the heterocyclic ring can be substituted on a carbon atom or on a nitrogen atom if the resulting compound is stable.
  • Examples include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, tetrahydrothienyl, imidazolidinyl, hexahydropyrimidinyl, benzodiazepines, and the like.
  • 5-membered heterocyclic ring includes any of the above-mentioned heterocyclic groups that are 5-membered, i.e., that have 5 ring atoms.
  • the term "5-membered, partially unsaturated, N-containing heterocyclo” includes any of the above-mentioned heterocyclo groups that are 5- membered, partially unsaturated and contain at least one nitrogen atom as a ring member.
  • Useful heterocycloalkyl groups include any of the above-mentioned Ci-io alkyl groups substituted by any of the above-mentioned heterocyclic groups.
  • amino or “amino group” refers to -NH 2 .
  • Useful aminoalkyl groups include any of the above-mentioned C MO alkyl groups substituted with an amino group.
  • Useful diaminoalkyl groups include any of the above-mentioned Ci-io alkyl groups substituted with two amino groups.
  • Useful alkylamino and dialkylamino groups are -NHR 15 and -NR 15 R 16 , respectively, wherein R 15 and R 16 are each independently selected from a Ci -10 alkyl group.
  • Useful hydroxyalkylamino groups are — NHR 15 , wherein R 15 is any of the above-mentioned hydroxyalkyl groups.
  • Useful arylamino groups are — NHR 15 , wherein R 15 is any of the above- mentioned aryl groups, such as phenylamino.
  • Useful aryl(alkyl)amino groups are — NR 15 R 16 , wherein R 15 is any of the above- mentioned aryl groups and R 16 is any of the above-mentioned Ci -I0 alkyl groups (e.g., phenyl(methyl)amino, phenyl(ethyl)amino, phenyl(propyl)amino, and phenyl(iso- propyl)amino groups.)
  • Useful alkylaminoalkyl and dialkylaminoalkyl groups are any of the above- mentioned Ci.io alkyl groups substituted by any of the above-mentioned alkylamino and dialkylamino groups, respectively.
  • Useful alkylcarbonylamino groups include any of the above-mentioned alkylcarbonyl groups attached to an amino nitrogen, such as methylcarbonylamino.
  • Useful mercaptoalkyl groups include any of the above-mentioned Ci -I0 alkyl groups substituted by a -SH group.
  • Useful carboxyalkyl groups include any of the above-mentioned Ci-I 0 alkyl groups substituted by -COOH.
  • the term “azido” refers to -N 3 .
  • the term “optionally substituted” refers to a group that may be unsubstituted or substituted.
  • Optional substituents on optionally substituted groups when not otherwise indicated, include one or more groups, preferably 1, 2, or 3 groups, independently selected from the group consisting of halo, halo(C 1-6 )alkyl, aryl, heterocycle, cycloalkyl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl(Ci -6 )alkyl, aryl(C 2-6 )alkenyl, aryl(C 2 .
  • Preferred optional substituents include halo, halo(Ci.o)alkyl, hydroxy(C 1-6 )alkyl, amino(Ci -6 )alkyl, hydroxy, nitro, C 1-6 alkyl, alkoxy, and amino.
  • prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo.
  • prodrugs will be a functional derivative of a compound of Formula I-XII which is readily convertible in vivo, e.g. , by being metabolized, into the required compound of Formula I-XII.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, Design of Prodrugs, H. Bundgaard ed., Elsevier (1985); "Drug and Enzyme Targeting, Part A," K. Widder et al. eds., Vol.
  • Non-limiting examples of prodrugs include esters or amides of compounds of any of Formulae I-XII having hydroxyalkyl or aminoalkyl as a substituent, and these may be prepared by reacting such parent compounds with anhydrides such as succinic anhydride.
  • the invention disclosed herein is also intended to encompass any of the disclosed compounds being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 U, 11 C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively, and preferably 3 H, 11 C, and 14 C.
  • Isotopically-labeled compounds of the present invention can be prepared by methods known in the art.
  • the present invention is also directed specifically to 3 H, 11 C, or 14 C radiolabeled compounds of any of Formulae I-XII, as well as their pharmaceutically acceptable salts, prodrugs and solvates, and the use of any such compounds as radioligands for their binding site on the calcium channel.
  • one use of the labeled compounds of the present invention is the characterization of specific receptor binding.
  • Another use of a labeled compound of the present invention is an alternative to animal testing for the evaluation of structure-activity relationships.
  • the receptor assay may be performed at a fixed concentration of a labeled compound of the invention and at increasing concentrations of a test compound in a competition assay.
  • a tritiated compound of any of Formulae I-XII can be prepared by introducing tritium into the particular compound, for example, by catalytic dehalogenation with tritium.
  • This method may include reacting a suitably halogen- substituted precursor of the compound with tritium gas in the presence of a suitable catalyst, for example, Pd/C, in the presence or absence of a base.
  • a suitable catalyst for example, Pd/C
  • Other suitable methods for preparing tritiated compounds can be found in Filer, Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987).
  • 14 C-labeled compounds can be prepared by employing starting materials having a 14 C carbon.
  • Some of the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
  • the present invention is meant to encompass the uses of all such possible forms, as well as their racemic and resolved forms and mixtures thereof.
  • the individual enantiomers may be separated according to methods known to those of ordinary skill in the art in view of the present disclosure.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
  • stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • chiral center refers to a carbon atom to which four different groups are attached.
  • enantiomer and “enantiomeric” refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
  • racemic refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.
  • resolution refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
  • treating or “treatment” is meant to encompass administering to a subject a compound of the present invention for the purposes of amelioration or cure, including preemptive and palliative treatment.
  • the invention disclosed herein also encompasses the use of salts of the disclosed compounds, including all non-toxic pharmaceutically acceptable salts thereof of the disclosed compounds.
  • pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts.
  • the pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexyl amine salt, N,N'-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate,
  • Acid addition salts can be formed by mixing a solution of the particular compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like.
  • Basic salts can be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.
  • solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents.
  • solvate as used herein is a combination, physical association and/or solvation of a compound of the present invention with a solvent molecule such as, e.g. a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present invention is 2:1, 1:1 or 1:2, respectively.
  • solvate encompasses both solution-phase and isolatable solvates.
  • Compounds of any of Formulae I-XII may be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the invention includes both solvated and unsolvated forms of compounds of any of Formulae I-XII.
  • a pharmaceutically acceptable solvent such as water, methanol, ethanol, and the like
  • solvate includes both solvated and unsolvated forms of compounds of any of Formulae I-XII.
  • One type of solvate is a hydrate.
  • a "hydrate” relates to a particular subgroup of solvates where the solvent molecule is water.
  • Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et a.l, J. Pharmaceut. Sci., 95 (JJ: 601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E.C. van Tonder et ai, AAPS Pharm. Sci. Tech., 5(1): Article 12 (2004), and A.L. Bingham et ai, Chem. Commun.: 603-604 (2001).
  • a typical, non-limiting, process of preparing a solvate would involve dissolving a compound of any of Formulae I-XII in a desired solvent (organic, water, or a mixture thereof) at temperatures above about 20°C to about 25°C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration.
  • a desired solvent organic, water, or a mixture thereof
  • Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
  • the present invention is thus directed generally to a method for treating a disorder responsive to the blockade of calcium channels, and particularly the selective blockade of N-type calcium channels, in an animal suffering from, or at risk of suffering from, said disorder, said method comprising administering to the animal an effective amount of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • the present invention is further directed to a method of modulating calcium channels, especially N-type calcium channels, in an animal in need thereof, said method comprising administering to the animal at least one compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • the present invention provides a method of treating stroke, the neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia.
  • the invention provides a method of treating pain, hi another embodiment, the type of pain treated is chronic pain. In another embodiment, the type of pain treated is neuropathic pain. In another embodiment, the type of pain treated is inflammatory pain.
  • the type of pain treated is surgical pain
  • hi another embodiment the type of pain treated is acute pain
  • hi another embodiment the treatment of pain (e.g., chronic pain, such as neuropathic pain or inflammatory pain, acute pain or surgical pain) is preemptive
  • hi another embodiment the treatment of pain is palliative.
  • such method of treatment requires administering to an animal in need of such treatment an amount of a compound of the present invention that is therapeutically effective in achieving said treatment, hi one embodiment, the amount of such compound is the amount that is effective as to block calcium channels in vivo.
  • Chronic pain includes, but is not limited to, inflammatory pain, neuropathic pain, postoperative pain, cancer pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, and other forms of neuralgia, neuropathic, and idiopathic pain syndromes.
  • the inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances (Levine, Inflammatory Pain, In: Textbook of Pain, Wall and Melzack eds., 3 rd ed., 1994). Inflammation often occurs at the site of injured tissue, or foreign material, and contributes to the process of tissue repair and healing.
  • the cardinal signs of inflammation include erythema (redness), heat, edema (swelling), pain and loss of function (ibid.).
  • the majority of patients with inflammatory pain do not experience pain continually, but rather experience enhanced pain when the inflamed site is moved or touched. Inflammatory pain includes, but is not limited to, that associated with osteoarthritis and rheumatoid arthritis.
  • Chronic neuropathic pain is a heterogenous disease state with an unclear etiology.
  • the pain can be mediated by multiple mechanisms. This type of pain generally arises from injury to the peripheral or central nervous tissue.
  • the syndromes include pain associated with spinal cord injury, multiple sclerosis, post-herpetic neuralgia, trigeminal neuralgia, phantom pain, causalgia, and reflex sympathetic dystrophy and lower back pain.
  • Chronic pain is different from acute pain in that patients suffer the abnormal pain sensations that can be described as spontaneous pain, continuous superficial burning and/or deep aching pain.
  • the pain can be evoked by heat-, cold-, and mechano-hyperalgesia or by heat-, cold-, or mechano-allodynia.
  • Neuropathic pain can be caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to, pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiences. Stroke (spinal or brain) and spinal cord injury can also induce neuropathic pain. Cancer-related neuropathic pain results from tumor growth compression of adjacent nerves, brain, or spinal cord. In addition, cancer treatments, including chemotherapy and radiation therapy, can also cause nerve injury. Neuropathic pain includes but is not limited to pain caused by nerve injury such as, for example, the pain from which diabetics suffer.
  • the present invention is also directed to the use of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating a disorder responsive to the blockade of calcium channels (e.g., any of the disorders listed above) in an animal suffering from said disorder.
  • a disorder responsive to the blockade of calcium channels e.g., any of the disorders listed above
  • the disorder is responsive to the selective blockade of N-type calcium channels.
  • the present invention is directed to a method of modulating calcium channels, especially N-type calcium channels, in an animal in need thereof, said method comprising administering to the animal at least one compound represented by any defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • the present invention is also directed to the use of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament, in particular a medicament for modulating calcium channels, especially N-type calcium channels, in an animal in need thereof.
  • the compounds of the present invention can be prepared using methods known to those skilled in the art in view of this disclosure.
  • compounds of Formula I where n, X, Z, R 1 , R 2 , R 8 , R 9 , and m are as described above, can be prepared as shown in Scheme 1. Additional methods of synthesis are described and illustrated in the working examples set forth below.
  • Representative compounds of the present invention were assessed by calcium mobilization and/or electrophysiological assays for calcium channel blocker activity.
  • One aspect of the present invention is based on the use of the compounds herein described as N-type calcium channel blockers.
  • certain compounds herein described show selectivity as N-type calcium channel blockers. Based upon this property, these compounds are considered useful in treating stroke, neuronal damage resulting from head trauma, migraine, epilepsy, a mood disorder, schizophrenia, a neurodegenerative disorder (such as, e.g., Alzheimer's disease, ALS, or Parkinson's disease), a psychosis, depression, anxiety, hypertension, or cardiac arrhythmia.
  • the compounds of the present invention are also expected to be effective in treating pain, such as acute pain, chronic pain, which includes but is not limited to neuropathic pain and inflammatory pain, or surgical pain.
  • those compounds having preferred N-type calcium channel blocking properties exhibit an IC 50 of about 100 ⁇ M or less in the calcium mobilization and/or electrophysiological assays described herein.
  • the compounds of the present invention exhibit an IC 50 of 10 ⁇ M or less. More preferably, the compounds of the present invention exhibit an IC 50 of about 6 ⁇ M or less. Most preferably, the compounds of the present invention exhibit an IC 50 of about 1.0 ⁇ M or less.
  • Compounds of the present invention can be tested for their N-type and L-type Ca 2+ channel blocking activity by the following calcium mobilization and/or electrophysiological assays.
  • compounds useful in the present invention are those represented by any one of Formulae I-XII that exhibit selectivity for N-type calcium channels over L-type calcium channels in the calcium mobilization and/or electrophysiological assays described herein.
  • the phrase "selectivity for N-type calcium channels over L-type calcium channels" is used herein to mean that the ratio of an IC 5 o for L-type channel blocking activity for a compound of the present invention over an IC 50 for N-type channel blocking activity for the same compound is more than 1, i.e., LTCC IC 50 / NTCC IC 5 O > 1.
  • compounds of the present invention exhibit an LTCC IC 5O / NTCC IC 50 ratio of about 2 or more, about 10 or more, about 20 or more, about 30 or more, about 50 or more, or about 100 or more.
  • LTCC IC 5O / NTCC IC 50 ratio of about 2 or more, about 10 or more, about 20 or more, about 30 or more, about 50 or more, or about 100 or more.
  • cell maintenance and differentiation were purchased from Mediatech of Herndon, MD. IMR32 cells (American Type Culture Collection, ATCC, Manassas, VA) were routinely cultured in growth medium consisting of minimum essential medium containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 2 mM L- glutamine, 1 mM sodium pyruvate, and Ix MEM non-essential amino acids. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: Growth medium plus 1 mM dibutyryl cyclic AMP (Sigma, St. Louis, MO), and 2.5 ⁇ M bromodeoxyuridine (Sigma). Cells were differentiated for 8 days by replacing differentiation medium every 2-3 days.
  • A7r5 (ATCC) cells were maintained and routinely cultured in A7r5 growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 4 mM L-glutamine, and 0.15% sodium bicarbonate. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: A7r5 Growth Medium plus 1 mM dibutyryl cyclic AMP (Sigma). Cells were differentiated for 8 days by replacing differentiation medium every 2-3 days.
  • A7r5 growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 4 mM L-glutamine, and 0.15% sodium bicarbonate. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: A7r5 Growth Medium plus 1 mM dibut
  • Recombinant human embryonal kidney cells HEK293, ATCC stably transfected with either N-type calcium channel (NTCC) subunits ( ⁇ lb, ⁇ 2 ⁇ , and ⁇ 3) or L-type calcium channel (LTCC) subunits ( ⁇ lc, ⁇ 2 ⁇ , and ⁇ l) were routinely cultured in growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 4 mM L-glutamine, 500 ⁇ g/mL geneticin (G418), 20 ⁇ g/mL Blasticidin S (InVivogen, San Diego, CA) and 500 ⁇ g/mL zeocin (InVivogen).
  • NTCC N-type calcium channel
  • LTCC L-type calcium channel
  • IMR32 buffer 127 mM NaCl, 1 mM KCl, 2 mM MgCl 2 , 700 ⁇ M NaH 2 PO 4 , 5 mM CaCl 2 , 5 mM NaHCO 3 , 8 mM HEPES, 10 mM glucose, pH 7.4
  • KCl KCl dissolved in IMR32 buffer, plus Fluo-4 were added (3 ⁇ M final concentration, Molecular Probes, Eugene, OR).
  • Final test compound concentrations ranged from about 846 pM to about 17 ⁇ M, final nitrendipine concentration was 5 ⁇ M, and final KCl concentration was 90 mM.
  • the cells were washed twice with 0.05 mL of each compound tested in nitrendipine- containing IMR32 buffer (no KCl or Fluo-4), and then replaced with 0.1 mL of each compound tested in nitrendipine-containing IMR32 buffer. Plates were then transferred to a Fluorimetric Imaging Plate Reader (FLIPR 96 , Molecular Devices, Inc., Sunnyvale, CA) for assay.
  • FLIPR 96 Fluorimetric Imaging Plate Reader
  • the FLIPR measured basal Fluo-4 fluorescence for 315 seconds (i.e., 5 minutes and 15 seconds), then added 0.1 mL KCl agonist dissolved in IMR32 buffer and measured fluorescence for another 45 seconds.
  • Final test compound concentrations on the cells after FLIPR read ranged from about 846 pM to about 17 ⁇ M, final nitrendipine concentration was 5 ⁇ M, and final KCl concentration was 90 mM.
  • Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism (version 3.02, Graph Pad, San Diego, CA), or an in-house non-linear regression analysis software.
  • HEK293 cells stably expressing recombinant rat L-type calcium channel (LTCC) subunits ( ⁇ lc, ⁇ 2 ⁇ , and ⁇ l) were trypsinized, then seeded on poly-D-lysine-coated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at 75,000 cells/well.
  • LTCC recombinant rat L-type calcium channel
  • LTCC wash buffer 127 mM NaCl, 2 mM MgCl 2 , 700 ⁇ M NaH 2 PO 4 , 5 mM CaCl 2 , 5 mM NaHCO 3 , 8 mM HEPES, 10 mM glucose, pH 7.4
  • LTCC wash buffer containing Fluo-4 (3 ⁇ M final concentration, Molecular Probes, Eugene, OR).
  • Fluo-4 3 ⁇ M final concentration
  • the following cell line and procedure may be used for the FLIPR calcium mobilization assay for L-type calcium channel.
  • differentiated A7r5 cells are trypsinized, then seeded on tissue culture treated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at a dilution of 1 : 1 from a confluent Tl 50 cm 2 flask.
  • A7r5 wash buffer (127 mM NaCl, 2 mM MgCl 2 , 700 ⁇ M NaH 2 PO 4 , 5 mM CaCl 2 , 5 mM NaHCO 3 , 8 mM HEPES, 10 mM glucose, pH 7.4), then loaded with 0.1 mL of A7r5 wash buffer containing Fluo-4 (3 ⁇ M final concentration, Molecular Probes, Eugene, OR).
  • the cells are washed with 0.1 mL A7r5 wash buffer and resuspended in 0.05 mL A7r5 assay buffer that is composed of A7r5 wash buffer plus 50 ⁇ M valinomycin (Sigma). Plates are then transferred to a FLIPR 96 for assay.
  • the FLIPR measures basal Fluo-4 fluorescence for 15 seconds, then adds 0.05 mL of each compound tested diluted in A7r5 assay buffer at final concentrations ranging from about 846 pM to about 17 ⁇ M. Fluo-4 fluorescence is then measured for 5 minutes.
  • KCl agonist dissolved in A7r5 assay buffer is then added to the cells to produce a final concentration of 90 mM KCl, and fluorescence was measured for another 45 seconds. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or an in-house regression analysis software.
  • cDNAs encoding subunits of the rat N- or L-type calcium channels were cloned by PCR amplification in order to reconstitute functional channels in a heterologous system. These were the alpschreib ( ⁇ lb), betal ( ⁇ l), beta3 ( ⁇ 3), alpha2delta ( ⁇ 2 ⁇ ), and alphalc ( ⁇ lc) subunit cDNAs.
  • the alpschreib subunit cDNA has been described by Dubel et al. in Proc. Natl. Acad. Sci. U.S.A 89: 5058-5062 (1992).
  • the betal subunit cDNA has been described by Pragnell et al. in FEBS Lett. 291: 253-258 (1991).
  • the beta3 subunit cDNA has been described by Castellano et al. in J. Biol. Chem. 268: 12359-12366 (1993).
  • the alpha2delta subunit cDNA has been described by Kim et al. in Proc. Natl. Acad. ScL U.S.A. 89: 3251-3255 (1992).
  • the alphalc subunit cDNA has been described by Koch et al in J. Biol. Chem. 265: 17786-17791 (1990).
  • PCR amplified as two overlapping cDNA fragments i.e., a 2.7 kb 5' fragment and a 4.4 kb 3' fragment.
  • the 5' fragment was amplified from rat brain cDNA using primers 1 (SEQ ID NO:1, TABLE 1) and 2 (SEQ ID NO:2, TABLE 1), and the 3' fragment was amplified from rat spinal cord cDNA using primers 3 (SEQ ID NO:3, TABLE 1) and 4 (SEQ ID NO:4, TABLE 1).
  • the two fragments were joined by ligation at a common restriction site to create the entire 7.0 kb cDNA.
  • This ORF encodes the protein isoform generated by alternative splicing termed "+A ⁇ SFMG ⁇ ET” according to the nomenclature of Lin et al. ⁇ Neuron 18: 153-166 (1997)).
  • the entire cDNA was sequenced with redundant coverage on both strands.
  • the cDNA was then inserted into the mammalian expression vector pcDNA6.2DEST (Invitrogen, Carlsbad CA) by homologous recombination using the Gateway system (Invitrogen).
  • Primers 5 (SEQ ID NO:5, TABLE 1) and 6 (SEQ ID NO:6, TABLE 1) were used for the ⁇ l cDNA amplification; primers 7 (SEQ ED NO:7, TABLE 1) and 8 (SEQ ID NO:8, TABLE 1) were used for the ⁇ 3 cDNA amplification; and primers 9 (SEQ ID NO:9, TABLE 1) and 10 (SEQ ID NO: 10, TABLE 1) were used for the ⁇ 2 ⁇ cDNA amplification. PCR products were subcloned and fully sequenced on both strands.
  • ⁇ 3 expression vector proper protein expression was confirmed by Western blot analysis of lysates of transfected HEK293 cells using a rabbit polyclonal antiserum directed against the rat ⁇ 3 subunit (USA Biological).
  • the 6.5 kb cDNA encoding the L-type calcium channel ⁇ lc subunit was cloned by PCR amplification from rat heart cDNA using primers 11 (SEQ ID NO:11, TABLE 1) and 12 (SEQ ID NO: 12, TABLE 1). The PCR fragment was subcloned and fully sequenced on both strands to confirm its identity.
  • a clone matching consensus reference sequence AF394939 and rat genomic DNA sequences was recombined into the mammalian expression vector pcDNA6.2DEST. Sequences around the recombinogenic region were sequenced to confirm accurate recombination into the expression vector.
  • N-type Recombinant Cell Line Development N-type calcium channel expressing HEK-293 cells were created in two stages. Stage 1 was created as follows. The rat ⁇ lb, and ⁇ 3 cDNA expression constructs (2.5 ⁇ g each) were co-transfected into human embryonic kidney (HEK-293) cells by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 ⁇ g/mL blasticidin and 500 ⁇ g/mL geneticin, and incubated for 3 weeks at 37 0 C, 5 % CO 2 , 95 % humidity.
  • Plates containing ⁇ 1 clone per well were cultured until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate, and partly split into 6-well plates for culture maintenance. Array plates were washed once with EMR32 buffer and cells loaded for 1 hour with 0.1 mL of IMR32 buffer containing Fluo-4 (3 ⁇ M final concentration, Molecular Probes). Then they were washed twice with 0.1 mL of IMR32 buffer, and replaced with 0.1 mL IMR32 buffer. Plates were then transferred to a FLEPR 96 for assay.
  • the FLEPR measured basal Fluo-4 fluorescence for 315 seconds, then added 0.1 mL KCl agonist dissolved in EMR32 buffer and measured fluorescence for another 45 seconds. Final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base (version 5.1, EDBS, Parsippany, NJ) software. The clone with the greatest signal-to-noise ratio, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) was expanded, characterized and used for stage 2 cell line development.
  • Stage 2 of N-type cell line development was carried out as follows.
  • the rat ⁇ 2 ⁇ cDNA expression construct (5 ⁇ g each) was transfected into the stage 1 N-type clonal cell line by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 ⁇ g/mL blasticidin, 500 ⁇ g/mL geneticin, and 250 ⁇ g/mL zeocin and incubated for 3 weeks at 37°C, 5% CO 2 , 95% humidity. Plates containing ⁇ 1 clone per well were cultured and handled according to the same steps and procedures described above for the stage 1 cell line.
  • L-type Recombinant Cell Line Development L-type calcium channel expressing HEK-293 cells were created in two stages. Stage 1 was created as follows. The rat ⁇ lc, and ⁇ l cDNA expression constructs (2.5 ⁇ g each) were co-transfected into human embryonic kidney (HEK-293) cells by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 ⁇ g/mL blasticidin and 500 ⁇ g/mL geneticin, and incubated for 3 weeks at 37 °C, 5 % CO 2 , 95 % humidity.
  • Plates containing ⁇ 1 clone per well were cultured until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate, and partly split into 6-well plates for culture maintenance. Array plates were washed once with LTCC wash (or assay) buffer and cells loaded for 1 hour with 0.1 mL of LTCC buffer containing Fluo-4 (3 ⁇ M final concentration, Molecular Probes). Then they were washed twice with 0.1 mL of LTCC buffer, and replaced with 0.1 mL LTCC buffer. Plates were then transferred to a FLIPR 96 for assay.
  • the FLIPR measured basal Fluo-4 fluorescence for 315 seconds, then added 0.1 mL KCl agonist dissolved in LTCC buffer and measured fluorescence for another 45 seconds. Final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base software. The clone with the greatest signal-to-noise ratio, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) was expanded, characterized and used for stage 2 cell line development.
  • Stage 2 of L-type cell line development was carried out as follows.
  • the rat ⁇ 2 ⁇ cDNA expression construct (5 ⁇ g each) was transfected into the stage 1 L-type clonal cell line by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 ⁇ g/mL blasticidin, 500 ⁇ g/mL geneticin, and 250 ⁇ g/mL zeocin and incubated for 3 weeks at 37°C, 5% CO 2 , 95% humidity. Plates containing ⁇ 1 clone per well were cultured and handled according to the same steps and procedures described above for the stage 1 cell line. The three clones with the greatest signal-to- noise, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) were expanded and characterized.
  • N-type Electrophysiology in Recombinant Cells For electrophysiological recording, the cells expressing ⁇ lb, ⁇ 3 and ⁇ 2 ⁇ subunits were seeded on 35-mm culture Petri dishes at a density of approximately 10 4 cells/dish and kept in an incubator for up to three days for subsequent recordings. For recordings, the dishes were positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised OfBaCl 2 (11 mM), MgCl 2 (1.5 mM), HEPES (1O mM), TEA chloride (12O mM), glucose (1O mM) adjusted to pH 7.4 with KOH.
  • a bath solution comprised OfBaCl 2 (11 mM), MgCl 2 (1.5 mM), HEPES (1O mM), TEA chloride (12O mM), glucose (1O mM) adjusted to pH 7.4 with KOH.
  • the pipettes were back-filled with internal solution containing CsCl (HOmM), MgCl 2 (3 mM), EGTA (3 mM), HEPES (40 mM), Mg-ATP (4 mM), Na 2 GTP (0.5 mM), and adjusted to pH 7.2 with CsOH.
  • the pipette resistance ranged from 2 to 3 MOhm and was compensated by 75-80 % by the built-in electronic circuitry.
  • N-type Electrophysiology in Neuronal Cells To determine dissociation constants in resting versus inactivated state for N-type calcium channels, neuronal cells that endogenously express N-type calcium channels can be used. For electrophysiological recording, the neuronal cells expressing N-type calcium channels are seeded on 35-mm culture Petri dishes at a density of approximately 10 4 cells/dish and kept in an incubator for up to three days for subsequent recordings.
  • the dishes are positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised of BaCl 2 (11 mM), MgCl 2 (1.5 mM), HEPES (10 mM), TEA chloride (120 mM), glucose (10 mM) adjusted to pH 7.4 with KOH.
  • a bath solution comprised of BaCl 2 (11 mM), MgCl 2 (1.5 mM), HEPES (10 mM), TEA chloride (120 mM), glucose (10 mM) adjusted to pH 7.4 with KOH.
  • Whole-cell voltage-clamp recordings are made using conventional patch-clamp techniques (Hamill et al., Pfluegers Arch. 391 : 85-100 (1981)) at room temperature (22-24 0 C).
  • the patch-clamp pipettes are pulled from WPI, thick-walled borosilicate glass (WPI, Sarasota, FL).
  • a Hill equation is used to fit the concentration-response curves and to determine IC 50 values.
  • a Boltzman equation is used to fit inactivation curves, returning half-inactivation voltage, Vo 5 , slope p and the amplitude of current at the most negative voltage where eventually all channels are in the resting state.
  • the compounds of the present invention can be tested for in vivo anticonvulsant activity after i.v., p.o., or i.p. injection using any of a number of anticonvulsant tests in mice, including the maximum electroshock seizure test (MES).
  • MES maximum electroshock seizure test
  • Maximum electroshock seizures are induced in male NSA mice weighing between 15-20 g and in male Sprague-Dawley rats weighing between 200-225 g by application of current (for mice: 50 mA, 60 pulses/sec, 0.8 msec pulse width, 1 sec duration, D. C; for rats: 99 mA, 125 pulses/sec, 0.8 msec pulse width, 2 sec duration, D.
  • mice are restrained by gripping the loose skin on their dorsal surface and saline-coated corneal electrodes are held lightly against the two corneae. Rats are allowed free movement on the bench top and ear-clip electrodes are used. Current is applied and animals are observed for a period of up to 30 seconds for the occurrence of a tonic hindlimb extensor response.
  • a tonic seizure is defined as a hindlimb extension in excess of 90 degrees from the plane of the body. Results can be treated in a quantal manner.
  • mice Male Swiss Webster NIH mice (20-30 g; Harlan, San Diego, CA) can be used in all experiments. Food is withdrawn on the day of experiment. Mice are placed in Plexiglass jars for at least 1 hour to acclimate to the environment. Following the acclimation period mice are weighed and given either the compound of interest administered i.p.
  • mice Fifteen minutes after the i.p. dosing, and 30 minutes after the p.o. dosing mice are injected with formalin (20 ⁇ L of 5% formaldehyde solution in saline) into the dorsal surface of the right hind paw. Mice are transferred to the Plexiglass jars and monitored for the amount of time spent licking or biting the injected paw. Periods of licking and biting are recorded in 5-minute intervals for 1 hour after the formalin injection. All experiments are done in a blinded manner during the light cycle.
  • formalin 20 ⁇ L of 5% formaldehyde solution in saline
  • the early phase of the formalin response is measured as licking / biting between 0-5 minutes, and the late phase is measured from 15-50 minutes. Differences between vehicle and drug treated groups can be analyzed by one-way analysis of variance (ANOVA). A P value ⁇ 0.05 is considered significant. Compounds are considered to be efficacious for treating acute and chronic pain if they have activity in blocking both the early and second phase of formalin-induced paw-licking activity.
  • Compounds can be tested for their potential to treat chronic pain (i.e., antiallodynic and antihyperalgesic activities) using the Chung model of peripheral neuropathy (Kim and Chung, Pain 50: 355-363 (1992)).
  • Male Sprague-Dawley rats weighing between 200-225 g are anesthetized with halothane (1-3 % in a mixture of 70 % air and 30 % oxygen), and their body temperature controlled during anesthesia through use of a homeothermic blanket.
  • a 2-cm dorsal midline incision is then made at the L5 and L6 level, and the para-vertebral muscle groups retracted bilaterally.
  • L5 and L6 spinal nerves are then exposed, isolated, and tightly ligated with 6-0 or 7-0 silk suture.
  • a sham operation is performed exposing the contralateral L5 and L6 spinal nerves, without ligating, as a negative control.
  • Tactile Allodynia Sensitivity to non-noxious mechanical stimuli can be measured in animals to assess tactile allodynia. Rats are transferred to an elevated testing cage with a wire mesh floor and allowed to acclimate for five to ten minutes. A series of von Frey monofilaments are applied to the plantar surface of the hindpaw to determine the animal's withdrawal threshold. The first filament used possesses a buckling weight of 9.1 gms (.96 log value) and is applied up to five times to see if it elicits a withdrawal response. If the animal has a withdrawal response, then the next lightest filament in the series would be applied up to five times to determine if it also could elicit a response.
  • Mechanical Hyperalgesia Sensitivity to noxious mechanical stimuli can be measured in animals using the paw pressure test to assess mechanical hyperalgesia, hi rats, hind paw withdrawal thresholds ("PWT"), measured in grams, in response to a noxious mechanical stimulus are determined using an analgesymeter (Model 7200, commercially available from Ugo Basile of Italy), as described in Stein (Biochemistry & Behavior 31: 451-455 (1988)). The rat's paw is placed on a small platform, and weight is applied in a graded manner up to a maximum of 250 grams. The endpoint is taken as the weight at which the paw is completely withdrawn. PWT is determined once for each rat at each time point.
  • PWT can be measured only in the injured paw, or in both the injured and non-injured paw.
  • mechanical hyperalgesia associated with nerve injuty induced pain can be assessed in rats. Rats are tested prior to surgery to determine a baseline, or normal, PWT. Rats are tested again 2 to 3 weeks post-surgery, prior to, and at different times after (e.g. 1, 3, 5 and 24 hr) drug administration. An increase in PWT following drug administration indicates that the test compound reduces mechanical hyperalgesia.
  • a compound of the present invention may be administered to a mammal in the form of a raw chemical without any other components present, the compound is preferably administered as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier.
  • a suitable pharmaceutically acceptable carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.
  • compositions within the scope of the present invention include all compositions where a compound of the present invention is combined with a pharmaceutically acceptable carrier.
  • the compound is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art.
  • the compounds may be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt, prodrug, or solvate thereof, per day to treat, prevent or ameliorate the particular disorder.
  • a useful oral dose of a compound of the present invention administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • the dose is typically about one-half of the oral dose.
  • a unit oral dose may comprise from about 0.01 to about 50 mg, and preferably about 0.1 to about 10 mg, of the compound.
  • the unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 to about 50 mg of the compound, or an equivalent amount of a pharmaceutically acceptable salt, prodrug or solvate thereof.
  • a pharmaceutical composition of the present invention can be administered to any animal that may experience the beneficial effects of a compound of the present invention.
  • animals e.g., humans and companion animals, although the invention is not intended to be so limited.
  • a pharmaceutical composition of the present invention can be administered by any means that achieves its intended purpose.
  • administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation.
  • the dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • a pharmaceutical composition of the present invention can be administered orally and is formulated into tablets, dragees, capsules or an oral liquid preparation.
  • the oral formulation comprises extruded multiparticulates comprising the compound of the invention.
  • a pharmaceutical composition of the present invention can be administered rectally, and is formulated in suppositories.
  • a pharmaceutical composition of the present invention can be administered by injection.
  • a pharmaceutical composition of the present invention can be administered transdermally.
  • composition of the present invention can be administered by inhalation or by intranasal or transmucosal administration.
  • a pharmaceutical composition of the present invention can be administered by the intravaginal route.
  • a pharmaceutical composition of the present invention can contain from about
  • a method of the present invention such as a method for treating a disorder responsive to the blockade of calcium channels in an animal in need thereof, can further comprise administering a second therapeutic agent to the animal in combination with a compound of the present invention, hi one embodiment, the other therapeutic agent is administered in an effective amount.
  • a compound of the present invention i.e., the first therapeutic agent
  • the second therapeutic agent can be used to treat a disorder or condition that is different from the disorder or condition for which the first therapeutic agent is being administered, and which disorder or condition may or may not be a condition or disorder as defined herein.
  • a compound of the present invention is administered concurrently with a second therapeutic agent; for example, a single composition comprising both an effective amount of a compound of any of Formulae I- XII, and an effective amount of the second therapeutic agent can be administered.
  • the present invention further provides a pharmaceutical composition comprising a combination of a compound of the present invention, the second therapeutic agent, and a pharmaceutically acceptable carrier.
  • a first pharmaceutical composition comprising an effective amount of a compound of any of Formulae I-XII and a second pharmaceutical composition comprising an effective amount of the second therapeutic agent can be concurrently administered.
  • an effective amount of a compound of the present invention is administered prior or subsequent to administration of an effective amount of the second therapeutic agent.
  • the compound of the present invention is administered while the second therapeutic agent exerts its therapeutic effect, or the second therapeutic agent is administered while the compound of the present invention exerts its therapeutic effect for treating a disorder or condition.
  • the second therapeutic agent can be an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-II inhibitor, a ⁇ -adrenergic blocker, an anticonvulsant, an antidepressant, an anticancer agent, an agent for treating addictive disorder, an agent for treating Parkinson's disease and parkinsonism, an agent for treating anxiety, an agent for treating epilepsy, an agent for treating a seizure, an agent for treating a stroke, an agent for treating a pruritic condition, an agent for treating psychosis, an agent for treating ALS, an agent for treating a cognitive disorder, an agent for treating a migraine, an agent for treating vomiting, an agent for treating dyskinesia, or an agent for treating depression, or a mixture thereof.
  • Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, l
  • the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.
  • non-opioid analgesics include non-steroidal antiinflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfen
  • non-opioid analgesics include the following, non limiting, chemical classes of analgesic, antipyretic, nonsteroidal antiinflammatory drugs: salicylic acid derivatives, including aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and olsalazin; para aminophennol derivatives including acetaminophen and phenacetin; indole and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (fenamates), including mefenamic acid, and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutylbut
  • Cox-II inhibitors and 5- lipoxygenase inhibitors, as well as combinations thereof, are described in U.S. Patent No. 6,136,839, which is hereby incorporated by reference in its entirety.
  • useful Cox II inhibitors include, but are not limited to, rofecoxib and celecoxib.
  • Examples of useful antimigraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocryptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserin, lisuride, lomerizine, methylergonovine, methysergide, metoprolol, naratriptan, oxetorone, pizotyline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.
  • Examples of useful ⁇ -adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulabol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol
  • Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5- hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metharbital, methetoin, methsuximide, 5-methyl-5-(3- phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin,
  • Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S)-citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrocholoride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexip
  • Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chloram
  • Therapeutic agents useful for treating an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxypyridine, or a serotonin antagonist.
  • Examples of useful therapeutic agents for treating Parkinson's disease and parkinsonism include, but are not limited to, carbidopa/levodopa, pergolide, bromocriptine, ropinirole, pramipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride.
  • Examples of useful therapeutic agents for treating anxiety include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam; non-benzodiazepine agents, such as buspirone, gepirone, ipsapirone, tiospirone, zolpicone, Zolpidem, and zaleplon; tranquilizers, such as barbituates, e.g., amobarbital, aprobarbital, butabarbital, butalbital, me
  • Examples of useful therapeutic agents for treating epilepsy or seizure include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gamma-vinyl GABA, acetazolamide, and felbamate.
  • Examples of useful therapeutic agents for treating stroke include, but are not limited to, anticoagulants such as heparin, agents that break up clots such as streptokinase or tissue plasminogen activator, agents that reduce swelling such as mannitol or corticosteroids, and acetylsalicylic acid.
  • anticoagulants such as heparin
  • agents that break up clots such as streptokinase or tissue plasminogen activator
  • agents that reduce swelling such as mannitol or corticosteroids
  • acetylsalicylic acid acetylsalicylic acid
  • Examples of useful therapeutic agents for treating a pruritic condition include, but are not limited to, naltrexone; nalmefene; danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those given below; menthol; camphor; phenol; pramoxine; capsaicin; tar; steroids; and antihistamines.
  • Examples of useful therapeutic agents for treating psychosis include, but are not limited to, phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride; thioxanthenes such as chloroprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine; quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone.
  • phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride
  • thioxanthenes such as chloroprothixene and thiothixene hydrochloride
  • clozapine r
  • Examples of useful therapeutic agents for treating ALS include, but are not limited to, baclofen, neurotrophic factors, riluzole, tizanidine, benzodiazepines such as clonazepan and dantrolene.
  • Examples of useful therapeutic agents for treating cognitive disorders include, but are not limited to, agents for treating or preventing dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below.
  • Examples of useful therapeutic agents for treating a migraine include, but are not limited to, sumatriptan; methysergide; ergotamine; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex.
  • Examples of useful therapeutic agents for treating vomiting include, but are not limited to, 5-HT3 receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron; dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone; and benzodiazepines such as lorazepam and alprazolam.
  • 5-HT3 receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron
  • dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone
  • glucocorticoids such as dexamethasone
  • benzodiazepines such as lorazepam and alprazolam.
  • Examples of useful therapeutic agents for treating dyskinesia include, but are not limited to, reserpine and tetrabenazine.
  • Examples of useful therapeutic agents for treating depression include, but are not limited to, tricyclic antidepressants such as amitryptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, trazodone, trimipramine, and venlafaxine; selective serotonin reuptake inhibitors such as citalopram, (S)-citalopram, fluoxetine, fluvoxamine, paroxetine, and setraline; monoamine oxidase inhibitors such as isocarboxazid, pargyline, phenelzine, and tranylcypromine; and psychostimulants such as dextroamphetamine and methylphenidate.
  • tricyclic antidepressants such as amitryptyline, amoxapine, bupropion, clomipramine, des
  • a pharmaceutical composition of the present invention is preferably manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes.
  • pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropyimethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • saccharides for example, lactose, sucrose, mannitol or sorbitol
  • cellulose preparations for example, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate)
  • binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropyimethyl
  • one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries are typically flow-regulating agents and lubricants such as, for example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol.
  • Dragee cores are provided with suitable coatings that are resistant to gastric juices.
  • concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate
  • Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain a compound in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin.
  • stabilizers may be added.
  • Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base.
  • Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution.
  • a suspension of the active compound may be prepared as an oily suspension.
  • Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400).
  • An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may optionally contain stabilizers.
  • r-(4-Trifluoromethoxybenzyl)-l',2',3 t ,6 t -tetrahydro-[2,4 1 ]bipyridinyl-6- carboxylic acid cyclopropylamide (9) was prepared by adding diisopropyl ethyl amine to a suspension of compound 5 (72 mg, 0.25 mmol), 4-trifluoromethoxybenzaldehyde (8) (Aldrich) and 3A molecular sieves (200 mg, Aldrich). The mixture was stirred for 12 hours and NaCNBH 3 was added.
  • [3,4']bipyridinyl-2-carboxylic acid methyl ester (19) was prepared by first treating compound 17 with 4N HCl to obtain compound 18 according to the procedure described in Example 4 for preparing compound 5.
  • Compound 18 was allowed to react with 3-trifluoromethylbenzenesulfonyl chloride (6) to obtain compound 19 (yield 38%) as described in Example 2 for preparing compound 7.
  • [2,4']bipyridinyl-6-carboxylic acid amide (28) was prepared as follows. A solution of compound 25 (55 mg, 0.13 mmol) in 2 M NH 3 in methanol was stirred at room temperature for 12 hours. The mixture was concentrated and the solid was washed with 20% EtOAc in hexane and dried to give the title compound 28 (44 mg, yield 85%).
  • [2,4']bipyridinyl-6-carbonitrile (32) was synthesized similarly to compound 7 in Example 1 starting with 2-chloro-6-cyanopyridine (22) instead of compound 1.
  • Diisopropyl ethyl amine (138 ⁇ l, 0.75 mmol) and cyclopropylamine (20 ⁇ l, 0.27 mmol) were added sequentially to a solution of compound 36 (75 mg, 0.25 mmol), HOBt (33 mg, 0.25 mmol), N-(3- dimethylaminopropyl)-N'ethylcabodiimide hydrochloride (53 mg, 0.27 mmol) in dichloromethane at 0 °C.
  • the mixture was allowed to warm to room temperature and stirred for 3 hours.
  • the mixture was concentrated to dryness to give the crude compound 37 (150 mg, yield 50%).
  • step b) The residue from step a) was dissolved in EtOAc and then HCl in 1,4- dioxane was added at 0 °C. The mixture was slowly warmed to room temperature and stirred for 12 hours. The solid was filtered and washed with hexane and dried to give compound 38. To a suspension of compound 38 in dichloromethane at 0 0 C was added diisopropyl ethyl amine (138 ml, 0.75 mmol) followed by 3- trifluoromethylbenzenesulfonyl chloride.
  • [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (44) was synthesized according to the procedure described in Example 8 for preparing compound 39 starting from 3,6- dichloropyridine-2-carboxylic acid (40) (Matrix) instead of compound 35.
  • [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (45) was prepared as follows. Excess MnO 2 was added to a solution of compound 7 prepared in Example 2 (140 mg, 0.31 mmol) in dichloromethane (10 ml) at room temperature. The resulting suspension was stirred for 12 hours. The mixture was filtered through paper and purified on the CombiFlash ® without an aqueous work-up to give the title compound 45 (11 mg, yield 8%).
  • 6-[8-(3-Trifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-3- yl]pyridine-2-carboxylic acid cyclopropylamide (55) was prepared as follows: [0353] a) A solution of compound 46 (1 g, 4.4 mmol, Chem-Impex) in THF (5 ml) to sodium hexamethyldisilate (2.4 ml, 2M/THF, Aldrich) in 10 ml of THF at -60 °C. After the addition, the mixture was allowed to warm to -20 0 C and this temperature was maintained for 20 minutes.
  • Example 6 for preparing compound 23 starting from compound 50 (Aldrich). To the solution of compound 51 (72 mg, 0.21 mmol) in methanol (ImI) was added aqueous NaOH (1 ml, 2N). The resulting solution was stirred for 12 hours. Methanol was removed under reduced pressure and the residue was diluted with water and acidified with aqueous HCl to pH 5 at 0 °C. The suspension with white precipitate was extracted with EtOAc (3 x 20 ml) and the combined organic phase was dried with Na 2 SO 4 , filtered, and concentrated to dryness to give compound 52 (60 mg, yield 87%).
  • N-bromosuccinimide (NBS) (4.98 g, 28.0 mmol, Aldrich) in N,N-dimethylformamide (15 ml) was added dropwise over 15 minutes to a solution of (E)-2,2,2-trifluoroacetaldehyde oxime (70) (4.93 g, 28.0 mmol) in N,N- dimethylformamide (6 ml) and the whole was stirred for 16 hours.
  • the reaction mixture was poured into ice-water (60 g), extracted with diethyl ether (60 ml x 3), washed with H 2 O and brine, dried over MgSO 4 , filtered and concentrated in vacuo. The residue was purified by distillation to give (Z)-2,2,2-trifluoro-N- hydroxyacetimidoyl bromide (71) (5.37 g, yield 69 %) as an orange oil (bp: 80-116 "C).
  • N-type calcium channel (NTCC) blockers Evaluation of the tested compounds as N-type calcium channel (NTCC) blockers after a calcium mobilization in vitro assay

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R1, R2, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

Description

TETRAHYDROPYRIDINYLAND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF
Background of the Invention
Field of the Invention
[0001] This invention is in the field of medicinal chemistry. The invention relates to novel tetrahydropyridinyl and dihydropyrrolyl compounds and the use of these compounds as blockers of calcium (Ca2+) channels.
Background Art
[0002] Calcium ions play fundamental roles in the regulation of many cellular processes. It is therefore essential that their intracellular levels be maintained under strict, yet dynamic control (Davila, H. M., Annals of the New York Academy of Sciences, pp. 102-117 (1999)). Voltage-gated calcium channels (VGCC) serve as one of the important mechanisms for fast calcium influx into the cell. Calcium channels are hetero-oligomeric proteins consisting of a pore- forming subunit (αl), which is able to form functional channels on its own in heterologous expression systems, and a set of auxiliary or regulatory subunits. Calcium channels have been classified based on their pharmacological and/or electrophysiological properties. The classification of voltage- gated calcium channels divides them into three groups: (i) high voltage-activated (HVA) channels, which include L-, N-, P-, and Q-types; (ii) intermediate (IVA) voltage-activated R-type channels; and (iii) low voltage-activated (LVA) T-type channels (Davila, supra). Voltage-gated calcium channels (VGCC) are also known as voltage-dependent calcium channels (VDCC) or voltage-sensitive calcium channels (VSCC).
[0003] Voltage-sensitive calcium channels (VSCC) regulate intracellular calcium concentration, which affects various important neuronal functions such as cellular excitability, neurotransmitter release, hormone secretion, intracellular metabolism, neurosecretory activity and gene expression (Hu et ah, Bioorganic & Medicinal Chemistry 5:1203-1212 (2000)). N-type channels are found mainly in central and peripheral neurons, being primarily located on presynaptic nerve terminals. These channels regulate the calcium flux required for depolarization-evoked release of a transmitter from synaptic endings. The transmission of pain signals from the periphery to the central nervous system (CNS) is mediated by N-type calcium channels located in the spinal cord (Song et al, J. Med. Chem. 43:341 '4-3477 (2000)).
[0004] The six types of calcium channels (i.e., L, N, P, Q, R, and T) are expressed throughout the nervous system (Wallace, M. S., The Clinical Journal of Pain 16:580- 585 (2000)). Voltage-sensitive calcium channels of the N-type exist in the superficial laminae of the dorsal horn and are thought to modulate nociceptive processing by a central mechanism. Blockade of the N-type calcium channel in the superficial dorsal horn modulates membrane excitability and inhibits neurotransmitter release, resulting in pain relief. Wallace (supra) suggests that based on animal models, N-type calcium channel antagonists have a greater analgesic potency than sodium channel antagonists.
[0005] N-type calcium channel blockers have usefulness for neuroprotection and analgesia. Ziconotide, which is a selective N-type calcium channel blocker, has been found to have analgesic activity in animal models and neuroprotective activity in focal and global ischemia models (Song et al., supra). Examples of known calcium channel blockers include fiunarizine, fluspirilene, cilnipide, PD 157767, SB-201823, SB- 206284, NNC09-0026, and PD 151307 (Hu et al., supra).
[0006] Blockade of N-type channels can prevent and/or attenuate subjective pain as well as primary and/or secondary hyperalgesia and allodynia in a variety of experimental and clinical conditions (Vanegas, H. et al, Pain 55:9-18 (2000)). N-type voltage-gated calcium channels (VGCC) play a major role in the release of synaptic mediators such as glutamate, acetylcholine, dopamine, norepinephrine, gamma- aminobutyric acid (GABA) and calcitonin gene-related peptide (CGRP).
[0007] Inhibition of voltage-gated L-type calcium channels has been shown to be beneficial for neuroprotection (Song et al, supra). However, inhibition of cardiac L- type calcium channels can lead to hypotension. It is believed that a rapid and profound lowering of arterial pressure tends to counteract the neuroprotective effects of L-type calcium channel blockers. A need exists for antagonists that are selective for N-type calcium channels over L-type calcium channels to avoid potential hypotensive effects. Brief Summary of the Invention
[0008] The present invention is related to the use of tetrahydropyridinyl and dihydropyrrolyl compounds represented by Formula I, below, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, as blockers of calcium (Ca2+) channels. Compounds of Formula I show selectivity as N-type calcium channel blockers.
[0009] The invention is also related to treating a disorder responsive to the blockade of calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, as described herein. Specifically, the invention is related to treating a disorder responsive to the blockade of N-type calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, as described herein.
[0010] Compounds useful in the present invention have not been heretofore reported.
Thus, one aspect of the present invention is directed to novel compounds of Formula I, as well as their pharmaceutically acceptable salts, prodrugs and solvates.
[0011] Another aspect of the present invention is directed to the use of the novel compounds of Formula I, and their pharmaceutically acceptable salts, prodrugs and solvates, as blockers of N-type calcium channels.
[0012] A further aspect of the present invention is to provide a method for treating pain
(e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain and inflammatory pain, or surgical pain) by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a mammal in need of such treatment. Specifically, the present invention provides a method for preemptive or palliative treatment of pain by administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a mammal in need of such treatment.
[0013] A further aspect of the present invention is to provide a method for treating stroke, neuronal damage resulting from head trauma, epilepsy, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, by administering an effective amount of - A -
a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a mammal in need of such treatment.
[0014] A further aspect of the present invention is to provide a pharmaceutical composition useful for treating a disorder responsive to the blockade of calcium ion channels, especially N-type calcium ion channels, said pharmaceutical composition containing an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in a mixture with one or more pharmaceutically acceptable carriers.
[0015] Also, an aspect of the invention is to provide a method of modulating calcium channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
[0016] A further aspect of the present invention is to provide radiolabeled compounds of Formula I and the use of such compounds, or their pharmaceutically acceptable salts, prodrugs or solvates, as radioligands for their binding site on the calcium channel.
[0017] A further aspect of the invention is to provide a method for screening a candidate compound for the ability to bind to a binding site on a protein using a radiolabeled compound of Formula I, which includes but is not limited to, a 3H, 11C, and 14C radiolabeled compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof. This method comprises a) introducing a fixed concentration of the radiolabeled compound to a soluble or membrane-associated protein or fragment thereof to form a mixture; b) titrating the mixture with a candidate compound; and c) determining the binding of the candidate compound to said binding site.
[0018] A further aspect of the invention is to provide the use of a compound of
Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating pain in a mammal. In one embodiment, the invention provides the use of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for palliative or premptive treatment of pain, such as acute pain, chronic pain, or surgical pain.
[0019] A further aspect of the invention is to provide the use of a compound of
Formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating stroke, neuronal damage resulting from head trauma, epilepsy, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia in a mammal.
[0020] Additional embodiments and advantages of the invention will be set forth in part in the description that follows, and will flow from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
[0021] It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Detailed Description of the Invention
[0022] One aspect of the present invention is based on the use of compounds of
Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, as blockers of Ca2+ channels. In view of this property, compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, are useful for treating disorders responsive to the blockade of calcium ion channels. In one aspect, compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, selectively block N-type calcium ion channels and, thus, are useful for treating disorders responsive to the selective blockade of N-type calcium ion channels.
[0023] The compounds useful in this aspect of the invention are compounds represented by Formula I:
Figure imgf000008_0001
and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: [0024] Hy is a 6-membered heteroaromatic ring, a 5-membered heteroaromatic ring, or a 5-membered heterocyclic ring, wherein said Hy has at least one nitrogen atom, and wherein said Hy is attached to the tetrahydropyridinyl or dihydropyrrolyl ring by a carbon atom; [0025] R1 is attached to a carbon atom of said Hy ring and is selected from the group consisting of a) -C(=W)NR3R4; b) -C(=O)OR5; c) -NR6-C(=O)R7; d) cyano; e) hydroxyalkyl; and f) a 5-membered, N-containing heteroaryl or a 5-membered, partially unsaturated, N-containing heterocyclo each of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; wherein
[0026] W is O or NR14, wherein
[0027] R14 is hydrogen or alkyl;
[0028] R3, R4, and R7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and
[0029] R5 and R6 are hydrogen or alkyl;
[0030] R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, nitro, cyano, amino, alkylamino, and dialkylamino;
[0031] m is 0, 1, 2, or 3;
[0032] n is O or l;
[0033] X is -CHR8- or -C(=O)- ;
[0034] R8 and R9 are both hydrogen or together form a bridge -(CH2)P-, wherein
[0035] p is 2, 3, or 4;
[0036] Z is Z1 or Z2, wherein
[0037] Z1 is -SO2- R10, wherein
[0038] R10 is selected from the group consisting of C3-I2 alkyl, halo(C3-i2)alkyl, C5-I2 cycloalkyl, (C3-J2 cycloalkyl)alkyl, C5-I2 cycloalkenyl, (C3-12 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and
[0039] Z2 is -C(R1 'R12)R13, wherein
[0040] R11 and R12 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and
[0041] R13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino. [0042] The carbon of Z2 attached to the tetrahydropyridinyl and dihydropyrrolyl ring can be a chiral center. Accordingly, the configuration at those carbon atoms can be (R) or (S). [0043] One group of compounds useful in this aspect of the present invention includes compounds of Formula I as defined above, with the following provisos when X is
-CHR8- and R8 is hydrogen: [0044] 1) when R1 l and R12 are both hydrogen and R13 is aryl or arylalkyl, then the aryl portion of R13 is substituted with at least one of haloalkyl or haloalkoxy; or [0045] 2) when Hy is a pyridin-2-yl ring, then R1 is other than optionally substituted 2-aminophenylaminocarbonyl or 2-hydroxyphenylaminocarbonyl. [0046] In one embodiment, compounds useful in the present invention are compounds of Formula I, where n is 1 (tetrahydropyridinyl). [0047] In one embodiment, compounds useful in the present invention are compounds of Formula I, where n is 0 (dihydropyrrolyl). [0048] In one embodiment, tetrahydopyridinyl compounds useful in the present invention are compounds of Formula I, where n is 1 , X is -CHR -, and R and R are both hydrogen, having the Formula II:
Figure imgf000010_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, and m are as defined above.
[0049] In one embodiment, tetrahydropyridinyl compounds useful in the present invention are compounds of Formula I, where n is 1, X is -CHR8-, and R8 and R9 together form a bridge -(CH2)P-, having the Formula III:
Figure imgf000011_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, m and p are as defined above.
[0050] In one embodiment, compounds useful in the present invention are compounds of Formula III, where p is 2, having the Formula IV:
Figure imgf000011_0002
and pharmaceutically acceptable salts, prodrugs, and solvates thereof. [0051] In another embodiment, compounds useful in the present invention are compounds of Formula III, where p is 3. [0052] In a further embodiment, compounds useful in the present invention are compounds of Formula III, where p is 4. [0053] In one embodiment, tetrahydropyridinyl compounds useful in the present invention are compounds of Formula I, where n is 1, X is -C(=O)-, and R9 is hydrogen, having the Formula V:
Figure imgf000012_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, and m are as defined above.
[0054] In one embodiment, dihydropyrrolyl compounds useful in the present invention are compounds of Formula I, where n is 0, X is -CHR8-, and R8 and R9 are both hydrogen, having the Formula VI:
Figure imgf000012_0002
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, and m are as defined above.
[0055) In one embodiment, dihydropyrrolyl compounds useful in the present invention are compounds of Formula I, where n is 0, X is -CHR8-, and R8 and R9 together form a bridge -(CH2)P-, having the Formula VII:
Figure imgf000013_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, m and p are as defined above.
[0056] In one embodiment, compounds useful in the present invention are compounds of Formula VII, where p is 2, having the Formula VIII:
Figure imgf000013_0002
and pharmaceutically acceptable salts, prodrugs, and solvates thereof. [0057] In another embodiment, compounds useful in the present invention are compounds of Formula VII, where p is 3. [0058] In a further embodiment, compounds useful in the present invention are compounds of Formula VII, where p is 4. [0059] In one embodiment, dihydropyrrolyl compounds useful in the present invention are compounds of Formula I, where n is 0, X is -C(=O)-, and R9 is hydrogen, having the Formula IX:
Figure imgf000014_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein Hy, R1, R2, Z, and m are as defined above.
[0060] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-IX, where Hy is a 6-membered heteroaromatic ring having at least one nitrogen atom. In another embodiment, compounds useful in the present invention are compounds of any of Formulae I-IX, where Hy is a 5-membered heteroaromatic ring or a 5-membered heterocyclic ring having at least one nitrogen atom. Useful compounds include those where Hy is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, and 1,2,4-oxadiazolyl. Preferably, Hy is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, imidazol-2- yl, imidazol-4-yl, and oxazol-2-yl. More preferably, Hy is pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, or oxazol-2-yl.
[0061] The group R1 takes the place of a hydrogen atom that would otherwise be present in any carbon atom in the Hy ring to which R1 group is attached. Preferably, R1 is attached to a carbon atom adjacent to a nitrogen atom in the Hy ring.
[0062] The group R2 takes the place of a hydrogen atom that would otherwise be present in any carbon atom in the Hy ring to which R2 group is attached. R1 and R2 can be attached to the same or different carbon atoms in the Hy ring.
[0063] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-IX, wherein R1 is attached to a carbon atom adjacent to a nitrogen atom of the Hy ring. In one embodiment, compounds useful in this aspect of the invention include tetrahydropyridinyl compounds having the Formula X:
Figure imgf000015_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein [0064] one of Q1, Q2, or Q3 is N and the remaining two are each CH; or
[0065] Q1 , Q2, and Q3 are each CH; and
[0066] X, Z, R1, R2, R9 and m are as defined above for Formula I.
[0067] In one embodiment, useful compounds of Formula X include those where one of Q1, Q2, or Q3 is N and the remaining two are CH. In another embodiment, useful compounds of Formula X include those where Q1, Q2, or Q3 are each CH, having the
Formula XI:
XI
Figure imgf000015_0002
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein X, Z, R1 , R2, R9 and m are as defined above for Formula I.
[0068] In one embodiment, compounds useful in the present invention, where R1 is attached to a carbon atom adjacent to a nitrogen atom of the Hy ring are compounds of Formula XII:
Figure imgf000016_0001
and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein X, Z, R1, R2, R9 and m are as defined above for Formula I.
[0069] In one embodiment, compounds useful in the present invention are compounds of any one of Formulae X-XII, where X is -CHR8- and R8 and R9 both are hydrogen.
[0070] In one embodiment, compounds useful in the present invention are compounds of any one of Formulae X-XII, where X is -CHR8- and R8 and R9 together form a bridge -(CH2)P- and p is 2, 3, or 4. Preferably, p is 2.
[0071] In one embodiment, compounds useful in the present invention are compounds of any one of Formulae X-XII, where X is -C(=O)- and R9 is hydrogen.
[0072] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is -C(=W)NR3R4, wherein W, R3, and R4 are as defined above for Formula I. In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein W is O and R3 and R4 are as defined above for Formula I. In another embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein W is NR14 and R3, R4, and R14 are as defined above for Formula I. Preferably, R14 is hydrogen or Ci-4 alkyl. Useful compounds include those where R14 is hydrogen.
[0073] hi one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is -C(=W)NR3R4 and R3 is hydrogen or alkyl, preferably hydrogen or Ci-6 alkyl, and R4 is as defined above for Formula I.
[0074] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is -C(=W)NR3R4 and R3 is hydrogen and R4 is as defined above for Formula I.
[0075] Useful compounds include those where R4 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and wherein R4 is preferably selected from the group consisting of Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo(Ci-6)alkyl, hydroxy(Ci. 6)alkyl, C3-7 cycloalkyl, C3-7 (cycloalkyl)(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 (cycloalkenyl)(Ci-4)alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered heterocyclo(Ci-4)alkyl, aryl, aryl(Ci.-i)alkyl, 5- or 6-membered heteroaryl, and 5- or 6- membered heteroaryl(Ci-4)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
[0076] More preferably, R4 is selected from the group consisting of Ci-6 alkyl, C2-6 alkenyl, halo(Ci-6)alkyl, monohydroxy(C].6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Cj-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci.6 alkyl, Ci-6 alkoxy, halogen,
Figure imgf000017_0001
hydroxy, hydroxy(Ci-6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, di(Ci- 6)alkylamino, and hydroxy(Ci-6)alkylamino. Advantageously, R4 is selected from the group consisting of methyl; ethyl; propyl; isopropyl; butyl; tert-butyl; trifluoromethyl; 2,2,2-trifluoroethyl; 3,3,3-trifluoropropyl; 4,4,4-trifluorobutyl; hydroxymethyl; 2- hydroxyethyl; 3-hydroxypropyl; l,3-dihydroxyprop-2-yl; cyclopropyl; cyclopentyl; cyclohexyl; cyclopropylmethyl; phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(C]-6)alkyl, halo(Cj-6)alkoxy, hydroxy, hydroxy(Ci-6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, di(Ci-6)alkylamino, and hydroxy(Ci-6)alkylamino; and benzyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting Of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci. 6)alkoxy, hydroxy, hydroxy(Ci-6)alkyl, cyano, amino, amino(C i^alkyl, C1-6 alkylamino, di(Ci-6)alkylamino, and hydroxy(C1-6)alkylamino.
[0077] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is -C(=O)OR5, wherein R5 is hydrogen or alkyl, preferably Ci-6 alkyl, and more preferably Ci-4 alkyl.
[0078] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is -NR6-C(=O)R7, wherein R6 and R7 are as defined above for Formula I. Useful compounds include those where R6 is hydrogen or Ci-6 alkyl, preferably hydrogen or Ci-4 alkyl, and more preferably hydrogen, and R7 is as defined above for Formula I. Useful compounds include those where R7 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; preferably selected from the group consisting of Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, haloCCi-tOalkyl,
Figure imgf000018_0001
C3-7 cycloalkyl, C3-7 (cycloalkyl)(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7
Figure imgf000018_0002
5- or 6-membered heterocyclo, 5- or 6- membered heterocyclo(Ci-4)alkyl, aryl, aryl(Ci-4)alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(Ci-4)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
[0079] More preferably, R7 is selected from the group consisting of Ci-6 alkyl, C2-6 alkenyl, halo(Ci-6)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Cj-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(Ci-6)alkyl, cyano, amino, amino(Ci-6)alkyl, C1-6 alkylamino, di(Ci_ 6)alkylamino, and hydroxy(Ci-6)alkylamino. Advantageously, R7 is selected from the group consisting of methyl; ethyl; propyl; isopropyl; butyl; tert-butyl; trifluoromethyl; 2,2,2-trifluoroethyl; 3,3,3-trifluoropropyl; 4,4,4-trifluorobutyl; hydroxymethyl; 2- hydroxyethyl; 3-hydroxypropyl; l,3-dihydroxyprop-2-yl; cyclopropyl; cyclopentyl; cyclohexyl; cyclopropylmethyl; phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(C1-6)alkyl, cyano, amino, amino(C1-6)alkyl, Ci-6 alkylamino, di(C1-6)alkylamino, and hydroxy(Ci-6)alkylamino; and benzyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting Of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci_ 6)alkoxy, hydroxy, hydroxy(Ci-6)alkyl, cyano, amino,
Figure imgf000019_0001
Ci-6 alkylamino, di(Ci-6)alkylamino, and hydroxy(Ci-6)alkylamino.
[0080] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is cyano.
[0081] hi one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is hydroxyalkyl. Useful compounds include those where R1 is monohydroxy(Ci-6)alkyl or dihydroxy(Ci-6)alkyl, such as hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, and l,3-dihydroxyprop-2-yl.
[0082] hi one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where R1 is a 5-membered, N-containing heteroaryl or a 5- membered, partially unsaturated, N-containing heterocyclo each of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino. Useful compounds are compounds of any of Formulae I-XII where R1 is selected from the group consisting of oxazolyl; 1,2,4-oxadiazolyl; 1,3,4-oxadiazolyl, and thiazolyl, any of which is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; preferably independently selected from the group consisting Of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(C1-6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, and di(Ci-6)alkylamino; more preferably independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, 1IaIo(C1 -4)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(d.4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-2 alkylamino', and di(C i -2)alkylamino .
[0083] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R1 is selected from the group consisting of
Figure imgf000020_0001
, wherein R101 is selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; preferably selected from the group consisting of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, hydroxy, hydroxy(Ci. 6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, and di(Ci-6)alkylamino; more preferably selected from the group consisting of Q-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci.4)alkyl, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-2 alkylamino, and di(Ci-2)alkylamino; A is O or S; and — is an optional bond forming a double bond.
[0084] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where m is 0, 1 , or 2, and preferably m is 0 or 1. Useful compounds include those where R2 is selected from the group consisting of CM alkyl, halo(C1-4)alkyl, halogen, hydroxy(Ci-4)alkyl, hydroxy, Ci-4 alkoxy, Ci-4 alkoxy(C]. 4)alkyl, halo(Ci ^alkoxy, halo(Ci-4)alkoxy(Ci-4)alkyl, nitro, cyano, amino, Ci-4 alkylamino, and di(Ci-4)alkylamino. Advantageously, R2 is selected from the group consisting of Ci-4 alkyl, halo(Ci-4)alkyl, halogen, hydroxy(Ci-4)alkyl, hydroxy, Ci-4 alkoxy, halo(Ci-4)alkoxy, halo(Ci-4)alkoxy(Ci-4)alkyl, nitro, cyano, and amino; preferably selected from the group consisting of Ci-4 alkyl, monohalo(Ci-4)alkyl, trihalo(C M)alkyl, halogen, monohydroxy(Ci-4)alkyl, dihydroxy(C i-^alkyl, hydroxy, C1- 4 alkoxy, trihalo(Ci-4)alkoxy, trihalo(Ci-4)alkoxy(Ci-4)alkyl, nitro, cyano, and amino; and more preferably selected from the group consisting of methyl, ethyl, propyl, iso- propyl, butyl, tert-butyl, fluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3- trifluoropropyl, fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, 1,3- dihydroxyprop-2-yl, hydroxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, trifiuoromethoxymethyl, nitro, cyano, and amino.
[0085] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where Z is Z1, that is -SO2-R10. Useful compounds include those where R10 is selected from the group consisting Of C4-8 alkyl, halo(C3-6)alkyl, C5- i2 cycloalkyl, (C3-I2 cycloalkyl)alkyl, C5-I2 cycloalkenyl, (C3-I2 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino. Preferably, R10 is selected from the group consisting of C4-6 alkyl, monohalo(C3-6)alkyl, dihalo(C3-6)alkyl, trihalo(C3-6)alkyl, C5-8 cycloalkyl, C3-8 cycloalkyl(Ci-2)alkyl, C5-8 cycloalkenyl, C3-8 cycloalkenyl(Ci-2)alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered heterocyclo(Ci-2)alkyl, C6-I4 aryl, C6- 14 aryl(Ci-2)alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(Ci. 2)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci. 4)alkoxy, hydroxy, hydroxy(C1-4)alkyl, cyano, amino, amino(Ci-4)alkyl, C1-4 alkylamino, di(Ci-4)alkylamino, and hydroxy(Ci-4)alkylamino.
[0086] Useful compounds include those where R10 is selected from the group consisting of C4-6 alkyl; trifluoro(C3-6)alkyl; C5-8 cycloalkyl; C3-8 cycloalkyl(C1-2)alkyl; C5-8 cycloalkenyl; C3-8 cycloalkenyl(Ci-2)alkyl; heterocyclo selected from the group consisting of pyrrolidinyl, piperidinyl, hexahydropyrimidinyl, oxazolidinyl, and tetrahydrothienyl; heterocyclo(C1-2)alkyl selected from the group consisting of pyrrolidinyl(C i -2)alkyl, piperidinyl(C i -2)alkyl, hexahydropyrimidinyl(C i -2)alkyl, oxazolidinyl(C1-2)alkyl, and tetrahydrothienyl(C1-2)alkyl; C6-1O aryl; C6-I0 aryl(Ci. 2)alkyl; heteroaryl selected from the group consisting of pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, and thienyl; and heteroaryl(C1-2)alkyl selected from the group consisting of pyrrolyl(Ci-2)alkyl, pyridyl(C1-2)alkyl, pyrimidyl(C1-2)alkyl, isoxazolyl(C1-2)alkyl, OXaZoIyI(C1 -2)alkyl, and thienyl(C1-2)alkyl; wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of C1-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(C1-4)alkyl, cyano, amino, amino(C1-4)alkyl, Ci-4 alkylamino, di(Ci_ 4)alkylamino, and hydroxy(Ci-4)alkylamino.
[0087] Advantageously, R10 is selected from the group consisting of
[0088] a) cyclohexyl;
[0089] b) cycloheptyl;
[0090] c) cyclohexylmethyl;
[0091] d) cycloheptylmethyl;
[0092] e) phenyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, haϊo(Ci-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci ^alkylamino, and hydroxy(Ci ^alkylamino, and preferably substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0093] f) benzyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Q-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci^)alkoxy, hydroxy, hydroxy^i^alkyl, cyano, amino, amino(Ci-4)alkyl, C1-4 alkylamino,
Figure imgf000023_0001
and hydroxy(C1-4)alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(C1-4)alkoxy, and cyano;
[0094] g) phenyl ethyl, unsubstituted or substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, halogen, halo(C1-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(C1-4)alkyl, cyano, amino, amino(C1-4)alkyl, C1-4 alkylamino, di(C1-4)alkylamino, and hydroxy(Ci-4)alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0095] h) pyridin-1-yl, pyridin-2-yl, or pyridin-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0096] i) thiophen-2-yl or thiophen-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Cj. 4)alkyl, halo(C1-4)alkoxy, and cyano;
[0097] j) isoxazol-3-yl, isoxazol-4-yl, or isoxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(d -4)alkoxy, and cyano;
[0098] k) oxazol-2-yl, oxazol-4-yl, or oxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(Ci-4)alkoxy, and cyano; and
[0099] 1) isoxazol-3-ylmethyl, isoxazol-4-ylmethyl, or isoxazol-5-ylmethyl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(Ci-4)alkoxy, and cyano.
[0100] In one embodiment, R10 is a substituted phenyl, benzyl, or phenylethyl, preferably phenyl, and the substituent is at the 2-position of the phenyl portion. Preferably, the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
[0101] In one embodiment, R10 is a substituted phenyl, benzyl, or phenylethyl, preferably phenyl, and the substituent is at the 3-position of the phenyl portion. Preferably, the substituent is halogen, trifluoromethyl, trifluoromethoxy, cyano. [0102] In one embodiment, R10 is a substituted phenyl, benzyl, or phenyl ethyl, preferably phenyl, and the substituent is at the 4-position of the phenyl portion. Preferably, the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
[0103] Advantageously, when R10 is a substituted phenyl, benzyl, or phenylethyl, the substituent is at the 3-position of the phenyl portion.
[0104] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII where Z is Z2, that is, -C(RπR12)R13. In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R11 and R12 are both hydrogen and R13 is as defined above for Formula I. In this aspect of the invention, when X is -CHR8- and R8 is hydrogen and R13 is aryl or arylalkyl, then the aryl portion thereof is substituted by at least one of haloalkyl or haloalkoxy, and especially trifluoromethyl or trifluoromethoxy. In one aspect of the present invention, when X is -CHR8- and R8 and R9 form a bridge (CH2)P with p=2 or 3, Z is Z2, R11 and R12 are both hydrogen, and R13 is aryl or arylalkyl, then R1 is not cyano or a 5-membered, N-containing heteroaryl. In one aspect of the present invention, when Hy is a 6-membered heteroaromatic ring, R1 is -C(=W)NR3R4, Z=Z2, and R11 and R12 are both hydrogen, then R13 is an aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein the aryl portion is not fluorenyl and consists of a monocyclic or bicyclic ring structure that is optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
[0105] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R11 is hydrogen, R12 is selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R13 is as defined above for Formula I.
[0106] In one embodiment, compounds useful in the present invention are compounds of any of Formulae I-XII, wherein R11 and R12 are each independently selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R13 is as defined above for Formula I. [0107] Useful compounds include those where R11 and R12, when other than hydrogen, are each independently selected from the group consisting of CM alkyl, halo(C1-4)alkyl, hydroxy(C1-4)alkyl, halogen, hydroxy, C1-4 alkoxy, C1-4 alkoxy(Ci-4)alkyl, halo(Ci. 4)alkoxy, halo(Ci-4)alkoxy(C1-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino(Ci-4)aUcyl, and
Figure imgf000025_0001
preferably each independently selected from the group consisting of Ci-4 alkyl, halo(Ci-4)alkyl, hydroxy(Ci-4)alkyl, halogen, hydroxy, halo(Ci-4)alkoxy, and halo(Ci ^aIkOXy(Ci- 4)alkyl; more preferably each independently selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 2-hydroxyethyl, l,3-dihydroxyprop-2-yl, fluoro, chloro, bromo, trifluoromethoxy, 2-trifluoroethoxy, and trifluoromethoxymethyl.
[0108] Useful compounds include those where R13 is selected from the group consisting of C6-io aryl, C6-I0 aryl(Ci-2)alkyl, 5- or 6-membered heteroaryl, and 5- or 6- membered heteroaryl(Ci-2)alkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and preferably optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci
Figure imgf000025_0002
Preferably, R13 is phenyl, benzyl, phenylethyl, pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, thienyl, pyrrolyl(Ci-2)alkyl, pyridyl(Ci-2)alkyl, pyrimidyl(Ci-2)alkyl, isoxazolyl(Ci-2)alkyl, oxazolyl(Ci-2)alkyl, or thienyl(Ci-2)alkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, CM alkylamino, di(Ci ^alkylamino, and hydroxy(Ci.4)alkylamino.
[0109] Advantageously, R13 is selected from the group consisting of
[0110] a) phenyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of CM alkyl, CM alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(CM)alkyl, cyano, amino, amino(Ci-4)alkyl, C1-4 alkylamino, di(Ci -^alkylamino, and hydroxy(Ci -^alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci .^alkoxy, and cyano;
[0111] b) benzyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of CM alkyl, C1-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(C1-4)alkyl, cyano, amino,
Figure imgf000026_0001
Ci-4 alkylamino, di(Ci-4)alkylamino, and hydroxy(Ci-4)alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0112] c) phenylethyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci ^alkylamino, and hydroxy(Ci ^alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, 1IaIo(C1 -4)alkyl, halo(Ci ^alkoxy, and cyano;
[0113] d) pyridin-1-yl, pyridin-2-yl, or pyridin-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0114] e) thiophen-2-yl or thiophen-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci- 4)alkyl, halo(C i^alkoxy, and cyano;
[0115] f) isoxazol-3-yl, isoxazol-4-yl, or isoxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano;
[0116] g) oxazol-2-yl, oxazol-4-yl, or oxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano; and
[0117] h) isoxazol-3-ylmethyl, isoxazol-4-ylmethyl, or isoxazol-5-ylmethyl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, and cyano. [0118] In one embodiment, R13 is a substituted phenyl, benzyl, or phenyl ethyl, preferably phenyl, and the substituent is at the 4-position of the phenyl portion. Preferably, the substituent is halogen, trifluoromethyl, trifluoromethoxy, or cyano.
[0119] In one embodiment, compounds useful in the present invention are compounds of Formula XI or XII, wherein Z is Z1, and X, R1, R2, R9, m, and R10 are as defined for Formula I. Preferably, in these compounds, R10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci-4)alkylamino, and hydroxy(Ci- 4)alkylamino; and preferably substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano; more preferably substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, trifluoromethoxy, and cyano. Useful compounds include those where m is 0 or 1, and R2 is selected from the group consisting of chloro, fluoro and bromo. Advantageously, in these compounds, R1 is -C(=W)NR3R4, wherein W, R3 and R4 are as defined above for Formula I.
[0120] In one embodiment, compounds useful in the present invention are compounds of Formula XI or XII, wherein
[0121] R1 is -C(=W)NR3R4, wherein
[0122] W is O;
[0123] R3 is hydrogen; and
[0124] R4 is Ci-6 alkyl, C2-6 alkenyl, halo(C]-6)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
[0125] R2 is fluoro, chloro or bromo;
[0126] m is O or l;
[0127] X is -CHR8-; [0128] R8 and R9 are both hydrogen or together form a bridge -(CH2)P-, wherein
[0129] p is 2, 3, or 4; and
[0130] Z is Z1; and R10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, C1-4 alkoxy, halogen,
Figure imgf000028_0001
hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, C1-4 alkylamino, di(Ci .^alkylamino, and hydroxy(Ci-4)alkylamino. In one embodiment, R and R are both hydrogen. In another embodiment, R and R together form a bridge -(CH2)P-.
[0131] In one embodiment, compounds useful in the present invention are compounds of Formula XI or XII, wherein
[0132] R1 is -C(=W)NR3R4, wherein
[0133] W is O;
[0134] R3 is hydrogen; and
[0135] R4 is Ci-6 alkyl, C2-6 alkenyl, halo(C)-6)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
[0136] R2 is fluoro, chloro or bromo;
[0137] m is O or l;
[0138] X is -C(=O)- ;
[0139] R9 is hydrogen; and
[0140] Z is Z1; and R10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci-4)alkoxy, hydroxy, hydroxy(Ci_4)alkyl, cyano, amino,
Figure imgf000028_0002
[0141] Optional substituents attached to aryl, phenyl, and heteroaryl rings each take the place of a hydrogen atom that would otherwise be present in any position on the aryl, phenyl or heteroaryl rings.
[0142] Exemplary preferred compounds useful in the present invention include: 1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ^2\3\6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2l,3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-chlorobenzenesulfonyl)-r,2',3l,6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; l'-(2-trifluoromethylbenzenesulfonyl)-r,2t,3l,6l-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(4-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4l]bipyridinyl-6- carboxylic acid cyclopropylamide;
1 '-(4-fluorobenzenesulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-(3-cyanobenzenesulfonyl)-r,2l,3l,6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-dimethylsulfamoyl- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-(3,3,3-trifluoropropylsulfonyl)-l1,2l,3l,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-cyclohexylsulfonyl-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(2,4-dichlorobenzenesulfonyl)- 1 ',2I,3l,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-cyano-4-fluorobenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(pyridin-2-ylsulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(pyridin-3-ylsulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-(3-trifluoromethylbenzylsulfonyl)-ll,2',3l,6l-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; 1 '-(3,5-dichlorobenzenesulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; l'-(2,4,6-trifluorobenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; l'-(2-methylprop-l-ylsulfonyl)-lI,2l,3l,6l-tetrahydro-[2,41]bipyridinyl-6- carboxylic acid cyclopropylamide; r-cyclopentylsulfonyl-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(thiophen-3-ylsulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(4-trifluoromethoxybenzyl)- 1 ',2',3',6t-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide;
2-[ 1 -(4-trifluoromethoxybenzenesulfonyl)- 1,2,3 ,6-tetrahydropyridin-4-yl] - pyrimidine-4-carboxylic acid amide;
2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4-yl]- pyrimidine-4-carboxylic acid amide; ll-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid methyl ester; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3l,6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid cyclopropylmethylamide; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6l-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 2,2,2-trifluoroethylamide; ll-(3-trifluoromethylbenzenesulfonyl)-ll,2',3l,6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 2,2,2-trifluoroethylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6I-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid cyclopropyhnethylamide;
1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ',2l,3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropyhnethylamide; l'-CS-trifluoromethylbenzenesulfonyO-r^'^'^'-tetrahydro-tZ^^-bipyridinyl-o- carboxylic acid 2,2,2-trifluoroethylamide; r-(3-trifluoromethylbenzenesulfonyl)-r,2I,3',6'-tetrahydro-[2,4l]-bipyridinyl-6- carboxylic acid 3,3,3-trifluoropropylamide;
1 '-(4-trifluoromethoxybenzenesulfonyl)- 1 ',2',3l,6'-tetrahydro-[2,4']-bipyridinyl- 6-carboxylic acid 2,2,2-trifluoroethylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4l]-bipyridinyl- 6-carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']-bipyridinyl- 6-carboxylic acid 4-fluorophenylamide; r-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid amide; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid 2-hydroxyethylamide; l'-(3-trifluoromethylbenzenesulfonyl)-ll,21,3l,6l-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid l,3-dihydroxyprop-2-ylamide; r-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6l-tetrahydro-[2,4l]bipyridinyl-6- carbonitrile;
N-cyclopropylmethyl- r-(4-trifluoromethoxybenzenesulfonyl)- 1 ',2',3',6'- tetrahydro-[2,4']bipyridinyl-6-carboxamidine;
2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide;
2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylmethylamide;
2-[l-(4-trifluoromethoxybenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide;
S-chloro-r-CS-trifluoromethylbenzenesulfony^-r^'^'jό'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
5-chloro- 1 '-(4-trifluoromethoxybenzenesulfonyl)- 1 ',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; ό'-oxo-r-CS-trifluoromethylbenzenesulfonyO-r^'^'^'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; 6-[8-(3-tτifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-3- yl]pyridine-2-carboxylic acid cyclopropylamide;
2-[ 1 -(4-trifluoromethoxybenzenesulfonyl)- 1 ,2,3 ,6-tetrahydropyridin-4- yl]oxazole-4-carboxylic acid cyclopropylamide; l'-[2,2,2-trifluoro-l-(4-trifluoromethoxyphenyl)-ethyl]-l',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; l'-[2,2,2-trifluoro-l-(4-hydroxymethylphenyl)-ethyl]-l',21,3I,6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
N-cyclopropyl-6- { 1 -[(3-trifluoromethylisoxazol-5-yl)methyl]- 1 ,2,3,6- tetrahydropyridin-4-yl}picolinamide; r-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid methyl ester; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6t-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid; r-(3-trifluoromethylbenzenesulfonyl)-l',21,3',6'-tetrahydro-[2,4']bipyridinyl-6- yl]methanol ;
1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ',2',3',6'-tetrahydro[2,4']bipyridinyl-6- cyclopropanoylamine; r-[(3-trifluoromethylbenzene)aminosulfonyl]-r,2',3',6l-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; and the pharmaceutically acceptable salts, prodrugs and solvates thereof. [0143] Useful cycloalkyl groups are selected from C3-I2 cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0144] Useful cycloalkenyl groups are selected from C3-12 cycloalkenyl. Typical cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
[0145] Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.
[0146] Useful alkyl groups are selected from straight-chained and branched Ci-10 alkyl groups, more preferably straight chain C \^ alkyl groups and branched chain C3-$ alkyl groups, and more preferably straight chain Ci-4 alkyl groups and branched chain C3-4 alkyl groups. Typical CMO alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, wo-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl and decyl, among others. [0147] Useful alkenyl groups are selected from C2-6 alkenyl groups, preferably C2^ alkenyl. Typical C2-6 alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl. Typical C2-4 alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, and sec-butenyl. [0148] Useful alkynyl groups are selected from C2-6 alkynyl groups, preferably C2-4 alkynyl. Typical C2-6 alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups. Typical C2-4 alkynyl groups include ethynyl, propynyl, butynyl, and 2-butynyl groups. [0149] Useful arylalkyl groups include any of the above-mentioned Ci-I0 alkyl groups substituted by any of the C6-I4 aryl groups mentioned below. Typical arylalkyl groups include benzyl, phenethyl, and naphthylmethyl. [0150] Useful arylalkenyl groups include any of the above-mentioned C2-6 alkenyl groups substituted by any of the C6-I4 aryl groups mentioned below. [0151] Useful arylalkynyl groups include any of the above-mentioned C2-6 alkynyl groups substituted by any of the C6-I4 aryl groups mentioned below. [0152] Useful (cycloalkyl)alkyl groups include any of the above-mentioned Ci-I0 alkyl groups substituted by any of the above-mentioned cycloalkyl groups. [0153] Useful haloalkyl groups include any of the above-mentioned CMO alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2- difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups). [0154] Useful hydroxyalkyl groups include any of the above-mentioned CMO alkyl groups substituted by one or more hydroxy groups, such as monohydroxyalkyl and dihydroxyalkyl groups (e.g., hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, and especially hydroxymethyl, 1 -hydroxyethyl, 2-hydroxyethyl,
2-hydroxypropyl, 3-hydroxypropyl, 3 -hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-l- methylpropyl, and l,3-dihydroxyprop-2-yl). [0155] Useful alkoxy groups include oxygen substituted by one of the C]-1O alkyl groups mentioned above (e.g., methoxy, ethoxy, propoxy, iso-propoxy, butoxy, tert- butoxy, iso-butoxy, sec-butoxy, and pentyloxy).
[0156] Useful alkoxyalkyl groups include any of the above-mentioned C1-I0 alkyl groups substituted with any of the above-mentioned alkoxy groups (e.g., methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec- butoxymethyl, and pentyloxymethyl).
[0157] Useful haloalkoxy groups include oxygen substituted by one of the Ci-I0 haloalkyl groups mentioned above (e.g., fluoromethoxy, difiuoromethoxy, trifiuoromethoxy, and 2,2,2-trifluoroethoxy).
[0158] Useful aryl groups are C6-I4 aryl, especially C6-10 aryl. Typical C6-I4 aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups, more preferably phenyl, naphthyl, and biphenyl groups.
[0159] The term "heteroaryl" or "heteroaromatic" as employed herein refers to groups having 5 to 14 ring atoms, with 6, 10 or 14 π electrons shared in a cyclic array, and containing carbon atoms and 1, 2, or 3 oxygen, nitrogen or sulfur heteroatoms, or 4 nitrogen atoms. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2//-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. Preferred heteroaryl groups include thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1Η- pyrrol-2-yl and lΗ-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4- yl), pyrazolyl (e.g., lH-pyrazol-3-yl, lH-pyrazol-4-yl, and lH-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl).
[0160] As used herein, the term "6-membered heteroaromatic ring" includes any of the above-mentioned heteroaromatic groups that have 6 ring atoms.
[0161] As used herein, the term "5-membered heteroaromatic ring" includes any of the above-mentioned heteroaromatic groups that have 5 ring atoms.
[0162] As used herein, the term "5-membered, N-containing heteroaryl" includes any of the above-mentioned heteroaryl groups that have 5 ring atoms and at least one nitrogen atom as a ring atom.
[0163] Useful heteroarylalkyl groups include any of the above-mentioned Ci-I0 alkyl groups substituted by any of the heteroaryl groups mentioned above. Useful values include, for example, pyridin-2-ylmethyl, pyridin-3-ylmethyl, and pyridin-4-ylmethyl.
[0164] The terms "heterocyclic" and "heterocyclo" are used herein to mean saturated or wholly or partially unsaturated 3-7 membered monocyclic, or 7-10 membered bicyclic ring system, which consist of carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and wherein the heterocyclic ring can be substituted on a carbon atom or on a nitrogen atom if the resulting compound is stable. Examples include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, tetrahydrothienyl, imidazolidinyl, hexahydropyrimidinyl, benzodiazepines, and the like.
[0165] As used herein, the term "5-membered heterocyclic ring" includes any of the above-mentioned heterocyclic groups that are 5-membered, i.e., that have 5 ring atoms.
[0166] As used herein, the term "5-membered, partially unsaturated, N-containing heterocyclo" includes any of the above-mentioned heterocyclo groups that are 5- membered, partially unsaturated and contain at least one nitrogen atom as a ring member.
[0167] Useful heterocycloalkyl groups include any of the above-mentioned Ci-io alkyl groups substituted by any of the above-mentioned heterocyclic groups. [0168] As used herein, the term "amino" or "amino group" refers to -NH2.
[0169] Useful aminoalkyl groups include any of the above-mentioned CMO alkyl groups substituted with an amino group.
[0170] Useful diaminoalkyl groups include any of the above-mentioned Ci-io alkyl groups substituted with two amino groups.
[0171] Useful alkylamino and dialkylamino groups are -NHR15 and -NR15R16, respectively, wherein R15 and R16 are each independently selected from a Ci-10 alkyl group.
[0172] Useful hydroxyalkylamino groups are — NHR15, wherein R15 is any of the above-mentioned hydroxyalkyl groups.
[0173] Useful arylamino groups are — NHR15, wherein R15 is any of the above- mentioned aryl groups, such as phenylamino.
[0174] Useful aryl(alkyl)amino groups are — NR15R16, wherein R15 is any of the above- mentioned aryl groups and R16 is any of the above-mentioned Ci-I0 alkyl groups (e.g., phenyl(methyl)amino, phenyl(ethyl)amino, phenyl(propyl)amino, and phenyl(iso- propyl)amino groups.)
[0175] Useful alkylaminoalkyl and dialkylaminoalkyl groups are any of the above- mentioned Ci.io alkyl groups substituted by any of the above-mentioned alkylamino and dialkylamino groups, respectively.
[0176] As used herein, the term "aminocarbonyl" refers to -C(=O)NH2.
[0177] Useful alkylcarbonyl groups include a carbonyl group, i.e., -C(=O)-, substituted by any of the above-mentioned CM0 alkyl groups.
[0178] Useful alkylcarbonylamino groups include any of the above-mentioned alkylcarbonyl groups attached to an amino nitrogen, such as methylcarbonylamino.
[0179] Useful mercaptoalkyl groups include any of the above-mentioned Ci-I0 alkyl groups substituted by a -SH group.
[0180] As used herein, the term "carboxy" refers to -COOH.
[0181] Useful carboxyalkyl groups include any of the above-mentioned Ci-I0 alkyl groups substituted by -COOH.
[0182] As used herein, the term "ureido" refers to -NH-C(=O)-NH2.
[0183] As used herein, the term "azido" refers to -N3. [0184] As used herein, the term "optionally substituted" refers to a group that may be unsubstituted or substituted.
[0185] Optional substituents on optionally substituted groups, when not otherwise indicated, include one or more groups, preferably 1, 2, or 3 groups, independently selected from the group consisting of halo, halo(C1-6)alkyl, aryl, heterocycle, cycloalkyl, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl(Ci-6)alkyl, aryl(C2-6)alkenyl, aryl(C2.6)alkynyl, cycloalkyl(C1-6)alkyl, heterocyclo(Ci-6)alkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, carboxy(Ci-6)alkyl, alkoxy(Ci-6)alkyl, nitro, amino, ureido, cyano, alkylcarbonylamino, hydroxy, thiol, alkylcarbonyloxy, azido, alkoxy, carboxy, aminocarbonyl, and mercapto(Ci-6)alkyl groups mentioned above. Preferred optional substituents include halo, halo(Ci.o)alkyl, hydroxy(C1-6)alkyl, amino(Ci-6)alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino.
[0186] The invention disclosed herein is also meant to encompass prodrugs of any of the disclosed compounds. As used herein, prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo. In general, such prodrugs will be a functional derivative of a compound of Formula I-XII which is readily convertible in vivo, e.g. , by being metabolized, into the required compound of Formula I-XII. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, Design of Prodrugs, H. Bundgaard ed., Elsevier (1985); "Drug and Enzyme Targeting, Part A," K. Widder et al. eds., Vol. 112 in Methods in Enzymology, Academic Press (1985); Bundgaard, "Design and Application of Prodrugs," Chapter 5 (pp. 113-191) in A Textbook of Drug Design and Development, P. Krogsgaard-Larsen and H. Bundgaard eds., Harwood Academic Publishers (1991); Bundgaard et al, Adv. Drug Delivery Revs. 8:1-38 (1992); Bundgaard et al., J. Pharmaceut. Sci. 77:285 (1988); and Kakeya et al, Chem. Pharm. Bull. 32:692 (1984). Non-limiting examples of prodrugs include esters or amides of compounds of any of Formulae I-XII having hydroxyalkyl or aminoalkyl as a substituent, and these may be prepared by reacting such parent compounds with anhydrides such as succinic anhydride.
[0187] The invention disclosed herein is also intended to encompass any of the disclosed compounds being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3U, 11C, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, and 36Cl, respectively, and preferably 3H, 11C, and 14C. Isotopically-labeled compounds of the present invention can be prepared by methods known in the art.
[0188] The present invention is also directed specifically to 3H, 11C, or 14C radiolabeled compounds of any of Formulae I-XII, as well as their pharmaceutically acceptable salts, prodrugs and solvates, and the use of any such compounds as radioligands for their binding site on the calcium channel. For example, one use of the labeled compounds of the present invention is the characterization of specific receptor binding. Another use of a labeled compound of the present invention is an alternative to animal testing for the evaluation of structure-activity relationships. For example, the receptor assay may be performed at a fixed concentration of a labeled compound of the invention and at increasing concentrations of a test compound in a competition assay. For example, a tritiated compound of any of Formulae I-XII can be prepared by introducing tritium into the particular compound, for example, by catalytic dehalogenation with tritium. This method may include reacting a suitably halogen- substituted precursor of the compound with tritium gas in the presence of a suitable catalyst, for example, Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Filer, Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987). 14C-labeled compounds can be prepared by employing starting materials having a 14C carbon.
[0189] Some of the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present invention is meant to encompass the uses of all such possible forms, as well as their racemic and resolved forms and mixtures thereof. The individual enantiomers may be separated according to methods known to those of ordinary skill in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
[0190] As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
[0191] The term "chiral center" refers to a carbon atom to which four different groups are attached.
[0192] The terms "enantiomer" and "enantiomeric" refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
[0193] The term "racemic" refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.
[0194] The term "resolution" refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
[0195] The terms "a" and "an" refer to one or more.
[0196] The term "treating" or "treatment" is meant to encompass administering to a subject a compound of the present invention for the purposes of amelioration or cure, including preemptive and palliative treatment.
[0197] The invention disclosed herein also encompasses the use of salts of the disclosed compounds, including all non-toxic pharmaceutically acceptable salts thereof of the disclosed compounds. Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts. The pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexyl amine salt, N,N'-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, asparginate, glutamate and he like.
[0198] Acid addition salts can be formed by mixing a solution of the particular compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like. Basic salts can be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.
[0199] The invention disclosed herein is also meant to encompass solvates of any of the disclosed compounds. Solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents. The term "solvate" as used herein is a combination, physical association and/or solvation of a compound of the present invention with a solvent molecule such as, e.g. a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present invention is 2:1, 1:1 or 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding, hi certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, "solvate" encompasses both solution-phase and isolatable solvates. Compounds of any of Formulae I-XII may be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the invention includes both solvated and unsolvated forms of compounds of any of Formulae I-XII. One type of solvate is a hydrate. A "hydrate" relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et a.l, J. Pharmaceut. Sci., 95 (JJ: 601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E.C. van Tonder et ai, AAPS Pharm. Sci. Tech., 5(1): Article 12 (2004), and A.L. Bingham et ai, Chem. Commun.: 603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a compound of any of Formulae I-XII in a desired solvent (organic, water, or a mixture thereof) at temperatures above about 20°C to about 25°C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
[0200] Since compounds of Formulae I-XII are blockers of calcium (Ca2+) channels, a number of diseases and conditions mediated by calcium ion influx can be treated by employing these compounds (See, e.g., Gould et al, Proc. Natl. Acad. Sci. USA 50:5122-5125 (1983); Schwartz et al, Am. J. Cardiol. 623G-6G (1988); Ito, M., Ann. Rev. Neurosci. /2:85-102 (1989); Nuglisch et al, J. Cereb. Blood Flow Metab. 10:654- 659 (1990); Janis, RJ. & Toggle, D.J., Drugs Acting on Calcium Channels, in Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance, p. 195-249, Hurwitz et al. eds., CRC Press, London (1991); Hu et al, Bioorg. Med. Chem. Lett. 9:2151-2156 (1999); Hu et al, J. Med. Chem. 42:4239-4249 (1999); Hu et al, Bioorg. Med. Chem. 5:1203-1212 (2000); Song et al, J. Med. Chem. 43:2,A1A-2A11 (2000); Vanegas et al, Pain 55:9-18 (2000); Wallace, M.S., The Clinical Journal of Pain 75:S80-S85 (2000); and Lukyanetz et al, Epilepsia 4J:9-18 (2002)). The present invention is thus directed generally to a method for treating a disorder responsive to the blockade of calcium channels, and particularly the selective blockade of N-type calcium channels, in an animal suffering from, or at risk of suffering from, said disorder, said method comprising administering to the animal an effective amount of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
[0201] The present invention is further directed to a method of modulating calcium channels, especially N-type calcium channels, in an animal in need thereof, said method comprising administering to the animal at least one compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
[0202] More specifically, the present invention provides a method of treating stroke, the neuronal damage resulting from head trauma, epilepsy, pain (e.g., acute pain, chronic pain, which includes but is not limited to neuropathic pain and inflammatory pain, or surgical pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia. In one embodiment, the invention provides a method of treating pain, hi another embodiment, the type of pain treated is chronic pain. In another embodiment, the type of pain treated is neuropathic pain. In another embodiment, the type of pain treated is inflammatory pain. In another embodiment, the type of pain treated is surgical pain, hi another embodiment, the type of pain treated is acute pain, hi another embodiment, the treatment of pain (e.g., chronic pain, such as neuropathic pain or inflammatory pain, acute pain or surgical pain) is preemptive, hi another embodiment, the treatment of pain is palliative. In each instance, such method of treatment requires administering to an animal in need of such treatment an amount of a compound of the present invention that is therapeutically effective in achieving said treatment, hi one embodiment, the amount of such compound is the amount that is effective as to block calcium channels in vivo.
[0203] Chronic pain includes, but is not limited to, inflammatory pain, neuropathic pain, postoperative pain, cancer pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, and other forms of neuralgia, neuropathic, and idiopathic pain syndromes.
[0204] Chronic somatic pain generally results from inflammatory responses to tissue injury such as nerve entrapment, surgical procedures, cancer or arthritis (Brower, Nature Biotechnology 2000; 18: 387-391).
[0205] The inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances (Levine, Inflammatory Pain, In: Textbook of Pain, Wall and Melzack eds., 3rd ed., 1994). Inflammation often occurs at the site of injured tissue, or foreign material, and contributes to the process of tissue repair and healing. The cardinal signs of inflammation include erythema (redness), heat, edema (swelling), pain and loss of function (ibid.). The majority of patients with inflammatory pain do not experience pain continually, but rather experience enhanced pain when the inflamed site is moved or touched. Inflammatory pain includes, but is not limited to, that associated with osteoarthritis and rheumatoid arthritis.
[0206] Chronic neuropathic pain is a heterogenous disease state with an unclear etiology. In chronic neuropathic pain, the pain can be mediated by multiple mechanisms. This type of pain generally arises from injury to the peripheral or central nervous tissue. The syndromes include pain associated with spinal cord injury, multiple sclerosis, post-herpetic neuralgia, trigeminal neuralgia, phantom pain, causalgia, and reflex sympathetic dystrophy and lower back pain. Chronic pain is different from acute pain in that patients suffer the abnormal pain sensations that can be described as spontaneous pain, continuous superficial burning and/or deep aching pain. The pain can be evoked by heat-, cold-, and mechano-hyperalgesia or by heat-, cold-, or mechano-allodynia.
[0207] Neuropathic pain can be caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to, pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiences. Stroke (spinal or brain) and spinal cord injury can also induce neuropathic pain. Cancer-related neuropathic pain results from tumor growth compression of adjacent nerves, brain, or spinal cord. In addition, cancer treatments, including chemotherapy and radiation therapy, can also cause nerve injury. Neuropathic pain includes but is not limited to pain caused by nerve injury such as, for example, the pain from which diabetics suffer.
[0208] The present invention is also directed to the use of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating a disorder responsive to the blockade of calcium channels (e.g., any of the disorders listed above) in an animal suffering from said disorder. In one embodiment, the disorder is responsive to the selective blockade of N-type calcium channels.
[0209] Furthermore, the present invention is directed to a method of modulating calcium channels, especially N-type calcium channels, in an animal in need thereof, said method comprising administering to the animal at least one compound represented by any defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
[0210] The present invention is also directed to the use of a compound represented by any of defined Formulae I-XII, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament, in particular a medicament for modulating calcium channels, especially N-type calcium channels, in an animal in need thereof.
Synthesis of Compounds
[0211] The compounds of the present invention can be prepared using methods known to those skilled in the art in view of this disclosure. For example, compounds of Formula I where n, X, Z, R1, R2, R8, R9, and m are as described above, can be prepared as shown in Scheme 1. Additional methods of synthesis are described and illustrated in the working examples set forth below.
Scheme 1
Figure imgf000044_0001
Figure imgf000044_0002
Testing of Compounds
[0212] Representative compounds of the present invention were assessed by calcium mobilization and/or electrophysiological assays for calcium channel blocker activity. One aspect of the present invention is based on the use of the compounds herein described as N-type calcium channel blockers. In one aspect of the present invention, it has been found that certain compounds herein described show selectivity as N-type calcium channel blockers. Based upon this property, these compounds are considered useful in treating stroke, neuronal damage resulting from head trauma, migraine, epilepsy, a mood disorder, schizophrenia, a neurodegenerative disorder (such as, e.g., Alzheimer's disease, ALS, or Parkinson's disease), a psychosis, depression, anxiety, hypertension, or cardiac arrhythmia. The compounds of the present invention are also expected to be effective in treating pain, such as acute pain, chronic pain, which includes but is not limited to neuropathic pain and inflammatory pain, or surgical pain.
[0213] More specifically, the present invention is directed to compounds of Formulae
I-XII that are blockers of calcium channels. According to the present invention, those compounds having preferred N-type calcium channel blocking properties exhibit an IC50 of about 100 μM or less in the calcium mobilization and/or electrophysiological assays described herein. Preferably, the compounds of the present invention exhibit an IC50 of 10 μM or less. More preferably, the compounds of the present invention exhibit an IC50 of about 6 μM or less. Most preferably, the compounds of the present invention exhibit an IC50 of about 1.0 μM or less. Compounds of the present invention can be tested for their N-type and L-type Ca2+ channel blocking activity by the following calcium mobilization and/or electrophysiological assays.
[0214] In one embodiment, compounds useful in the present invention are those represented by any one of Formulae I-XII that exhibit selectivity for N-type calcium channels over L-type calcium channels in the calcium mobilization and/or electrophysiological assays described herein. The phrase "selectivity for N-type calcium channels over L-type calcium channels" is used herein to mean that the ratio of an IC5o for L-type channel blocking activity for a compound of the present invention over an IC50 for N-type channel blocking activity for the same compound is more than 1, i.e., LTCC IC50 / NTCC IC5O > 1. Preferably, compounds of the present invention exhibit an LTCC IC5O / NTCC IC50 ratio of about 2 or more, about 10 or more, about 20 or more, about 30 or more, about 50 or more, or about 100 or more. Calcium Mobilization and Electrophysiological Assay Protocols:
[0215] Cell maintenance and differentiation. Unless noted otherwise, cell culture reagents were purchased from Mediatech of Herndon, MD. IMR32 cells (American Type Culture Collection, ATCC, Manassas, VA) were routinely cultured in growth medium consisting of minimum essential medium containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L- glutamine, 1 mM sodium pyruvate, and Ix MEM non-essential amino acids. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: Growth medium plus 1 mM dibutyryl cyclic AMP (Sigma, St. Louis, MO), and 2.5 μM bromodeoxyuridine (Sigma). Cells were differentiated for 8 days by replacing differentiation medium every 2-3 days.
[0216] A7r5 (ATCC) cells were maintained and routinely cultured in A7r5 growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 4 mM L-glutamine, and 0.15% sodium bicarbonate. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: A7r5 Growth Medium plus 1 mM dibutyryl cyclic AMP (Sigma). Cells were differentiated for 8 days by replacing differentiation medium every 2-3 days.
[0217] Recombinant human embryonal kidney cells (HEK293, ATCC) stably transfected with either N-type calcium channel (NTCC) subunits (αlb, α2δ, and β3) or L-type calcium channel (LTCC) subunits (αlc, α2δ, and βl) were routinely cultured in growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 4 mM L-glutamine, 500 μg/mL geneticin (G418), 20 μg/mL Blasticidin S (InVivogen, San Diego, CA) and 500 μg/mL zeocin (InVivogen).
[0218] FLIPR Calcium Mobilization Assay for N-type Calcium Channel. One day prior to performing this assay, differentiated IMR32 cells were treated with Ix CellStripper, and seeded on poly-D-lysine-coated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at 200,000 cells/well. On the day of the assay, the cell plates were washed with IMR32 buffer (127 mM NaCl, 1 mM KCl, 2 mM MgCl2, 700 μM NaH2PO4, 5 mM CaCl2, 5 mM NaHCO3, 8 mM HEPES, 10 mM glucose, pH 7.4), then pre-stimulated with KCl and loaded as follows: 0.05 mL of IMR32 buffer, 0.05 mL of each compound tested diluted in IMR32 buffer containing 20 μM nitrendipine (Sigma), and 0.1 mL KCl dissolved in IMR32 buffer, plus Fluo-4 were added (3 μM final concentration, Molecular Probes, Eugene, OR). Final test compound concentrations ranged from about 846 pM to about 17 μM, final nitrendipine concentration was 5 μM, and final KCl concentration was 90 mM. After 1 hour, the cells were washed twice with 0.05 mL of each compound tested in nitrendipine- containing IMR32 buffer (no KCl or Fluo-4), and then replaced with 0.1 mL of each compound tested in nitrendipine-containing IMR32 buffer. Plates were then transferred to a Fluorimetric Imaging Plate Reader (FLIPR96, Molecular Devices, Inc., Sunnyvale, CA) for assay. The FLIPR measured basal Fluo-4 fluorescence for 315 seconds (i.e., 5 minutes and 15 seconds), then added 0.1 mL KCl agonist dissolved in IMR32 buffer and measured fluorescence for another 45 seconds. Final test compound concentrations on the cells after FLIPR read ranged from about 846 pM to about 17 μM, final nitrendipine concentration was 5 μM, and final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism (version 3.02, Graph Pad, San Diego, CA), or an in-house non-linear regression analysis software. FLIPR Calcium Mobilization Assay for L-type Calcium Channel. One day prior to performing this assay, HEK293 cells stably expressing recombinant rat L-type calcium channel (LTCC) subunits (αlc, α2δ, and βl) were trypsinized, then seeded on poly-D-lysine-coated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at 75,000 cells/well. On the day of the assay, the plates were washed with LTCC wash buffer (127 mM NaCl, 2 mM MgCl2, 700 μM NaH2PO4, 5 mM CaCl2, 5 mM NaHCO3, 8 mM HEPES, 10 mM glucose, pH 7.4), then loaded with 0.1 mL of LTCC wash buffer containing Fluo-4 (3 μM final concentration, Molecular Probes, Eugene, OR). After 1 hour, the cells were washed with 0.1 mL LTCC wash buffer and resuspended in 0.05 mL LTCC assay buffer (same composition as LTCC wash buffer). Plates were then transferred to a FLIPR96 for assay. The FLEPR measured basal Fluo-4 fluorescence for 15 seconds, then added 0.05 mL of each compound tested diluted in LTCC assay buffer at final concentrations ranging from about 846 pM to about 17 μM. Fluo-4 fluorescence was then measured for 5 minutes. 0.1 mL KCl agonist dissolved in LTCC assay buffer was then added to the cells to produce a final concentration of 90 mM KCl, and fluorescence was measured for another 45 seconds. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or an in-house regression analysis software.
[0220] Alternative FLIPR Calcium Mobilization Assay for L-type Calcium Channel.
Alternatively, the following cell line and procedure may be used for the FLIPR calcium mobilization assay for L-type calcium channel. One day prior to performing this assay, differentiated A7r5 cells are trypsinized, then seeded on tissue culture treated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at a dilution of 1 : 1 from a confluent Tl 50 cm2 flask. On the day of the assay, the plates are washed with A7r5 wash buffer (127 mM NaCl, 2 mM MgCl2, 700 μM NaH2PO4, 5 mM CaCl2, 5 mM NaHCO3, 8 mM HEPES, 10 mM glucose, pH 7.4), then loaded with 0.1 mL of A7r5 wash buffer containing Fluo-4 (3 μM final concentration, Molecular Probes, Eugene, OR). After 1 hour, the cells are washed with 0.1 mL A7r5 wash buffer and resuspended in 0.05 mL A7r5 assay buffer that is composed of A7r5 wash buffer plus 50 μM valinomycin (Sigma). Plates are then transferred to a FLIPR96 for assay. The FLIPR measures basal Fluo-4 fluorescence for 15 seconds, then adds 0.05 mL of each compound tested diluted in A7r5 assay buffer at final concentrations ranging from about 846 pM to about 17 μM. Fluo-4 fluorescence is then measured for 5 minutes. 0.1 mL KCl agonist dissolved in A7r5 assay buffer is then added to the cells to produce a final concentration of 90 mM KCl, and fluorescence was measured for another 45 seconds. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or an in-house regression analysis software.
[0221] Cloning of N- and L-type calcium channel subunit open reading frame cDNAs.
Five cDNAs encoding subunits of the rat N- or L-type calcium channels were cloned by PCR amplification in order to reconstitute functional channels in a heterologous system. These were the alphalb (αlb), betal (βl), beta3 (β3), alpha2delta (α2δ), and alphalc (αlc) subunit cDNAs. The alphalb subunit cDNA has been described by Dubel et al. in Proc. Natl. Acad. Sci. U.S.A 89: 5058-5062 (1992). The betal subunit cDNA has been described by Pragnell et al. in FEBS Lett. 291: 253-258 (1991). The beta3 subunit cDNA has been described by Castellano et al. in J. Biol. Chem. 268: 12359-12366 (1993). The alpha2delta subunit cDNA has been described by Kim et al. in Proc. Natl. Acad. ScL U.S.A. 89: 3251-3255 (1992). The alphalc subunit cDNA has been described by Koch et al in J. Biol. Chem. 265: 17786-17791 (1990).
[0222] The 7.0 kb cDNA containing the entire αlb open reading frame (ORF) was
PCR amplified as two overlapping cDNA fragments, i.e., a 2.7 kb 5' fragment and a 4.4 kb 3' fragment. The 5' fragment was amplified from rat brain cDNA using primers 1 (SEQ ID NO:1, TABLE 1) and 2 (SEQ ID NO:2, TABLE 1), and the 3' fragment was amplified from rat spinal cord cDNA using primers 3 (SEQ ID NO:3, TABLE 1) and 4 (SEQ ID NO:4, TABLE 1). The two fragments were joined by ligation at a common restriction site to create the entire 7.0 kb cDNA. This ORF encodes the protein isoform generated by alternative splicing termed "+A ΔSFMG ΔET" according to the nomenclature of Lin et al. {Neuron 18: 153-166 (1997)). The entire cDNA was sequenced with redundant coverage on both strands. The cDNA was then inserted into the mammalian expression vector pcDNA6.2DEST (Invitrogen, Carlsbad CA) by homologous recombination using the Gateway system (Invitrogen).
[0223] The 1.8 kb cDNA encoding the βl subunit, the 1.45 kb cDNA encoding the beta3 subunit, and the 3.3 kb cDNA encoding the alpha2delta subunit were cloned by PCR amplification from rat spinal cord cDNA (βl) or brain cDNA (β3, α2δ). Primers 5 (SEQ ID NO:5, TABLE 1) and 6 (SEQ ID NO:6, TABLE 1) were used for the βl cDNA amplification; primers 7 (SEQ ED NO:7, TABLE 1) and 8 (SEQ ID NO:8, TABLE 1) were used for the β3 cDNA amplification; and primers 9 (SEQ ID NO:9, TABLE 1) and 10 (SEQ ID NO: 10, TABLE 1) were used for the α2δ cDNA amplification. PCR products were subcloned and fully sequenced on both strands. Clones matching the reference sequence (βl : NM_017346; β3: NM_012828; α2δ: M86621) and the gene's GenBank rat genomic DNA sequences were recombined into the mammalian expression vector pcDNA3.2DEST (βl, β3) or pcDNA3.1-Zeo (α2δ), which had been modified to a vector compatible with the Gateway recombination system using the Gateway vector adaptor kit (Invitrogen). Proper recombination was confirmed by sequencing of recombino genie regions. For β3 expression vector, proper protein expression was confirmed by Western blot analysis of lysates of transfected HEK293 cells using a rabbit polyclonal antiserum directed against the rat β3 subunit (USA Biological). [0224] The 6.5 kb cDNA encoding the L-type calcium channel αlc subunit was cloned by PCR amplification from rat heart cDNA using primers 11 (SEQ ID NO:11, TABLE 1) and 12 (SEQ ID NO: 12, TABLE 1). The PCR fragment was subcloned and fully sequenced on both strands to confirm its identity. A clone matching consensus reference sequence AF394939 and rat genomic DNA sequences was recombined into the mammalian expression vector pcDNA6.2DEST. Sequences around the recombinogenic region were sequenced to confirm accurate recombination into the expression vector.
TABLE 1
Figure imgf000050_0001
[0225] N-type Recombinant Cell Line Development. N-type calcium channel expressing HEK-293 cells were created in two stages. Stage 1 was created as follows. The rat αlb, and β3 cDNA expression constructs (2.5 μg each) were co-transfected into human embryonic kidney (HEK-293) cells by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μg/mL blasticidin and 500 μg/mL geneticin, and incubated for 3 weeks at 37 0C, 5 % CO2, 95 % humidity. Plates containing < 1 clone per well were cultured until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate, and partly split into 6-well plates for culture maintenance. Array plates were washed once with EMR32 buffer and cells loaded for 1 hour with 0.1 mL of IMR32 buffer containing Fluo-4 (3 μM final concentration, Molecular Probes). Then they were washed twice with 0.1 mL of IMR32 buffer, and replaced with 0.1 mL IMR32 buffer. Plates were then transferred to a FLEPR96 for assay. The FLEPR measured basal Fluo-4 fluorescence for 315 seconds, then added 0.1 mL KCl agonist dissolved in EMR32 buffer and measured fluorescence for another 45 seconds. Final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base (version 5.1, EDBS, Parsippany, NJ) software. The clone with the greatest signal-to-noise ratio, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) was expanded, characterized and used for stage 2 cell line development.
[0226] Stage 2 of N-type cell line development was carried out as follows. The rat α2δ cDNA expression construct (5 μg each) was transfected into the stage 1 N-type clonal cell line by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μg/mL blasticidin, 500 μg/mL geneticin, and 250 μg/mL zeocin and incubated for 3 weeks at 37°C, 5% CO2, 95% humidity. Plates containing < 1 clone per well were cultured and handled according to the same steps and procedures described above for the stage 1 cell line. The three clones with the greatest signal-to- noise, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) were expanded, characterized and tested in electrophysiology for the best current size, N-type pharmacology, N-type characteristic current-voltage relationship and kinetics as described below.
[0227] L-type Recombinant Cell Line Development. L-type calcium channel expressing HEK-293 cells were created in two stages. Stage 1 was created as follows. The rat αlc, and βl cDNA expression constructs (2.5 μg each) were co-transfected into human embryonic kidney (HEK-293) cells by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μg/mL blasticidin and 500 μg/mL geneticin, and incubated for 3 weeks at 37 °C, 5 % CO2, 95 % humidity. Plates containing < 1 clone per well were cultured until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate, and partly split into 6-well plates for culture maintenance. Array plates were washed once with LTCC wash (or assay) buffer and cells loaded for 1 hour with 0.1 mL of LTCC buffer containing Fluo-4 (3 μM final concentration, Molecular Probes). Then they were washed twice with 0.1 mL of LTCC buffer, and replaced with 0.1 mL LTCC buffer. Plates were then transferred to a FLIPR96 for assay. The FLIPR measured basal Fluo-4 fluorescence for 315 seconds, then added 0.1 mL KCl agonist dissolved in LTCC buffer and measured fluorescence for another 45 seconds. Final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base software. The clone with the greatest signal-to-noise ratio, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) was expanded, characterized and used for stage 2 cell line development.
[0228] Stage 2 of L-type cell line development was carried out as follows. The rat α2δ cDNA expression construct (5 μg each) was transfected into the stage 1 L-type clonal cell line by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μg/mL blasticidin, 500 μg/mL geneticin, and 250 μg/mL zeocin and incubated for 3 weeks at 37°C, 5% CO2, 95% humidity. Plates containing < 1 clone per well were cultured and handled according to the same steps and procedures described above for the stage 1 cell line. The three clones with the greatest signal-to- noise, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) were expanded and characterized.
[0229] N-type Electrophysiology in Recombinant Cells. For electrophysiological recording, the cells expressing αlb, β3 and α2δ subunits were seeded on 35-mm culture Petri dishes at a density of approximately 104 cells/dish and kept in an incubator for up to three days for subsequent recordings. For recordings, the dishes were positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised OfBaCl2 (11 mM), MgCl2 (1.5 mM), HEPES (1O mM), TEA chloride (12O mM), glucose (1O mM) adjusted to pH 7.4 with KOH. Whole-cell voltage-clamp recordings were made using conventional patch-clamp techniques (Hamill et al., Pfluegers Arch. 391 : 85-100 (1981)) at room temperature (22-24 0C). The patch-clamp pipettes were pulled from WPI, thick-walled borosilicate glass (WPI, Sarasota, FL). Currents were recorded using an Axopatch 200A amplifier (Axon Instruments, Union City, CA) and were leak-subtracted (P/4), low-pass filtered (1 kHz, 4-pole Bessel), digitized (20-50-μs intervals), and stored using Digidata 1200 B interface and Pclampδ.O/Clampex software (Axon Instruments, Union City, CA). The pipettes were back-filled with internal solution containing CsCl (HOmM), MgCl2 (3 mM), EGTA (3 mM), HEPES (40 mM), Mg-ATP (4 mM), Na2GTP (0.5 mM), and adjusted to pH 7.2 with CsOH. The pipette resistance ranged from 2 to 3 MOhm and was compensated by 75-80 % by the built-in electronic circuitry.
[0230] Currents were elicited by stepping from a holding potential of -90 mV to 0 mV for 20 ms every 20 sec. At the -90 mV membrane voltage about 50% of channels were in the inactivated state, and thus contact with a blocker would involve interaction with both resting and inactivated channels. Every drug was applied at 3 to 4 concentrations increasing in a cumulative manner. Fractional inhibition levels in steady-state were used to draw the partial inhibition concentration curves to get the IC50 (i.e. concentration causing 50% reduction in the size of the response) values at -90 mV.
[0231] Stock solutions of each test compound were prepared using DMSO. Serial dilutions to desired concentrations were done with bath solution; concentration of DMSO in final solutions was 0.1 %. Drugs were applied by gravity flow using a plane multi-barrel array shooter positioned 0.5 mm apart from the cell.
[0232] All curve fittings were carried out using Origin software (version 5.0, Microcal).
A Hill equation was fit to the concentration-inhibition curves to determine IC50 values.
[0233] N-type Electrophysiology in Neuronal Cells. To determine dissociation constants in resting versus inactivated state for N-type calcium channels, neuronal cells that endogenously express N-type calcium channels can be used. For electrophysiological recording, the neuronal cells expressing N-type calcium channels are seeded on 35-mm culture Petri dishes at a density of approximately 104 cells/dish and kept in an incubator for up to three days for subsequent recordings. For recordings, the dishes are positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised of BaCl2 (11 mM), MgCl2 (1.5 mM), HEPES (10 mM), TEA chloride (120 mM), glucose (10 mM) adjusted to pH 7.4 with KOH. Whole-cell voltage-clamp recordings are made using conventional patch-clamp techniques (Hamill et al., Pfluegers Arch. 391 : 85-100 (1981)) at room temperature (22-24 0C). The patch-clamp pipettes are pulled from WPI, thick-walled borosilicate glass (WPI, Sarasota, FL). Currents are recorded using an Axopatch 200A amplifier (Axon Instruments, Union City, CA) and leak-subtracted (P/4), low-pass filtered (1 kHz, 4-pole Bessel), digitized (20-50-μs intervals), and stored using Digidata 1200 B interface and Pclampδ.O/Clampex software (Axon Instruments, Union City, CA). The pipettes are back-filled with internal solution containing CsCl (HOmM), MgCl2 (3 mM), EGTA (3 mM), HEPES (40 mM), Mg-ATP (4 mM), Na2GTP (0.5 mM), and adjusted to pH 7.2 with CsOH. The pipette resistance ranges from 2 to 3 MOhm and is compensated by 75-80 % by the built-in electronic circuitry.
[0234] Currents are elicited by stepping from a holding potential of -90 mV to 0 mV for 20 ms every 10 sec. At the —90 mV membrane voltage a proportion of channels is in the inactivated state, and thus contact with a blocker would involve interaction with both resting and inactivated channels. This protocol is used as a first tier screen. For dissection of two components of inhibition (resting block with the apparent dissociation constant Kr and inactivated state block with K1), steady-state inactivation curves are collected using a double-pulse protocol. Three-second long depolarizing pre-pulse incrementing in 10 mV steps is followed by a 10 ms test pulse to 0 mV.
[0235] Stock solutions of each test compound are prepared using DMSO. Serial dilutions to desired concentrations are done with bath solution; concentration of DMSO in final solutions is 0.1 %. Drugs are applied by gravity flow using a plane multi-barrel array shooter positioned ~1 mm apart from the cell.
[0236] All curve fittings can be carried out using Origin software (version 5.0,
Microcal). A Hill equation is used to fit the concentration-response curves and to determine IC50 values. A Boltzman equation is used to fit inactivation curves, returning half-inactivation voltage, Vo 5, slope p and the amplitude of current at the most negative voltage where eventually all channels are in the resting state. These parameters are used to calculate the apparent dissociation constants: Kr = ((Ab/Ac)/(l-(Ab/Ac))*[b]) where [b] is the drug concentration, Ac is the maximum test current amplitude in control conditions and Ab is the maximum test current amplitude in the presence of a blocker; K; = [b]/((exp(-(dx/p))*(l+([b]/Kr)) - 1) where dx is the difference between half-inactivation voltage V0 5 in the presence and absence of drug and p is the slope.
In vivo Pharmacology
[0237] The compounds of the present invention can be tested for in vivo anticonvulsant activity after i.v., p.o., or i.p. injection using any of a number of anticonvulsant tests in mice, including the maximum electroshock seizure test (MES). Maximum electroshock seizures are induced in male NSA mice weighing between 15-20 g and in male Sprague-Dawley rats weighing between 200-225 g by application of current (for mice: 50 mA, 60 pulses/sec, 0.8 msec pulse width, 1 sec duration, D. C; for rats: 99 mA, 125 pulses/sec, 0.8 msec pulse width, 2 sec duration, D. C.) using a Ugo Basile ECT device (Model 7801). Mice are restrained by gripping the loose skin on their dorsal surface and saline-coated corneal electrodes are held lightly against the two corneae. Rats are allowed free movement on the bench top and ear-clip electrodes are used. Current is applied and animals are observed for a period of up to 30 seconds for the occurrence of a tonic hindlimb extensor response. A tonic seizure is defined as a hindlimb extension in excess of 90 degrees from the plane of the body. Results can be treated in a quantal manner.
[0238] The compounds can be tested for their antinociceptive activity in the formalin model as described in Hunskaar, S., O. B. Fasmer, and K. Hole, J. Neurosci. Methods 14: 69-76 (1985). Male Swiss Webster NIH mice (20-30 g; Harlan, San Diego, CA) can be used in all experiments. Food is withdrawn on the day of experiment. Mice are placed in Plexiglass jars for at least 1 hour to acclimate to the environment. Following the acclimation period mice are weighed and given either the compound of interest administered i.p. or p.o., or the appropriate volume of vehicle (for example, 10 % Tween-80 or 0.9 % saline, and other pharmaceutically acceptable vehicles) as control. Fifteen minutes after the i.p. dosing, and 30 minutes after the p.o. dosing mice are injected with formalin (20 μL of 5% formaldehyde solution in saline) into the dorsal surface of the right hind paw. Mice are transferred to the Plexiglass jars and monitored for the amount of time spent licking or biting the injected paw. Periods of licking and biting are recorded in 5-minute intervals for 1 hour after the formalin injection. All experiments are done in a blinded manner during the light cycle. The early phase of the formalin response is measured as licking / biting between 0-5 minutes, and the late phase is measured from 15-50 minutes. Differences between vehicle and drug treated groups can be analyzed by one-way analysis of variance (ANOVA). A P value <0.05 is considered significant. Compounds are considered to be efficacious for treating acute and chronic pain if they have activity in blocking both the early and second phase of formalin-induced paw-licking activity.
[0239] Compounds can be tested for their potential to treat chronic pain (i.e., antiallodynic and antihyperalgesic activities) using the Chung model of peripheral neuropathy (Kim and Chung, Pain 50: 355-363 (1992)). Male Sprague-Dawley rats weighing between 200-225 g are anesthetized with halothane (1-3 % in a mixture of 70 % air and 30 % oxygen), and their body temperature controlled during anesthesia through use of a homeothermic blanket. A 2-cm dorsal midline incision is then made at the L5 and L6 level, and the para-vertebral muscle groups retracted bilaterally. L5 and L6 spinal nerves are then exposed, isolated, and tightly ligated with 6-0 or 7-0 silk suture. A sham operation is performed exposing the contralateral L5 and L6 spinal nerves, without ligating, as a negative control.
[0240] Tactile Allodynia: Sensitivity to non-noxious mechanical stimuli can be measured in animals to assess tactile allodynia. Rats are transferred to an elevated testing cage with a wire mesh floor and allowed to acclimate for five to ten minutes. A series of von Frey monofilaments are applied to the plantar surface of the hindpaw to determine the animal's withdrawal threshold. The first filament used possesses a buckling weight of 9.1 gms (.96 log value) and is applied up to five times to see if it elicits a withdrawal response. If the animal has a withdrawal response, then the next lightest filament in the series would be applied up to five times to determine if it also could elicit a response. This procedure is repeated with subsequent lesser filaments until there is no response and the identity of the lightest filament that elicits a response is recorded. If the animal does not have a withdrawal response from the initial 9.1 gms filament, then subsequent filaments of increased weight are applied until a filament elicits a response and the identity of this filament is recorded. For each animal, three measurements are made at every time point to produce an average withdrawal threshold determination. Tests can be performed prior to, and at 1, 2, 4 and 24 hours post drug administration. [0241] Mechanical Hyperalgesia: Sensitivity to noxious mechanical stimuli can be measured in animals using the paw pressure test to assess mechanical hyperalgesia, hi rats, hind paw withdrawal thresholds ("PWT"), measured in grams, in response to a noxious mechanical stimulus are determined using an analgesymeter (Model 7200, commercially available from Ugo Basile of Italy), as described in Stein (Biochemistry & Behavior 31: 451-455 (1988)). The rat's paw is placed on a small platform, and weight is applied in a graded manner up to a maximum of 250 grams. The endpoint is taken as the weight at which the paw is completely withdrawn. PWT is determined once for each rat at each time point. PWT can be measured only in the injured paw, or in both the injured and non-injured paw. In one non-limiting embodiment, mechanical hyperalgesia associated with nerve injuty induced pain (neuropathic pain) can be assessed in rats. Rats are tested prior to surgery to determine a baseline, or normal, PWT. Rats are tested again 2 to 3 weeks post-surgery, prior to, and at different times after (e.g. 1, 3, 5 and 24 hr) drug administration. An increase in PWT following drug administration indicates that the test compound reduces mechanical hyperalgesia.
Pharmaceutical Compositions
[0242] Although a compound of the present invention may be administered to a mammal in the form of a raw chemical without any other components present, the compound is preferably administered as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier. Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.
[0243] Pharmaceutical compositions within the scope of the present invention include all compositions where a compound of the present invention is combined with a pharmaceutically acceptable carrier. In a preferred embodiment, the compound is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art. Typically, the compounds may be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt, prodrug, or solvate thereof, per day to treat, prevent or ameliorate the particular disorder. A useful oral dose of a compound of the present invention administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt, prodrug, or solvate thereof. For intramuscular injection, the dose is typically about one-half of the oral dose.
[0244] A unit oral dose may comprise from about 0.01 to about 50 mg, and preferably about 0.1 to about 10 mg, of the compound. The unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 to about 50 mg of the compound, or an equivalent amount of a pharmaceutically acceptable salt, prodrug or solvate thereof.
[0245] A pharmaceutical composition of the present invention can be administered to any animal that may experience the beneficial effects of a compound of the present invention. Foremost among such animals are mammals, e.g., humans and companion animals, although the invention is not intended to be so limited.
[0246] A pharmaceutical composition of the present invention can be administered by any means that achieves its intended purpose. For example, administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation. The dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
[0247] In one embodiment, a pharmaceutical composition of the present invention can be administered orally and is formulated into tablets, dragees, capsules or an oral liquid preparation. In one embodiment, the oral formulation comprises extruded multiparticulates comprising the compound of the invention.
[0248] Alternatively, a pharmaceutical composition of the present invention can be administered rectally, and is formulated in suppositories.
[0249] Alternatively, a pharmaceutical composition of the present invention can be administered by injection. [0250] Alternatively, a pharmaceutical composition of the present invention can be administered transdermally.
[0251] Alternatively, a pharmaceutical composition of the present invention can be administered by inhalation or by intranasal or transmucosal administration.
[0252] Alternatively, a pharmaceutical composition of the present invention can be administered by the intravaginal route.
[0253] A pharmaceutical composition of the present invention can contain from about
0.01 to 99 percent by weight, and preferably from about 0.25 to 75 percent by weight, of active compound(s).
[0254] A method of the present invention, such as a method for treating a disorder responsive to the blockade of calcium channels in an animal in need thereof, can further comprise administering a second therapeutic agent to the animal in combination with a compound of the present invention, hi one embodiment, the other therapeutic agent is administered in an effective amount.
[0255] Effective amounts of the other therapeutic agents are known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective-amount range.
[0256] A compound of the present invention (i.e., the first therapeutic agent) and the second therapeutic agent can act additively or, in one embodiment, synergistically. Alternatively, the second therapeutic agent can be used to treat a disorder or condition that is different from the disorder or condition for which the first therapeutic agent is being administered, and which disorder or condition may or may not be a condition or disorder as defined herein. In one embodiment, a compound of the present invention is administered concurrently with a second therapeutic agent; for example, a single composition comprising both an effective amount of a compound of any of Formulae I- XII, and an effective amount of the second therapeutic agent can be administered. Accordingly, the present invention further provides a pharmaceutical composition comprising a combination of a compound of the present invention, the second therapeutic agent, and a pharmaceutically acceptable carrier. Alternatively, a first pharmaceutical composition comprising an effective amount of a compound of any of Formulae I-XII and a second pharmaceutical composition comprising an effective amount of the second therapeutic agent can be concurrently administered. In another embodiment, an effective amount of a compound of the present invention is administered prior or subsequent to administration of an effective amount of the second therapeutic agent. In this embodiment, the compound of the present invention is administered while the second therapeutic agent exerts its therapeutic effect, or the second therapeutic agent is administered while the compound of the present invention exerts its therapeutic effect for treating a disorder or condition.
[0257] The second therapeutic agent can be an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-II inhibitor, a β-adrenergic blocker, an anticonvulsant, an antidepressant, an anticancer agent, an agent for treating addictive disorder, an agent for treating Parkinson's disease and parkinsonism, an agent for treating anxiety, an agent for treating epilepsy, an agent for treating a seizure, an agent for treating a stroke, an agent for treating a pruritic condition, an agent for treating psychosis, an agent for treating ALS, an agent for treating a cognitive disorder, an agent for treating a migraine, an agent for treating vomiting, an agent for treating dyskinesia, or an agent for treating depression, or a mixture thereof.
[0258] Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.
[0259] In certain embodiments, the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.
[0260] Examples of useful non-opioid analgesics include non-steroidal antiinflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and pharmaceutically acceptable salts thereof, and mixtures thereof. Examples of other suitable non-opioid analgesics include the following, non limiting, chemical classes of analgesic, antipyretic, nonsteroidal antiinflammatory drugs: salicylic acid derivatives, including aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and olsalazin; para aminophennol derivatives including acetaminophen and phenacetin; indole and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (fenamates), including mefenamic acid, and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutazone, oxyphenthartazone); and alkanones, including nabumetone. For a more detailed description of the NSAIDs, see Paul A. Insel, Analgesic Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff and Raymond W. Ruddon eds., 9th ed 1996) and Glen R. Hanson, Analgesic, Antipyretic and Anti Inflammatory Drugs in Remington: The Science and Practice of Pharmacy VoI II 1196-1221 (A.R. Gennaro ed. 19th ed. 1995) which are hereby incorporated by reference in their entireties. Suitable Cox-II inhibitors and 5- lipoxygenase inhibitors, as well as combinations thereof, are described in U.S. Patent No. 6,136,839, which is hereby incorporated by reference in its entirety. Examples of useful Cox II inhibitors include, but are not limited to, rofecoxib and celecoxib.
[0261] Examples of useful antimigraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocryptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserin, lisuride, lomerizine, methylergonovine, methysergide, metoprolol, naratriptan, oxetorone, pizotyline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.
[0262] Examples of useful β-adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulabol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol, moprolol, nadolol, nadoxolol, nebivalol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, sulfinalol, talinolol, tertatolol, tilisolol, timolol, toliprolol, and xibenolol.
[0263] Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5- hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metharbital, methetoin, methsuximide, 5-methyl-5-(3- phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin, narcobarbital, nimetazepam, nitrazepam, oxcarbazepine, paramethadione, phenacemide, phenetharbital, pheneturide, phenobarbital, phensuximide, phenylmethylbarbituric acid, phenytoin, phethenylate sodium, potassium bromide, pregabaline, primidone, progabide, sodium bromide, solanum, strontium bromide, suclofenide, sulthiame, tetrantoin, tiagabine, topiramate, trimethadione, valproic acid, valpromide, vigabatrin, and zonisamide.
[0264] Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S)-citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrocholoride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexiptiline, desipramine, dibenzepin, dimetacrine, dothiepin, doxepin, fluacizine, imipramine, imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, nortriptyline, noxiptilin, opipramol, pizotyline, propizepine, protriptyline, quinupramine, tianeptine, trimipramine, adrafinil, benactyzine, bupropion, butacetin, dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fenpentadiol, fluoxetine, fluvoxamine, hematopoφhyrin, hypericin, levophacetoperane, medifoxamine, milnacipran, minaprine, moclobemide, nefazodone, oxaflozane, piberaline, prolintane, pyrisuccideanol, ritanserin, roxindole, rubidium chloride, sulpiride, tandospirone, thozalinone, tofenacin, toloxatone, tranylcypromine, L-tryptophan, venlafaxine, viloxazine, and zimeldine.
[0265] Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, and cisplatin.
[0266] Therapeutic agents useful for treating an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxypyridine, or a serotonin antagonist.
[0267] Examples of useful therapeutic agents for treating Parkinson's disease and parkinsonism include, but are not limited to, carbidopa/levodopa, pergolide, bromocriptine, ropinirole, pramipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride.
[0268] Examples of useful therapeutic agents for treating anxiety include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam; non-benzodiazepine agents, such as buspirone, gepirone, ipsapirone, tiospirone, zolpicone, Zolpidem, and zaleplon; tranquilizers, such as barbituates, e.g., amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, and thiopental; and propanediol carbamates, such as meprobamate and tybamate. [0269] Examples of useful therapeutic agents for treating epilepsy or seizure include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gamma-vinyl GABA, acetazolamide, and felbamate. [0270] Examples of useful therapeutic agents for treating stroke include, but are not limited to, anticoagulants such as heparin, agents that break up clots such as streptokinase or tissue plasminogen activator, agents that reduce swelling such as mannitol or corticosteroids, and acetylsalicylic acid. [0271] Examples of useful therapeutic agents for treating a pruritic condition include, but are not limited to, naltrexone; nalmefene; danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those given below; menthol; camphor; phenol; pramoxine; capsaicin; tar; steroids; and antihistamines. [0272] Examples of useful therapeutic agents for treating psychosis include, but are not limited to, phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride; thioxanthenes such as chloroprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine; quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone. [0273] Examples of useful therapeutic agents for treating ALS include, but are not limited to, baclofen, neurotrophic factors, riluzole, tizanidine, benzodiazepines such as clonazepan and dantrolene. [0274] Examples of useful therapeutic agents for treating cognitive disorders include, but are not limited to, agents for treating or preventing dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below. [0275] Examples of useful therapeutic agents for treating a migraine include, but are not limited to, sumatriptan; methysergide; ergotamine; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex. [0276] Examples of useful therapeutic agents for treating vomiting include, but are not limited to, 5-HT3 receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron; dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone; and benzodiazepines such as lorazepam and alprazolam.
[0277] Examples of useful therapeutic agents for treating dyskinesia include, but are not limited to, reserpine and tetrabenazine.
[0278] Examples of useful therapeutic agents for treating depression include, but are not limited to, tricyclic antidepressants such as amitryptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, trazodone, trimipramine, and venlafaxine; selective serotonin reuptake inhibitors such as citalopram, (S)-citalopram, fluoxetine, fluvoxamine, paroxetine, and setraline; monoamine oxidase inhibitors such as isocarboxazid, pargyline, phenelzine, and tranylcypromine; and psychostimulants such as dextroamphetamine and methylphenidate.
[0279] A pharmaceutical composition of the present invention is preferably manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes. Thus, pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
[0280] Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropyimethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
[0281] Auxiliaries are typically flow-regulating agents and lubricants such as, for example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol. Dragee cores are provided with suitable coatings that are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate can be used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
[0282] Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain a compound in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin. In addition, stabilizers may be added.
[0283] Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base. Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.
[0284] Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution. Alternatively, a suspension of the active compound may be prepared as an oily suspension. Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400). An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. The suspension may optionally contain stabilizers.
[0285] The following examples are illustrative, but not limiting, of the compounds, compositions and methods of the present invention. Suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art in view of this disclosure are within the spirit and scope of the invention.
Examples
EXAMPLE 1
N-Cyclopropyl-6-(l,2,3,6-tetrahydropyridin-4-yl)picolinamide hydrochloride (5)
Figure imgf000067_0001
[0286] a) To a stirred suspension of compound 1 (500 mg, 3.18 mmol, Aldrich), 1- hydroxybenzotriazole hydrate (HOBt) (430 mg, 3.18 mmol, Aldrich), and N-(3- dimethylaminopropyl)-N'ethylcarbodiimide hydrochloride (EDCI) (672 mg, 3.50 mmol, Aldrich) in dichloromethane was added sequentially diisopropyl ethyl amine (1.1 ml, 6.4 mmol) and cyclopropyl amine (245 μl, 3.5mmol, Aldrich). The resulting mixture was slowly warmed to room temperature and stirred for 12 hours. The crude mixture was purified on CombiFlash® (Teledyne Isco, Inc., Lincoln, Nebraska) with a gradient of 20% to 80% EtOAc in hexane to provide compound 2 as a white solid (483 mg, yield 77%).
[0287] b) The suspension of compound 2 (180 mg, 0.92 mmol), 3,6-dihydro-2H- pyridine-l-tert-butoxycarbonyl-4-boronic acid pinacol ester (3) (284 mg, 0.92 mmol, Carbocore), potassium carbonate (254 mg, 1.84 mmol) and palladium bistriphenylphosphine dichloride (52 mg, 0.07 mmol, Aldrich) in ethyleneglycol dimethylether/ethano I/water in the ratio of 2/1/2 was heated in an oil bath at 95 °C while stirring for 0.5 hour. The crude product was purified without work-up on CombiFlash® with a gradient of 20-40% EtOAc in hexane to provide compound 4 (283 mg, yield 90%).
[0288] c) To a solution of compound 4 (283 mg, 0.83 mmol) in 10 ml of EtO Ac at
0 0C was added 4N HCl in 1 ,4-dioxane (5 ml, 20 mmol) while stirring. The resulting mixture was allowed to warm to room temperature and was stirred for 12 hours. The mixture was concentrated to dryness and then suspended in EtOAc. After filtration and washing with hexane, the title compound 5 was obtained as a solid (HCl salt, 173 mg, yield 85%): 1H NMR (400 MHz, CD3OD): δ 8.01 (m, 2H), 7.82 (m, IH), 6.88 (m, IH), 3.96 (m, 2H), 3.52 (m, 2H), 3.03 (m, 2H), 2.89 (m, IH), 0.87 (m, 2H), 0.69 (m, 2H).
EXAMPLE 2
r-(3-Trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (7)
Figure imgf000068_0001
[0289] Diisopropyl ethyl amine (66 ml, 0.36 mmol) and 3-(trifluoromethyl)benzene sulfonyl chloride (6) (44 mg, 0.18 mmol, Aldrich) were sequentially added to a suspension of compound 5 (50 mg, 0.18 mmol) in dichloromethane at 0 °C while stirring. The reaction was completed within 0.5 hour and the crude product was purified without work-up on CombiFlash® with a gradient of 50-100% EtOAc in hexane to provide the title compound 7 as a white solid (50 mg, yield 64%). 1H NMR (400 MHz, CD3OD): δ 8.15 (m, 2H), 8.02-7.83 (m, 4H), 7.67 (dd, IH, J=I.2, 7.6 Hz), 6.78 (m, IH), 3.92 (m, 2H), 3.45 (m, 2H), 2.87 (m, IH), 2.77 (m, 2H), 0.86 (m, 2H), 0.70 (m, 2H); MS: 452 (M + H+), 474 (M + Na).
[0290] Similarly, the following compounds were prepared by reacting compound 5 with an appropriate reagent (in parenthesis):
[0291] l'-(4-Trifluoromethoxybenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-
6-carboxylic acid cyclopropylamide (4-trifluoromethoxybenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.00 (m, 2H), 7.96 (dd, IH, J=I.2, 7.2 Hz), 7.91 (t, IH, J=7.6 Hz), 7.67 (dd, IH, J=1.2, 7.2 Hz), 7.54 (m, 2H), 6.771 (m, IH), 3.89 (m, 2H), 3.42 (m, 2H), 2.87 (m, IH), 2.78 (m, 2H), 0.87 (m, 2H), 0.70 (m, 2H); MS: 468 (M + H+), 490 (M + Na).
[0292] l'-(3-Chlorobenzenesulfonyl)-lI,2l,3',6t-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (3-chlorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.74-7.86 (m, 3H), 7.70 (m, IH), 7.47-7.60 (m, 3H), 6.65 (m, IH), 3.77 (m, 2H), 3.30 (m, 2H), 2.74 (m, IH), 2.65 (m, 2H), 0.74 (m, 2H), 0.59 (m, 2H); MS: 418 (M + H+), 440 (M + Na).
[0293] l'-(2-Trifluoromethylbenzenesulfonyl)-ll,2',31,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (2-trifluoromethylbenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.07 (dd, IH, J=7.2, 1.6 Hz), 7.89 (dd, IH, J=I.6, 7.6 Hz), 7.86 (dd, IH, J=I.2, 7.6 Hz), 7.81 (t, IH, J=7.6 Hz), 7.74 (m, 2H), 7.60 (dd, IH, J=1.2, 7.6 Hz), 6.71 (m, IH), 3.95 (m, 2H), 3.51 (t, 2H, J=5.6 Hz), 2.76 (m, IH), 2.68 (m, 2H), 0.73 (m, 2H), 0.60 (m, 2H); MS: 452 (M + H+), 475 (M + Na).
[0294] l1-(4-Trifluoromethylbenzenesulfonyl)-lt,2',3I,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (4-trifluoromethylbenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.96 (d, 2H, J=8.4 Hz), 7.84 (d, 2H, J=7.6 Hz), 7.79 (t, IH, J=7.6 Hz), 7.55 (dd, IH, J=I.2, 7.6 Hz), 6.65 (m, IH), 3.80 (m, 2H), 3.32 (t, 2H, J=5.6 Hz), 2.75 (m, IH), 2.67 (m, 2H), 0.76 (m, 2H), 0.56 (m, 2H); MS: 452 (M + H+), 474 (M + Na).
[0295] l1-(4-Fluorobenzenesulfonyl)-l',2I,31,6l-tetrahydro-[2,4t]bipyridinyl-6- carboxylic acid cyclopropylamide (4-fluorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.77 -7.86 (m, 4H), 7.56 (dd, IH, J=8, 1.2 Hz), 7.26 (m, 2H), 6.65 (m, IH), 3.75 (m, 2H), 3.26 (t, 2H, J=5.6 Hz), 2.75 (m, IH), 2.67 (m, 2H), 0.75 (m, 2H), 0.60 (m, 2H); MS: 402 (M + H+), 424 (M + Na).
[0296] l'-(3-Cyanobenzenesulfonyl)-l',2',3',6I-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (3-cyanobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.15 (m, IH), 8.05 (dt, IH, J=1.6, 7.6 Hz), 7.92 (dt, IH, J=1.2, 8 Hz), 7.84 (d, IH, J=7.6 Hz), 7.79 (t, IH, J=7.6 Hz), 7.70 (t, IH, J=8 Hz), 7.56 (dd, IH, J=8, 0.8 Hz), 6.67 (m, IH), 3.81 (m, 2H), 3.31 (t, 2H, J=5.6 Hz), 2.75 (m, IH), 2.66 (m, 2H), 0.73 (m, 2H), 0.59 (m, 2H); MS: 409 (M + H+), 431 (M + Na).
[0297] 1 '-Dimethylsulfamoyl- 1 ',21,31,6'-tetrahydro-[2,4l]bipyridinyl-6-carboxylic acid cyclopropylamide (N,N'-dimethylaminosulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.95 (dd, IH, J=0.8, 8 Hz), 7.90 (t, IH, J=7.6 Hz), 7.69 (dd, IH, J=7.6, 1.2 Hz), 6.81 (m, IH), 3.99 (m, 2H), 3.52 (t, 2H, J=6 Hz), 2.89 (m, IH), 2.85 (s, 6H), 2.77 (m, 2H), 0.84 (m, 2H), 0.71 (m, 2H); MS: 351 (M + H+), 373 (M + Na).
[0298] l'-(3,3,3-Trifluoropropylsulfonyl)-l',2I,3',6I-tetrahydro-[2,41]bipyridinyl-6- carboxylic acid cyclopropylamide (3,3,3-trifluoropropylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.86 (dd, IH, J=I .2, 7.6 Hz), 7.81 (t, IH, J=8 Hz), 7.61 (dd, IH, J=I.2, 7.6 Hz), 6.74 (m, IH), 3.99 (m, 2H), 3.50 (t, 2H, J=5.6 Hz), 3.25 (m, 4H), 2.76 (m, IH), 2.71 (m, 2H), 2.61 (m, 2H), 0.78 (m, 2H), 0.61 (m, 2H); MS: 404 (M + H+), 426 (M + Na).
[0299] ll-Cyclohexylsulfonyl-l',2',3',6'-tetrahydro-[2,41]bipyridinyl-6-carboxylic acid cyclopropylamide (cyclohexylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.85 (dd, IH, J=1.2, 7.6 Hz), 7.80 (t, IH, J=7.6 Hz), 7.59 (dd, IH, J=1.2, 7.6 Hz), 6.71 (m, IH), 3.99 (m, 2H), 3.49 (t, 2H, J=5.6 Hz), 3.02 (tt, IH, J=3.2, 12 Hz), 2.76 (m, IH), 2.65 (m, 2H), 2.03 (d, IH, J=12 Hz), 1.75 (dt, IH, J=13, 3.2 Hz), 1.60 (d, IH, J=12 Hz), 1.42 (m, 2H), 1.22 (m, 2H), 1.13 (m, IH), 0.74 (m, 2H), 0.61 (m, 2H); MS: 390 (M + H+), 412 (M + Na).
[0300] l1-(2,4-Dichlorobenzenesulfonyl)-lI,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (2,4-dichlorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 80.7 (id, IH, J=8.8 Hz), 7.94 (dd, IH, J=8, 1.2 Hz), 7.89 (t, IH, J=8 Hz), 7.68 (d, IH, J= 2), 7.67 (dt, IH, J=I.2, 7.6 Hz), 7.54 (dd, IH, J=2, 8.4 Hz), 6.79 (m, IH), 4.09 (m, 2H), 3.58 (t, 2H, J=5.6 Hz), 2.86 (m, IH), 2.73 (m, 2H), 0.85 (m, 2H), 0.71 (m, 2H); MS: 452 (M + H+). [0301] l'-(3-Trifluoromethoxybenzenesulfonyl)-l',2',3',6l-tetrahydro-[2,4I]bipyridinyl-
6-carboxylic acid cyclopropylamide (3-trifluoromethoxybenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.82 (dd, IH, J=I.2, 7.6 Hz), 7.77 (m, 2H), 7.64 (s, IH), 7.63 (t, IH, J=8 Hz), 7.52 (dd, IH, J=I .2, 8 Hz), 7.49 (m, IH), 6.63 (m, IH), 3.78 (m, 2H), 3.30 (t, 2H, J=5.6 Hz), 2.74 (m, IH), 2.63 (m, 2H), 0.75 (m, 2H), 0.58 (m, 2H); MS: 468 (M + H+).
[0302] ll-(3-Cyano-4-fluorobenzenesulfonyl)-l1,2!,3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (3-cyano-4-fluorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.18-8.08 (m, 3H), 8.00 (bd, IH, NH), 7.86 (t, IH, J=8 Hz), 7.52 (dd, IH, J=0.8, 8 Hz), 7.45 (t, IH, J=8.8 Hz), 6.57 (m, IH), 3.93 (m, 2H), 3.46 (t, 2H, J=5.6 Hz), 2.93 (m, IH), 2.81 (m, 2H), 0.91(m, 2H), 0.68 m, 2H); MS: 427 (M + H+).
[0303] l'-(Pyridin-2-ylsulfonyl)-l',2',3I,6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (pyridin-2-ylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.57 (m, IH), 7.97 (dt, IH, J=I.2, 7.2 Hz), 7.92 (m, IH), 7.85 (dd, IH, J=I.2, 7.6 Hz), 7.79 (t, IH, J=7.6 Hz), 7.56 (dd, IH, J=I .2, 7.6 Hz), 7.52 (ddd, IH, J=I.6, 4.4, 7.6 Hz), 6.67 (m, IH), 4.01 (m, 2H), 3.50 (t, 2H, J=5.6 Hz), 2.75 (m, IH), 2.64 (m, 2H), 0.76 (m, 2H), 0.60 (m, 2H); MS: 385 (M + H+), 407 (M + Na).
[0304] l1-(Pyridin-3-ylsulfonyl)-lt,2',31,6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (pyridin-3-ylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.91 (m, IH), 8.69 (m, IH), 8.18 (m, IH), 7.79 (m, 2H), 7.55 (m, 2H), 6.67 (m, IH), 3.81 (m, 2H), 3.33 (m, 2H), 2.75 (m, IH), 2.65 (m, 2H), 0.72 (m, 2H), 0.58 (m, 2H); MS: 385 (M + H+), 407 (M + Na).
[0305] l'-(3-Trifluoromethylbenzylsulfonyl)-l',2',3I,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (3-trifluoromethylbenzylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.86 (dd, IH, J=0.8, 7.6 Hz), 7.81 (t, IH, J=7.6 Hz), 7.67 (s, IH), 7.62 (d, IH, J=7.6 Hz), 7.58 (dd, IH, J=I.2, 7.6 Hz), 7.57 (d, IH, J=7.6 Hz), 7.46 (t, IH, J=7.6 Hz), 6.67 (m, IH), 4.41(s, 2H), 3.88 (m, 2H), 3.37 (t, 2H, J=5.6 Hz), 2.76 (m, IH), 2.58 (m, 2H), 0.76 (m, 2H), 0.60 (m, 2H); MS: 466 (M + H+), 488 (M + Na).
[0306] l1-(3,5-Dichlorobenzenesulfonyl)-l1,2',3',61-tetrahydro-[2,4t]bipyridinyl-6- carboxylic acid cyclopropylamide (3,5-dichlorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.85 (dd, IH, J=I.2, 7.6 Hz), 7.80 (t, IH, J=8 Hz), 7.72 (d, 2H, J=2 Hz), 7.68 (t, IH, J=2 Hz), 7.57 (dd, IH, J=I .2, 7.6 Hz), 6.66 (m, IH), 3.79 (m, 2H), 3.34 (t, 2H, J=5.6 Hz), 2.76 (m, IH), 2.66 (m, 2H), 0.75 (m, 2H), 0.60 (m, 2H); MS: 452 (M + H+).
[0307] r-(2,4,6-Trifluorobenzenesulfonyl)-l',2!,31,6I-tetrahydro-[2,4I]bipyridinyl-6- carboxylic acid cyclopropylamide (2,4,6-trifluorobenzenesulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.85 (dd, IH, J=I.6, 7.2 Hz), 7.81 (t, IH, J=7.6 Hz), 7.59 (dd, IH, J=0.8, 7.6 Hz), 7.02 (t, 2H, J=9.2 Hz), 6.71 (m, IH), 3.90 (m, 2H), 3.50 (t, 2H, J=5.6 Hz), 2.76 (m, IH), 2.70 (m, 2H), 0.76 (m, 2H), 0.62 (m, 2H); MS: 438 (M + H+).
[0308] r-(2-Methylprop-l-ylsulfonyl)-r,21,3I,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (2-methylprop-l-ylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.51 (bd, 0.5H, NH), 7.85 (dd, IH, J=0.8, 7.2 Hz), 7.80 (t, IH, J=7.6 Hz), 7.59 (dd, IH, J=0.8, 7.6 Hz), 6.73 (m, IH), 3.92 (m, 2H), 3.43 (t, 2H, J=6 Hz), 2.85 (d, 2H, J=6.4 Hz), 2.76 (m, IH), 2.69 (m, 2H), 2.15 (m, IH), 1.01 (d, 6H, J=6.8 Hz), 0.75 (m, 2H), 0.61 (m, 2H); MS: 364 (M + H+).
[0309] ll-Cyclopentylsulfonyl-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (cyclopentylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 7.98d, IH, J=7.6 Hz), 7.933 (t, IH, J=7.6 Hz), 7.74 (d, IH, J=7.6 Hz), 6.86 (m, IH), 4.11 (m, 2H), 3.72 (m, IH), 3.62 (t, 2H, J=5.6 Hz), 2.89 (m, IH), 2.81 (m, 2H), 2.02 (m, 4H), 1.80 (m, 2H), 1.67 (m, 2H), 0.87 (m, 2H), 0.72 (m, 2H); MS: 376 (M + H+).
[0310] l'-(Thiophen-3-ylsulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (thiophen-3-ylsulfonyl chloride): 1H NMR (400 MHz, CD3OD): δ 8.19 (dd, IH, J=0.8, 3.2 Hz), 7.96 (dd, IH, J=I.6, 7.2 Hz), 7.91 (t, IH, J=7.6 Hz), 7.69 (dd, IH, J=1.2, 7.6 Hz), 7.67 (dd, IH, J=3.2, 5.2 Hz), 7.41(dd, IH, J=1.2, 6.4 Hz), 6.79 (m, IH), 3.89 (m, 2H), 3.40 (t, 2H, J=5.6 Hz), 2.87 (m, IH), 2.80 (m, 2H), 0.87 (m, 2H), 0.72 (m, 2H); MS: 390 (M + H+). EXAMPLE 3
r-(4-Trifluoromethoxybenzyl)-r,2',3',6'-tetraliydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide (9)
Figure imgf000073_0001
r-(4-Trifluoromethoxybenzyl)-l',2',3t,6t-tetrahydro-[2,41]bipyridinyl-6- carboxylic acid cyclopropylamide (9) was prepared by adding diisopropyl ethyl amine to a suspension of compound 5 (72 mg, 0.25 mmol), 4-trifluoromethoxybenzaldehyde (8) (Aldrich) and 3A molecular sieves (200 mg, Aldrich). The mixture was stirred for 12 hours and NaCNBH3 was added. The crude product was filtered and then purified on Prep TLC (10 % MeOH in dichloromethane with 1 % NH4OH) to provide the title compound 9 (25 mg, yield 23%): 1H NMR (400 MHz, CD3OD, HCl-salt): δ 8.48 (bd, Ih, NH), 7.88 ( d, IH, J=7.6 Hz), 7.83 (t, IH, J=7.6 Hz), 7.65 (d, IH, J=7.6 Hz), 7.57 (m, 2H), 7.32 (d, 2H, J=8.8 Hz), 6.68 (m, IH), 4.39 (m, 2H), 3.85 (m, 2H), 3.68 (m, IH), 3.26 (m, IH), 3.12 (m, IH), 2.82 (m, IH), 2.71 (m, IH), 0.72 m, 2H), 0.54 (m, 2H); MS: 418.
EXAMPLE 4
2-[ 1 -(4-Trifluoromethoxybenzenesulfonyl)- 1 ,2,3,6-tetrahydropyridin-4-yl]- pyrimidine-4-carboxylic acid amide (15)
Figure imgf000074_0001
15
[0312] a) NaNO2 (10.4 g, 150 mmol) was added in portions to a solution of compound 10 (14 g, 95 mmol, Aldrich) in 50 ml of glacial acetic acid. Exothermal reaction occured and cooling with ice water was applied during the addition Of NaNO2. After the addition of NaNO2, the mixture was stirred at room temperature for 3 hours. The resulting suspension was filtered and compound 11 was obtained as a solid, which was washed with ice water and then dried in oven at 50 °C for 12 hours.
[0313] b) Compound 11 was added into 40 ml Of POCl3. The resulting mixture was heated until no violent reaction occurred, and then the mixture was stirred at room temperature for 12 hours. Dimethyl aniline (5ml) was added into the mixture and the resulting mixture was heated at 90 °C for 4 hours. After cooling to room temperature, the mixture was further cooled at 0 °C and ice was carefully added until no violent reaction was observed. The resulting mixture was extracted with diethyl ether (3 x 100 ml). The combined organic phase was washed with aqueous NaHCO3 and then dried with Na2SO4, filtered, and concentrated to dryness to give compound 12.
[0314] c) The mixture of compound 12 (3 g, 19 mmol), compound 3 (5.9 g, 19.1 mmol), K2CO3 (5.8 g, 42 mmol), and palladium bistriphenylphosphine dichloride (I g, 1.52 mmol) in 50 ml of a solvent mixture of ethyleneglycol dimethyl ether/ethanol/water in a ratio of 2/1/2 was heated in an oil bath at 95 °C while stirring for 2 hours. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was dissolved in EtOAc (150 ml) and washed with brine (2 x 100 ml). The combined aqueous phase was extracted with EtOAc (2 x 150 ml). The combined organic phase was dried with Na2SO4, filtered and concentrated to dryness. The obtained solid was washed with 50% EtOAc in hexane and then dried to give pure compound 13 ( 6 g, yield 100%). [0315] d) To a solution of compound 13 (140 mg, 0.46 mmol) in 5 ml of dichloromethane at 0 °C was added 1 ml of trifluoroacetic acid (TFA). After one hour, the mixture was concentrated to dryness to give crude compound 14 which was used without further purification.
[0316] e) Diisopropyl ethyl amine and 4-(trifluoromethoxy)benzenesulfonyl chloride were sequentially added to a solution of compound 14 (100 mg, 0.23 mmol) in dichloromethane at 0 °C. The reaction mixture was allowed to warm to room temperature and it was purified without work-up on CombiFlash® with a gradient of 50-80% EtOAc in hexane to provide the title compound 2-[l-(4- trifluoromethoxybenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4-yl]-pyrimidine-4- carboxylic acid amide (15) as a white solid (30 mg, yield 30%). 1H NMR (400 MHz, CD3OD): δ 8.98 (d, IH, J=5.2 Hz), 8.36 (bd, IH, NH), 7.99 (d, 2H, J=9.2 Hz), 7.96 (bd, IH, NH), 7.80 (d, IH, J=5.2 Hz), 7.63 (m, 2H), 7.39 (m, IH), 3.89 (m, 2H), 3.34 (m, 2H), 2.7 3 (m, 2H); MS: 429, 451.
[0317] Similarly, 2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]-pyrimidine-4-carboxylic acid amide was prepared from compound 14 and 3- trifluoromethylbenzenesulfonyl chloride. 1H NMR (400 MHz, CD3OD): δ 8.98 (d, IH, J=4.8 Hz), 8.36 (bd, IH, NH), 8.18 (d, IH, J=7.6 Hz), 8.11 (d, IH, J=8.4 Hz), 8.079 (s, IH), 7.96 (bd, IH, NH), 7.91 (t, IH, J=4.0 Hz), 7.80 (d, IH, J=4.8 Hz), 7.40 (m, IH), 3.92 (m, 2H), 3.36 t, 2H, J=5.6 Hz), 2.72 (m, 2H); MS: 413 (M + H+), 454 (M + Na).
EXAMPLE 5
r-(3-Trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid methyl ester (19)
ll-(3-Trifluoromethylbenzenesulfonyl)-ll,2',3I,6'-tetrahydro-[3,4']bipyridinyl- 2-carboxylic acid cyclopropylmethylamide (21)
Figure imgf000076_0001
[0318] a) To the methanol solution of compound 16a (1 g, 4.9 mmol, Matrix) at room temperature was added a few drops of concentrated sulfuric acid. The mixture was stirred for 12 hours. After removal of MeOH, the crude residue was purified on silica gel column on CombiFlash® with 20-50% EtOAc in hexane to provide compound 16b (450 mg, 41%). Compound 17 (yield 82%) was synthesized following the procedure described in Example 1 for preparing compound 4 starting from compound 16b.
[0319] b) l'-(3-Trifluoromethylbenzenesulfonyl)-r,2I,3',6'-tetrahydro-
[3,4']bipyridinyl-2-carboxylic acid methyl ester (19) was prepared by first treating compound 17 with 4N HCl to obtain compound 18 according to the procedure described in Example 4 for preparing compound 5. Compound 18 was allowed to react with 3-trifluoromethylbenzenesulfonyl chloride (6) to obtain compound 19 (yield 38%) as described in Example 2 for preparing compound 7. 1H NMR (400 MHz, CDCl3): δ
8.75 (dd, IH, J=2, 5.2 Hz), 8.11 (s, IH), 8.05 (d, IH, J=9.2 Hz), 7.92 (d, IH, J=8 Hz),
7.76 (t, IH, J=8 Hz), 7.71 (dd, IH, J=2, 7.6 Hz), 7.61 (dd, IH, J=4.8, 8 Hz), 5.59 (m, IH), 3.93 (s, 3H), 3.83 (m, 2H), 3.45 (t, 2H, J-5.6 Hz), 2.51 (m, 2H); MS: 427 (M+H+).
[0320] c) Compound 19 was treated with mixture of aqueous 2 N NaOH in methanol at room temperature for 12 hours, and then the mixture was cooled to 0 0C and acidified with dilute aqueous HCl to pH 1. The resulting mixture was freeze-dried and the crude compound 20 was used without further purification. 1H NMR (400 MHz, CD3OD): δ 8.67 (dd, IH, J=4.4, 2 Hz), 8.12 (s, IH), 8.05 (d, IH, J=8 Hz), 7.92 (d, IH, J=8 Hz), 7.75 (t, IH, J=8 Hz), 7.54 (dd, IH, J=7.6, 1.6 Hz), 7.45 (dd, IH, J=4.8, 8 Hz), 5.539 (m, IH), 3.82 (m, 2H), 3.45 (t, 2H, J=5.6 Hz), 2.51 (m, 2H); MS: 427, 450. [0321] d) Diisopropyl ethyl amine (72 ml, 0.39 mmol) and cyclopropylmethyl amine were sequentially added to a suspension of compound 20 (53 mg, 0.13 mmol), HOBt (17 mg, 0.13 mmol), and N-(3-dimethylaminopropyl)-N'ethylcabodiimide hydrochloride (25 mg, 0.13 mmol) in dichloromethane at 0 °C. The resulting mixture was allowed to warm to room temperature. The reaction mixture was purifϊded without work-up on CombiFlash with a gradient of 50-80% EtOAc in hexane to obtaine the title compound 21 (7 mg, yield 12 %). 1H NMR (400 MHz, CDCl3): δ 8.28 (dd, IH, J=I.6, 4.8 Hz), 8.00 (bt, IH, NH), 7.86 (s, IH), 7.79 (d, IH, J=7.6 Hz), 7.65 (d, IH, J=7.6 Hz), 7.48 (t, IH, J=8 Hz), 7.27 (dd, IH, J=2, 8 Hz), 7.17 (dd, IH, J=4.4, 7.6 Hz), 5.20 (m, IH), 3.58 (m, 2H), 3.23 (t, 2H, J=5.6 Hz), 2.97 (dd, 2H, 3=6, 7.2 Hz), 2.28 (m, 2H), 0.79 (m, IH), 0.30 (m, 2H), 0.010 (m, 2H); MS: 468 (M + H+).
[0322] Similarly, the following compounds were prepared by reacting compound 20 with an appropriate reagent (in parenthesis):
[0323] l'-(3-Trifluoromethylbenzenesulfonyl)-l1,2I,3l,6I-tetrahydro-[3,4l]bipyridinyl-2- carboxylic acid 2,2,2-trifluoroethylamide (2,2,2-trifluoroethylamine): 1H NMR (400 MHz, CDCl3): δ 8.55 (dd, IH, J=1.6, 4.4 Hz), 8.55 (bd, IH, NH), 8.12 (s, IH), 8.04 (d, IH, J=8 Hz), 7.90 (d, IH, J=7.6 Hz), 7.74 (t, IH, J=7.6 Hz), 7.57 (dd, IH, J=I.6, 8 Hz), 7.49 (dd, IH, J=4.8, 7.6 Hz), 5.50 (m, IH), 4.03 (m, 2H), 3.84 (m, 2H), 3.48 (t, 2H, J=5.6 Hz), 2.50 (m, 2H); MS: 494 (M + H+), 516 (M + Na).
[0324] l'-(3-Trifluoromethylbenzenesulfonyl)-l1,2',3',6'-tetrahydro-[3,4I]bipyridinyl-2- carboxylic acid 3,3,3-trifluoropropylamide (3,3,3-trifiuoropropylamine): 1H NMR (400 MHz, CDCl3): δ 8.52 (dd, IH, J=2, 4.8 Hz), 8.48 (bt, IH, NH), 8.12 (s, IH), 8.05 (d, IH, J=8 Hz), 7.90 (d, IH, J=8 Hz), 7.74 (t, IH, J=7.6 Hz), 7.56 (dd, IH, J=2, 8 Hz), 7.46 (dd, IH, J=4.8, 8 Hz), 5.48 (m, IH), 3.85 (m, 2H), 3.65 (q, 2H, J=6.4 Hz), 3.48 (t, 2H, J=5.2 Hz), 2.50 (m, 2H), 2.42 (m, 2H); MS: 508 (M + H+), 530 (M + Na).
[0325] The following compounds were prepared according to the procedure of
Example 5 using appropriate reagents:
[0326] lI-(4-Trifluoromethoxybenzenesulfonyl)-l',21,3I,6'-tetrahydro-[3,41]bipyridinyl-
2-carboxylic acid 2,2,2-trifluoroethylamide: 1H NMR (400 MHz, CDCl3): δ 8.55 (dd, IH, J=1.6, 4.8 Hz), 8.54 (bd, IH, NH), 7.91(m, 2H), 7.56 (dd, IH, J=1.6, 7.6 Hz), 7.47 (dd, IH, J=4.8, 7.6 Hz), 7.40 (m, 2H), 5.49 (m, IH), 4.02 (m, 2H), 3.82 (m, 2H), 3.48 (t, 2H, J=5.6 Hz), 2.49 (m, 2H); MS: 510 (M + H+), 532 (M + Na). [0327] l'-(4-Trifluoromethoxybenzenesulfonyl)-l',2',3l,6I-tetrahydro-[3,4']bipyridinyl-
2-carboxylic acid 3,3,3-trifluoropropylamide: 1H NMR (400 MHz, CDCl3): δ 8.52 (dd, IH, 3=2, 4.8 Hz), 8.47 (bt, IH, NH), 7.91 (m, 2H), 7.54 (dd, IH, J=2, 8 Hz), 7.45 (dd, IH, J=3.2, 8 Hz), 7.40 (m, 2H), 5.47 (m, IH), 3.84 (m, 2H), 3.65 (q, 2H, J=6.4, 6.8 Hz), 3.48 (t, 2H, J=5.2 Hz), 2.51 (m, 2H), 2.42 (m, 2H); MS: 524 (M + H+), 546 (M + Na).
[0328] l'-(4-Trifluoromethoxybenzenesulfonyl)-l',21,3',6'-tetrahydro-[3,4']bipyridinyl-
2-carboxylic acid cyclopropylmethylamide: 1H NMR (400 MHz, CDCl3): δ 8.29 (dd, IH, J=2, 4.8 Hz), 8.07 (bt, IH, NH), 7.65 (m, 2H), 7.31 (dd, IH, J=I.6, 7.6 Hz), 7.20 (dd, IH, J=4.8, 7.6 Hz), 7.16 (d, 2H, J=8 Hz), 5.22 (m, IH), 3.57 (m, 2H), 3.23 (t, 2H, J=5.2 Hz), 3.00 (dd, 2H, J=5.6, 7.2 Hz), 2.28 (m, 2H), 0.81 (m, IH), 0.32 (m, 2H), 0.026 (m, 2H); MS: 482 (M + H+), 504 (M + Na).
EXAMPLE 6
r-(3-Trifluoromethylbenzenesulfonyl)-ll,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylmethylamide (27)
r-(3-Trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl- 6-carboxylic acid amide (28)
Figure imgf000078_0001
[0329] a) lH3-Trifluoromethylbenzenesulfonyl)-1^2\3^6'-tetrahydro-[2,4']- bipyridinyl-6-carboxylic acid cyclopropylmethylamide (27) was synthesized according to the procedure described in Example 5 for preparing compound 21 in Example 5 using compound 22 as the starting material instead of compound 16. 1H NMR (400 MHz, CDCl3): δ 8.01 (s, IH), 7.98 (dd, IH, J=0.8, 8 Hz), 7.95 (d, IH, J=8 Hz), 7.91 (bt, IH, NH), 7.77 (d, IH, J=8 Hz), 7.71 (t, IH, J=7.6 Hz), 7.62 (t, IH, J=7.6 Hz), 7.38 (dd, IH, J=0.8, 8 Hz), 6.46 (m, IH), 3.81 (m, 2H), 3.34 (t, 2H, J=6 Hz), 3.24 (dd, 2H, J=6, 6.8 Hz), 2.71 (m, 2H), 0.98 (m, IH), 0.45 (m, 2H), 0.79 (m, 2H); MS: 466 (M + H+), 489 (M + Na).
[0330] Similarly, the following compounds were prepared starting from compound 26 using an appropriate reagent (in parenthesis):
[0331] r-(3-Trifluoromethylbenzenesulfonyl)-l',2',3',6l-tetrahydro-[2,4I]-bipyridinyl-6- carboxylic acid 2,2,2-trifluoroethylamide (2,2,2-trifluoroethylamine): 1H NMR (400 MHz, CDCl3): δ 8.24 (bt, IH, NH), 8.13 (s, IH), 8.12 (d, IH, J=7.6 Hz), 8.07 (d, IH, J=8 Hz), 7.89 (d, IH, J=7.6 Hz), 7.88 (t, IH, J=7.6 Hz), 7.74 (t, IH, J=7.6 Hz), 7.56 (d, IH, J=8 Hz), 6.59 (m, IH), 4.15 (m, 2H), 3.95 (m, 2H), 3.46 (t, 2H, J=5.6 Hz), 2.81 (m, 2H); MS: 494 (M + H+), 516 (M + Na).
[0332] l1-(3-Trifluoromethylbenzenesulfonyl)-l',2',3I,6l-tetrahydro-[2,4']-bipyridinyl-6- carboxylic acid 3,3,3-trifluoropropylamide (3,3,3-trifluoropropylamine): 1H NMR (400 MHz, CDCl3): δ 8.25 (bt, IH, NH), 8.13 (s, IH), 8.081 (m, IH), 7.90 (d, IH, J=7.6 Hz), 7.85 (t, IH, J=8 Hz), 7.74 (t, IH, J=8 Hz), 7.53 (dd, IH, J=0.8, 8.4 Hz), 6.58 (m, IH), 3.93 (m, 2H), 3.78 (q, 2H, J=6.4 Hz), 3.45 (t, 2H, J=6 Hz), 2.81 (m, 2H), 2.49 (m, 2H); MS: 508 (M + H+), 530 (M + Na).
[0333] The following compounds were prepared according to the procedure of
Example 6 using appropriate reagents:
[0334] 1 '-(4-Trifluoromethoxybenzenesulfonyl)- 1 t,2',3',6'-tetrahydro-[2,4']-bipyridinyl-
6-carboxylic acid 2,2,2-trifluoroethylamide: 1H NMR (400 MHz, CDCl3): δ 8.256 (bd, IH, NH), 8.12 (dd, IH, J=0.8, 7.6 Hz), 7.93 (m, 2H), 7.88 t, IH, J=8 Hz), 7.56 (dd, IH, J=1.2, 8 Hz), 7.40 (m, 2H), 6.58 (m, IH), 4.15 (m, 2H), 3.92 (m, 2H), 3.44 (t, 2H, J=5.6 Hz), 2.82 (m, 2H); MS: 510 (M + H+), 532 (M + Na).
[0335] lI-(4-Trifluoromethoxybenzenesulfonyl)-l1,2I,3',6'-tetrahydro-[2,4']-bipyridinyl-
6-carboxylic acid 3,3,3-trifluoropropylamide: 1H NMR (400 MHz, CDCl3): δ 8.29 (bt, IH, NH), 8.10 (dd, IH, J=0.8, 7.6 Hz), 7.93 (m, 2H), 7.86 (t, IH, J=7.6 Hz), 7.54 (dd, IH, J=I.2, 8 Hz), 7.40 (dd, 2H, J=0.8, 8.8 Hz), 6.58 (m, IH), 3.92 (m, 2H), 3.78 (m, 2H), 3.43 (t, 2H, J=5.6 Hz), 2.81 (m, 2H), 2.49 (m, 2H); MS: 524 (M + H+), 546 (M + Na).
[0336] lI-(4-Trifluoromethoxybenzenesulfonyl)-lI,2',3',6'-tetrahydro-[2,41]-bipyridinyl-
6-carboxylic acid 4-fluorophenylamide: 1H NMR (400 MHz, CD3OD): δ 8.09-7.96 (m, 4H), 7.80 (m, 2H), 7.76 (m, 2H), 7.55 (m, 2H), 7.15 (m, 2H), 6.85 (m, IH), 3.94 (m, 2H), 3.46 (t, 2H, J=6 Hz), 2.88 (m, 2H); MS: 522 (M + H+), 544 (M + Na).
[0337] b) 1 '-(3-Trifluoromethylbenzenesulfonyl)- 1 '^'^'^'-tetrahydro-
[2,4']bipyridinyl-6-carboxylic acid amide (28) was prepared as follows. A solution of compound 25 (55 mg, 0.13 mmol) in 2 M NH3 in methanol was stirred at room temperature for 12 hours. The mixture was concentrated and the solid was washed with 20% EtOAc in hexane and dried to give the title compound 28 (44 mg, yield 85%). 1H NMR (400 MHz, CD3OD): δ 8.16 (d, IH, J=7.6 Hz), 8.12 (s, IH), 8.00 (d, IH, J=8 Hz), 7.98 (dd, IH, J=I.2, 7.6 Hz), 7.91 (t, IH, J=7.6 Hz), 7.86 (t, IH, J=8 Hz), 7.70 (dd, IH, J=I.2, 8 Hz), 6.78 (m, IH), 3.93 (m, 2H), 3.45 (t, 2H, J=6 Hz), 2.79 (m, 2H); MS: 412 (M + H+), 434 (M + Na).
[0338] Similarly, the following compounds were prepared starting from compound 25 using an appropriate reagent (in parenthesis):
[0339] lI-(3-Trifluoromethylbenzenesulfonyl)-l1,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid 2-hydroxyethylamide (ethanol amine) [the product was purified without an aqueous work-up on CombiFlash® (44 mg, yield 70%)]: 1H NMR (400 MHz, CD3OD): 8.15 (m, IH), 8.12 (s, IH), 8.022-7.85 (m, 4H), 7.69 (m, IH), 6.79 (m, IH), 3.93 (m, 2H), 3.73 (m, 2H), 3.57 (m, 2H), 3.45 (m, 2H), 2.80 (m, 2H); MS: 456 (M + H+), 478 (M + Na).
[0340] l'-(3-Trifluoromethylbenzenesulfonyl)-ll,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid l,3-dihydroxyprop-2-ylamide (2-amino-l,3-propanediol) [the product was purified without an aqueous work-up on CombiFlash® (57 mg, yield 53%)]: 1H NMR (400 MHz, CD3OD): δ 8.16 (d, IH, J=8 Hz), 8.13 (s, IH), 8.00 (m, IH), 7.93 (t, IH, J=7.6 Hz), 7.86 (t, IH, J=7.6 Hz), 7.71 (dd, IH, J=1.2, 8 Hz), 6.77 (m, IH), 4.13 (m, IH), 3.92 (m, 2H), 3.81 (dd, 2H, J=5.2, 11 Hz), 3.74 (dd, 2H, J=5.2, 11 Hz), 3.45 (t, 2H, J=6 Hz), 2.80 (m, 2H); MS: 486 (M + H+). EXAMPLE 7
lI-(3-Trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carbonitrile (32)
N-Cyclopropylmethyl- 1 '-(4-trifluoromethoxybenzenesulfonyl)- 1 ',2',3',6'- tetrahydro-[2,4']bipyridinyl-6-carboxamidine (34)
Figure imgf000081_0001
33 34
[0341] a) l'-(3-Trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-
[2,4']bipyridinyl-6-carbonitrile (32) was synthesized similarly to compound 7 in Example 1 starting with 2-chloro-6-cyanopyridine (22) instead of compound 1. 1H NMR (400 MHz, CD3OD): δ 8.15 (d, IH, J=8.4 Hz), 8.12 (s, IH), 8.00 (d, IH, J=7.6 Hz), 7.92 (m, IH), 7.86 (m, IH), 7.80 (m, IH), 7.70 (m, IH), 6.76 (m, IH), 3.93 (m, 2H), 3.43 (m, 2H), 2.73 (m, 2H); MS: 394 (M + H+).
[0342] b) N-Cyclopropylmethyl- 1 '-(4-trifluoromethoxybenzenesulfonyl)- r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxamidine (34) was synthesized as follows. Compound 33 was prepared according to the procedure described above for preparing compound 32 using 4-(trifluoromethoxy)benzenesulfonyl chloride instead of 3- trifluoromethylbenzenesulfonyl chloride. To a solution of compound 33 (154 mg, 0.37 mmol) in ethanol was added cyclopropylmethylamine (52 mg, 0.75 mmol) and the resulting solution was heated at 55 °C for 12 hours. The mixture was purified, without an aqueous work-up, on CombiFlash® and further purified by Prep-TLC to obtain the title compound 34 (7 mg, yield 4%). 1H NMR (400 MHz, CD3OD): δ 7.97-7.85 (m, 4H), 7.77 (d, IH, J=8 Hz), 7.43 (d, 2H, J=8.8 Hz), 6.76 (m, IH), 3.81 (m, 2H), 3.32 (m, 4H), 2.71 (m, 2H), 1.14 (m, IH), 0.58 (m, 2H), 0.31 (m, 2H); MS: 481 (M + H+).
EXAMPLE 8
2-[l-(3-Trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide (39)
Figure imgf000082_0001
39
[0343] 2-[ 1 -(3-Trifluoromethylbenzenesulfonyl)- 1 ,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide (39) was prepared as follows:
[0344] a) Compound 37 was synthesized according to the procedure described in
Example 1 for preparing compound 4 starting from compound 35 (158 mg, 1 mmol, Chem-Impex) to first obtain compound 36. Diisopropyl ethyl amine (138 μl, 0.75 mmol) and cyclopropylamine (20 μl, 0.27 mmol) were added sequentially to a solution of compound 36 (75 mg, 0.25 mmol), HOBt (33 mg, 0.25 mmol), N-(3- dimethylaminopropyl)-N'ethylcabodiimide hydrochloride (53 mg, 0.27 mmol) in dichloromethane at 0 °C. The mixture was allowed to warm to room temperature and stirred for 3 hours. The mixture was concentrated to dryness to give the crude compound 37 (150 mg, yield 50%).
[0345] b) The residue from step a) was dissolved in EtOAc and then HCl in 1,4- dioxane was added at 0 °C. The mixture was slowly warmed to room temperature and stirred for 12 hours. The solid was filtered and washed with hexane and dried to give compound 38. To a suspension of compound 38 in dichloromethane at 0 0C was added diisopropyl ethyl amine (138 ml, 0.75 mmol) followed by 3- trifluoromethylbenzenesulfonyl chloride. The reaction was complete within ten mintues and the crude product was purified on CombiFlash without an aqueous workup to give the title compound 39 (28 mg, yield 25% from compound 36). 1H NMR (400 MHz, CD3OD): 8.81 (m, IH), 8.04 (m, 2H), 7.86 (m, IH), 7.71 (m, 2H), 7.28 (m, IH), 3.84 (m, 2H), 3.30 (m, 2H), 2.77 (m, IH), 2.68 (m, 2H), 0.74 (m, 2H), 0.59 (m, 2H); MS: 453 (M + H+).
[0346] The following compounds were prepared according to the procedure described above:
[0347] 2-[l-(3-Trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylmethylamide: 1H NMR (400 MHz, CDCl3): δ 8.82 (d, IH, J=4.8 Hz), 8.05 (s, IH), 7.97 (d, IH, J=8.4 Hz), 7.89 (bt, IH, NH), 7.87 (d, IH, J=4.8 Hz), 7.81 (d, IH, J=7.6 Hz), 7.65 (t, IH, J=7.2 Hz), 7.17 (m, IH), 3.90 (m, 2H), 3.37 (t, 2H, J=5.6 Hz), 3.28 (dd, 2H, J=5.6, 7.2 Hz), 2.80 (m, 2H), 1.01 (m IH), 0.52 (m, 2H), 0.23 (m, 2H); MS: 467 (M + H+).
[0348] 2-[l-(4-Trifluoromethoxybenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide: 1H NMR (400 MHz, CD3OD): δ 8.78 (d, IH, J=5.2 Hz), 7.85 (m, 2H), 7.70 (d, IH, J=5.2 Hz), 7.38 (m, 2H), 7.23 (m, IH), 3.80 (m, 2H), 3.27 (t, 2H, J=6 Hz), 2.75 (m, IH), 2.69 (m, 2H), 0.73 (m, 2H), 0.58 (m, 2H); MS: 469 (M + H+).
EXAMPLE 9
5-Chloro-r-(3-trifluoromethylbenzenesulfonyl)-l',2',3l,6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (44)
Figure imgf000083_0001
44 [0349] S-Chloro-r-CS-trifluoromethylbenzenesulfonyO-l'^'^'^'-tetrahydro-
[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (44) was synthesized according to the procedure described in Example 8 for preparing compound 39 starting from 3,6- dichloropyridine-2-carboxylic acid (40) (Matrix) instead of compound 35. 1H NMR (400 MHz, CD3OD): δ 8.15 (d, IH, J=7.6 Hz), 8.12 (s, IH), 8.02 (d, IH, J=8.4 Hz), 7.86 (m, 2H), 7.59 (d, IH, J=8.4 Hz), 6.72 (m, IH), 3.90 (m, 2H), 3.42 (t, 2H, J=5.6 Hz), 2.87 (m, IH), 2.72 (m, 2H), 0.84 (m, 2H), 0.66 (m, 2H); MS: 486 (M + H+).
[0350] Similarly, 5-chloro- 1 '-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetra- hydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide was synthesized using 4- trifluoromethoxybenzenesulfonyl chloride at the last step instead of 3- trifluoromethylbenzenesulfonyl chloride. 1H NMR (400 MHz, CD3OD): δ 7.99 (m, 2H), 7.85 (d, IH, J=8.4 Hz), 7.59 (d, IH, J=8.4 Hz), 7.54 (m, 2H), 6.72 (m, IH), 3.87 (m, 2H), 3.39 (t, 2H, J=5.6 Hz), 2.87 (m, IH), 2.73 (m, 2H), 0.83 (m, 2H), 0.66 (m, 2H); MS: 502 (M + H+).
EXAMPLE 10
6'-Oxo- 1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (45)
Figure imgf000084_0001
[0351] 6'-Oxo-r-(3-trifluoromethylbenzenesulfonyl)-r,2t,3',6'-tetrahydro-
[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (45) was prepared as follows. Excess MnO2 was added to a solution of compound 7 prepared in Example 2 (140 mg, 0.31 mmol) in dichloromethane (10 ml) at room temperature. The resulting suspension was stirred for 12 hours. The mixture was filtered through paper and purified on the CombiFlash® without an aqueous work-up to give the title compound 45 (11 mg, yield 8%). 1H NMR (400 MHz, CDCl3): δ 8.27 (d, IH, J=9.6 Hz), 8.26 (s, IH), 8.18 (dd, IH, J=0.8, 7.6 Hz), 7.87 (t, IH, J=8 Hz), 7.84 (d, IH, J=8 Hz), 7.77 (bd, IH, NH), 7.65 (m, 2H), 6.54 (m, IH), 4.19 (t, 2H, J=6.4 Hz), 3.09 (dt, J=I.2, 6.8 Hz), 2.84 (m, IH), 0.86 (m, 2H), 0.60 (m, 2H); MS: 466 (M + H+).
EXAMPLE 11
6-[8-(3-Trifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-3- yl]pyridine-2-carboxylic acid cyclopropylamide (55)
Figure imgf000085_0001
46 47 48 49
Figure imgf000085_0002
[0352] 6-[8-(3-Trifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-3- yl]pyridine-2-carboxylic acid cyclopropylamide (55) was prepared as follows: [0353] a) A solution of compound 46 (1 g, 4.4 mmol, Chem-Impex) in THF (5 ml) to sodium hexamethyldisilate (2.4 ml, 2M/THF, Aldrich) in 10 ml of THF at -60 °C. After the addition, the mixture was allowed to warm to -20 0C and this temperature was maintained for 20 minutes. Perfluorobutanesulfonyl fluoride (1.35 g, 4.4 mmol, Aldrich) was added at -20 0C and the mixture was stirred at -20 0C for 20 minutes. The crude product was purified on silica gel column with 0-10% EtOAc in hexane to obtain compound 47 (1.9 g, yield 85%).
[0354] b) The suspension of compound 47 (1.9 g, 3.75 mmol), compound 48 (948 mg, 3.75 mmol, Carbocore), PdCl2(dppf)CH2Cl2 (86 mg, 0.11 mmol, Aldrich), diphenylphosphinoferracene (61 mg, 0.11 mmol, Aldrich) and KOAc (1.03 g, 10.5 mmol) in 1,4-dioxane (15 ml) was heated at 85 °C for 1 hour. After cooling to room temperature, the reaction mixture was diluted with EtOAc (100 ml) and washed with brine. The aqueous phase was further extracted with EtOAc ( 2 x 100 ml) and the combined organic phase was dried with Na2SO4, filtered and concentrated to dryness. The residue was purified on CombiFlash® with 10-20% EtOAc in hexane to obtain compound 49 (688 mg, yield 55%).
[0355] c) Compound 51 was synthesized according to the procedure described in
Example 6 for preparing compound 23 starting from compound 50 (Aldrich). To the solution of compound 51 (72 mg, 0.21 mmol) in methanol (ImI) was added aqueous NaOH (1 ml, 2N). The resulting solution was stirred for 12 hours. Methanol was removed under reduced pressure and the residue was diluted with water and acidified with aqueous HCl to pH 5 at 0 °C. The suspension with white precipitate was extracted with EtOAc (3 x 20 ml) and the combined organic phase was dried with Na2SO4, filtered, and concentrated to dryness to give compound 52 (60 mg, yield 87%).
[0356] d) 6-[8-(3-Trifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-
3-yl]pyridine-2-carboxylic acid cyclopropylamide (55) was then synthesized according to the procedure described in Example 8 for preparing compound 39 starting from compound 52 in a 50% yield. 1H NMR (400 MHz, CDCl3): δ 8.16 (s, IH), 8.10 (d, IH, J=8 Hz), 8.09 (dd, IH, J=0.8, 7.6 Hz), 7.97 (bd, IH, NH), 7.78 (t, IH, J=8 Hz), 7.70 (d, IH, J=7.6 Hz), 7.56 (t, IH, J=7.6 Hz), 7.34 (dd, IH, J=0.8, 8 Hz), 6.84 (dt, IH, J=6, 1.6 Hz), 4.60 (m, 2H), 2.92 (m, 2H), 2.45 (d, IH, J=16 Hz), 2.18 (m, IH), 2.01 (m, 2H), 1.72 (m, IH), 0.92 (m, 2H), 0.68 (m, 2H); MS: 478 (M + H+), 500 (M + Na). EXAMPLE 12
2-[ 1 -(4-Trifluoromethoxybenzenesulfonyl)- 1 ,2,3 ,6-tetrahydropyridin-4- yl]oxazole-4-carboxylic acid cyclopropylamide (61)
Figure imgf000087_0001
[0357] 2-[ 1 -(4-Trifluoromethoxybenzenesulfonyl)- 1 ,2,3 ,6-tetrahydropyridin-4- yl]oxazole-4-carboxylic acid cyclopropylamide (61) was synthesized according to the procedure described for preparing compound 21 in Example 5 starting with compound 56 (Synchen). 1H NMR (400 MHz, CDCl3): δ 8.03 (s, IH), 7.80 (m, 2H), 7.30 (m, 2H), 6.85 (s, IH), 6.58 (m, IH), 3.79 (m, 2H), 3.28 (t, 2H, J=5.6 Hz), 2.78 (m, IH), 2.62 (m, 2H), 0.79 (m, 2H), 0.57 (m, 2H); MS: 458 (M + H+), 480 (M + Na).
EXAMPLE 13
l'-[2,2,2-Trifluoro-l-(4-trifluoromethoxyphenyl)ethyl]-l',2',31,6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (64)
Figure imgf000087_0002
64 [0358] a) A solution of l-bromo-4-(trifluoromethoxy)benzene (62) (23.4 g, 97.0 mmol, WACO) in diethyl ether (30 ml) was added dropwise over 30 minutes to a suspension of magnesium (2.60 g, 107 mmol) and catalytic amount of iodine in diethyl ether (8 ml) and the whole was stirred at room temperature for 1 hour. Trifluoroacetic anhydride (TFAA) (17.8 ml, 126 mmol) was added dropwise to the reaction mixture at 0 °C and stirred at room temperature for 1 hour. The reaction was quenched with aqueous HCl solution, extracted with ethyl acetate, washed with NaHCO3 solution, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate/hexane: 1/99 to 20/80) to give 2,2,2-trifluoro-l- (4-trifiuoromethoxyphenyl)ethanone (63) (599 mg, yield 2%) as colorless oil.
Figure imgf000088_0001
[0359] b) Titanium (IV) chloride (0.098 ml, 0.887 mmol) was added to a solution of N-cyclopropyl-6-(l,2,3,6-tetrahydropyridin-4-yl)picolinamide free base (5b) (432 mg, 1.77 mmol), 2,2,2-trifluoro-l-(4-trifluoromethoxyphenyl)ethanone (63) (458 mg, 1.77 mmol) and triethylamine (0.492 ml, 3.55 mmol) in CH2Cl2 (12 ml) and stirred at room temperature for 18 hours. Sodium cyanoborohydride (334 mg, 5.32 mmol) in methanol (4 ml) was added to the reaction mixture and stirred for 19 hours. The reaction was quenched with aqueous NaOH solution (2 N), extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate/hexane: 67/33) to give l'-[2,2,2-trifluoro-l-(4- trifluoromethoxyphenyl)ethyl]- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (64) (226 mg, yield 26 %) as a pale orange oil. 1H NMR (400 MHz, CDCIa): δ 8.04 (m, IH), 8.00 (brs, IH), 7.77 (t, J = 7.8 Hz, IH), 7.47 (m, 3H), 7.26 (m, 2H), 6.58 (m, IH), 4.21 (q, J = 7.9 Hz, IH), 3.45 (m, 2H), 2.97 (m, IH), 2.90 (m, IH), 2.80 (m, IH), 2.66 (m, 2H), 0.88 (m, 2H), 0.65 (m, 2H); MS: 486 (M + H+).
Figure imgf000089_0001
EXAMPLE 14
r-[2-Hydroxy-l-(4-trifluoromethoxyphenyl)ethyl]-l',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (67)
Figure imgf000089_0002
67
a) Sulfuric acid (0.484 ml, 9.08 mmol) was added dropwise to a solution of
2-(4-(trifluoromethoxy)phenyl)acetic acid (2.0 g, 9.08 mmol) in ethanol (20 ml), and heated under reflux for 5 hours. The reaction mixture was concentrated in vacuo, diluted with ethyl acetate (100 ml), washed with saturated NaHCO3 solution and brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate / hexane: 0/100 to 20/80) to give ethyl 2-(4- (trifluoromethoxy)phenyl)acetate (2.06 g, yield 91 %) as yellow oil.
Figure imgf000089_0003
[0361] b) A mixture of ethyl 2-(4-(trifluoromethoxy)phenyl)acetate (1.99 g, 8.00 mmol), N-bromosuccinimide (NBS) (1.57 g, 8.80 mmol) and 2,2'-azobis(2- methylpropionitrile) (AIBN) (66 mg, 0.400 mmol) in carbon tetrachloride (10 ml) was heated under reflux for 5 hours. The reaction mixture was concentrated in vacuo, diluted with diethyl ether (200 ml), washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo to give ethyl 2-bromo-2-(4- (trifluoromethoxy)phenyl)acetate (65) (2.70 g, quantitative yield) as yellow oil.
Figure imgf000090_0001
[0362] c) A mixture of N-cyclopropyl-6-(l,2,3,6-tetrahydropyridin-4- yl)picolinamide free base (5b) (200 mg, 0.822 mmol), ethyl 2-bromo-2-(4- (trifluoromethoxy)phenyl)acetate (65) (403 mg, 1.23 mmol), K2CO3 (227 mg, 1.64 mmol) and KI (14 mg, 0.082 mmol) was refluxed in acetonitrile (2 ml) for 2 hours. The reaction was quenched with H2O, extracted with CHCl3, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate/hexane: 67/33) to give 4-[l-(6-cyclopropylcarbamoyl- 3',6l-dihydro-2Η-[2,4']bipyridinyl-l'-yl)-2,2,2-trifluoroethyl]benzoic acid ethyl ester (66) (289 mg, yield 72 %) as a yellow syrup.
Figure imgf000090_0002
66 [0363] d) Lithium borohydride (34 mg, 1.6 mmol) was added to a solution of 4-[l-
(6-cyclopropylcarbamoyl-3',6'-dihydro-2'H-[2,4']bipyridinyl-r-yl)-2,2,2-trifluoro- ethyl]benzoic acid ethyl ester (66) (282 mg, 0.576 mmol) in tetrahydrofuran/ethanol (3:1, 4 ml) at room temperature and stirred for 20 hours. The reaction was quenched with H2O, extracted with ethyl acetate, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (methanol/ CHCl3: 10/90) to give 1 '-[2,2,2-trifluoro- 1 -(4-hydroxymethylphenyl)ethyl]- 1 ',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (67) (187 mg, yield 73 %) as a colorless foam. 1H NMR (400 MHz, CDCla): δ 8.05 (dd, J = 1.2, 7.8 Hz, IH), 8.00 (brs, IH), 7.78 (t, J = 7.8 Hz, IH), 7.49 (dd, J = 1.2, 7.8 Hz, IH), 7.34 (m, 2H ), 7.23 (m, 2H), 6.60 (m, IH), 4.02 (m, IH), 3.80 (m, 2H), 3.31 (m, 2H), 2.92 (m, 2H), 2.68 (m, 2H), 2.60 (m, IH), 0.88 (m, 2H), 0.65 (m, 2H); MS: 448 (M + H+).
Figure imgf000091_0001
66 67
EXAMPLE 15
N-Cyclopropyl-6- { 1 - [(3-trifluoromethylisoxazol-5 -yl)methyl] -1,2,3,6- tetrahydropyridin-4-yl}picolinamide hydrochloride (76)
Figure imgf000091_0002
76
[0364] a) A solution of 2,2,2-trifluoroacetic acid (68) (6.0 g, 52.6 mmol) in diethyl ether (80 ml) was added dropwise over 80 minutes to a suspension of lithium aluminiumhydride (1.52 g, 40.0 mmol) in diethyl ether (100 ml) at O °C and stirred at room temperature for 15 hours. The reaction was quenched with methanol (3.6 ml), H2O (3.2 ml) and concentrated H2SO4 (6.4 ml) and the resulting precipitation was filtered off. The filtrate was washed with H2O and brine, dried over MgSO4, filtered and concentrated in vacuo to give a crude product of 2,2,2-trifiuoroethane-l,l-diol (69). This was diluted with methanol (10 ml) and ice- water (20 g), and then hydroxylamine hydrochloride (4.06 g, 58.4 mmol) and aqueous NaOH solution (50 %, 8.8 g, 110 mmol) was added successively to the mixture. The reaction mixture was stirred at room temperature for 16 hours and washed with diethyl ether (50 ml). Thus obtained aqueous phase was neutralized (pH = 6) with concentrated hydrochloric acid, extracted with diethyl ether (100 ml x 3), washed with H2O and brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by distillation to give (E)-2,2,2- trifluoroacetaldehyde oxime (70) (4.94 g, yield 53 %) as a colorless oil (bp: 75 °C).
Figure imgf000092_0001
[0365] b) A solution of N-bromosuccinimide (NBS) (4.98 g, 28.0 mmol, Aldrich) in N,N-dimethylformamide (15 ml) was added dropwise over 15 minutes to a solution of (E)-2,2,2-trifluoroacetaldehyde oxime (70) (4.93 g, 28.0 mmol) in N,N- dimethylformamide (6 ml) and the whole was stirred for 16 hours. The reaction mixture was poured into ice-water (60 g), extracted with diethyl ether (60 ml x 3), washed with H2O and brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by distillation to give (Z)-2,2,2-trifluoro-N- hydroxyacetimidoyl bromide (71) (5.37 g, yield 69 %) as an orange oil (bp: 80-116 "C).
NBS ψ
F3(T N "" F3CT N
70 71
[0366] c) A solution of triethylamine (5.35 ml, 38.6 mmol) in toluene (15 ml) was added dropwise over 10 minutes to a solution of (Z)-2,2,2-trifluoro-N- hydroxyacetimidoyl bromide (71) (5.35 g, 19.3 mmol) and prop-2-yn-l-ol (72) (3.25 g, 57.9 mmol, TCI JP) in toluene (37.5 ml) and stirred for 10 hours at room temperature. The reaction was quenched with H2O (30 ml), extracted with ethyl acetate (50 ml), washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give a crude product of (3-(trifluoromethyl)isoxazol-5-yl)methanol (73) (1.88 g, yield 47 %) as a brown oil.
Figure imgf000093_0001
73
[0367] d) 2-Iodoxybenzoic acid (74) (804 mg, 2.87 mmol, Aldrich) was added to a solution of (3-(trifluoromethyl)isoxazol-5-yl)methanol (73) (300 mg, 1.44 mmol) in ethyl acetate (3 ml) at room temperature and stirred at 80 ° C for 4 hours. After cooling to 0 °C, insoluble materials were filtered off and the filtrate was concentrated in vacuo to give a crude product of 3-(trifiuoromethyl)isoxazole-5-carbaldehyde (75) (270 mg, 57) as a pale-yellow solid.
Figure imgf000093_0002
[0368] e) A mixture of N-cyclopropyl-6-(l,2,3,6-tetrahydropyridin-4- yl)picolinamide free base (5b) (133 mg, 0.545 mmol), 3-(trifiuoromethyl)isoxazole-5- carbaldehyde (75) (270 mg, 0.818 mmol) and acetic acid (0.037 ml, 0.654 mmol) in tetrahydrofuran (5 ml) was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (347 mg, 1.636 mmol) was added to the reaction mixture and stirred at room temperarure for 15 hours. The reaction was quenched with saturated NaHCO3 solution (10 ml), extracted with ethyl acetate (50 ml x 3), washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate / hexane: 75/25 to 85/15) to give the desired free base. This was diluted with ethyl acetate and HCl solution (4 N in 1,4-dioxane) was added to the solution. The resulted solid was triturated with hexane to give N- cyclopropyl-6-(l-((3-(trifluoromethyl)isoxazol-5-yl)methyl)-l,2,3,6-tetrahydropyridin- 4-yl)picolinamide hydrochloride (76) (33 mg, yield 14 %) as a pale yellow solid. 1H NMR (DMSO-de): δ 8.52 (brs, IH), 8.00 (m, IH), 7.92 (m, IH), 7.77 (m, IH), 7.47 (m, IH), 6.93 (s, IH), 4.77 (m, 2H), 3.93 (m, 2H), 2.83-3.20 (m, 5H ), 0.72 (m, 2H), 0.64 (m, 2H); MS: 393 (M + H+).
Figure imgf000094_0001
5b
76
EXAMPLE 16
1 '-(3-Trifluoromethylbenzenesulfonyl)- 11,21,3',6'-tetrahydro[2,4']bipyridinyl-6- cyclopropanoylamine (82)
Figure imgf000094_0002
a) Compound 77 (2.5 g, 10.3 mmol, Aldrich), compound 3 (3.8 g, 12.4 mmol), Na2CO3 (2.12 g, 20.6 mmol) and Pd(PPh3)2Cl2 (362 mg, 0.5 mmol) were dissolved in a mixture of DME (10 ml), EtOH (5 ml) and H2O (10 ml) in a round bottom flask. The mixture was stirred at 95 °C for 2 hours, cooled to room temperature and worked-up with EtOAc, which was separated, dried and evaporated under rotary evaporator. The residue was subjected to flash column (hexanes / EtOAc) to give compound 78 (2.6 g, yield 70%).
Figure imgf000095_0001
78
[0370] b) Compound 78 was dissolved in about 5 ml of DCM, and then about 20 ml of 2N HCl in Et2O was added. The resulting mixture was stirred at room temperature overnight. The precipitated compound 79 was filtered under vacuum and dried to give compound 79 quantitatively.
Figure imgf000095_0002
78 79
[0371] c) At -20 °C, benzenesulfonyl chloride (6) (0.65 ml, 4.06 mmol) in DCM
(5 ml) was added to a DCM suspension of compound 79 (1.0 g, 4.06 mmol) and TEA (2.2 ml, 16 mmol) dropwise. After the addition was complete, the mixture was slowly allowed to warm to room temperature over 2 hours, and then washed with water. The DCM layer was separated and dried over MgSO4. The solvent was evaporated and the crude compound 80 was used in the next step without further purification.
Figure imgf000096_0001
[0372] d) At 0 0C, compound 81 (0.1 ml, 0.55 mmol) was added to a DCM ( 5 ml) solution of compound 80 (191 mg, 0.5 mmol) and TEA (0.1 ml) dropwise. After the addition was complete, the reaction mixture was slowly warmed up to room temperature overnight. The mixture was directly loaded on a silica gel column (Flash chromatography; hexanes/EtOAc) to give the title compound 82 as a white solid (160 mg , yield 71%). 1H NMR (400 MHz, CD3OD): δ 8.02 (d, IH, J=7.2 Hz), 8.00 (s, IH), 7.89 (d, IH, J=8 Hz), 7.81 (d, IH, J=8.4 Hz), 7.74 (t, IH, J=7.6 Hz), 7.56 (t, IH, J=7.6 Hz), 7.07 (d, IH, J=7.6 Hz), 6.53 (m, 2H), 3.77 (m, 2H), 3.29 (t, 2H, J=6 Hz), 2.60 (m, 2H), 1.78 (m, IH), 0.86 (m, 2H), 0.76 (m, 2H); MS: 452 (M + H+).
Figure imgf000096_0002
TEA/ DCM
Figure imgf000096_0003
Figure imgf000096_0004
EXAMPLE 17
r-[(3-Trifluoromethylbenzene)aminosulfonyl]-r,2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide (86)
[0373] a) To a suspension of compound 5 in acetonitrile (5 ml) were added TEA and compound 82 (Aldrich). After the mixture was stirred at room temperature overnight, it was diluted with EtOAc, which was washed with water. The organic layer was isolated, dried and evaporated. The residue was subjected to flash column to give compound 83 as a white foam (0.23 g, yield 70%).
Figure imgf000097_0001
[0374] b) CF3SO3Me (0.07 ml, 0.62 mmol) was added to a DCM solution of compound 83 (0.23 g, 0.6 mmol) at 0°C and the resulting mixture was allowed to warm up to room temperature overnight. The precipitate was collected by vacuum filtration to give compound 84 as a white solid (200 mg, 85%).
Figure imgf000097_0002
[0375] c) Compound 84 (100 mg, 0.18 mmol) and a corresponding aniline 85 (32 mg, 0.2 mmol) were mixed with acetonitrile, and TEA (0.2 ml) was added to the mixture subsequently. The reaction mixture was stirred at room temperature for 14 hours and then the solvent was removed by rotary evaporator. The residue was subjected to flash column to give the title compound 86 as a white foam (60 mg, yield 71%). 1H NMR (CD3OD): δ 7.30- 8.1 (m, 7H), 6.85 (s, IH), 4.05 (s, 2H), 3.54 (m, 2H), 2.90 ( m, IH), 2.65 (m, 2H), 0.60-0.80 (m, 4H); MS: 467 (M + H+).
Figure imgf000098_0001
86
EXAMPLE 18
[0376] Compounds of the invention have been tested in the calcium mobilization and/or electrophysiological assay for N-type calcium channel blocking activity, which are described in detail above. Representative values are presented in TABLE 2.
TABLE 2
Evaluation of the tested compounds as N-type calcium channel (NTCC) blockers after a calcium mobilization in vitro assay
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
[0377] Compounds 1 '-(4-trifluoromethoxybenzyl)- 1 ',2',3',6'-tetrahydro-[2,4']-bi- pyridinyl-6-carboxylic acid cyclopropylamide (9) and 6'-oxo-r-(3-trifluoromethyl- benzenesulfonyl)- 1 ',2l,3',6'-tetrahydro-[2,4l]bipyridinyl-6-carboxylic acid cyclopropylamide (45) have also been tested in the calcium mobilization assay for L-type calcium channel blocking activity, which is described in detail above, and have an LTCC IC50 value of > 20 μM in that assay.
[0378] Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof.
[0379] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. All patents and publications cited herein are fully incorporated by reference herein in their entirety.

Claims

What is Claimed Is:
1. A compound having the Formula I:
Figure imgf000104_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
Hy is a 6-membered heteroaromatic ring, a 5-membered heteroaromatic ring, or a 5-membered heterocyclic ring, wherein said Hy has at least one nitrogen atom, and wherein said Hy is attached to the tetrahydropyridinyl or dihydropyrrolyl ring by a carbon atom;
R1 is attached to a carbon atom of said Hy ring and is selected from the group consisting of a) -C(=W)NR3R4; b) -C(=O)OR5; c) -NR6-C(=O)R7; d) cyano; e) hydroxyalkyl; and f) a 5-membered, N-containing heteroaryl or a 5-membered, partially unsaturated, N-containing heterocyclo each of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; wherein W is O or NR14, wherein R14 is hydrogen or alkyl; R3, R4, and R7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and
R5 and R6 are hydrogen or alkyl;
R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, nitro, cyano, amino, alkylamino, and dialkylamino; m is O, 1, 2, or 3; n is 0 or 1 ;
X is -CHR8- or -C(O)- ;
R8 and R9 are both hydrogen or together form a bridge -(CH2)P-, wherein p is 2, 3, or 4;
Z is Z1 or Z2, wherein
Z1 is -SO2- R10, wherein
R10 is selected from the group consisting of C3-12 alkyl, halo(C3-i2)alkyl, C5-12 cycloalkyl, (C3-I2 cycloalkyl)alkyl, C5-I2 cycloalkenyl, (C3-I2 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; and
Z2 is -C(R1 'R12)R13, wherein
R11 and R12 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkyl aminoalkyl, and dialkylaminoalkyl; and R13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino; with the following provisos when X is -CHR - and R is hydrogen:
1) when R11 and R12 are both hydrogen and R13 is aryl or arylalkyl, then the aryl portion of R13 is substituted with at least one of haloalkyl or haloalkoxy; or
2) when Hy is a pyridin-2-yl ring, then R1 is other than optionally substituted 2-aminophenylaminocarbonyl or 2-hydroxyphenylaminocarbonyl.
2. The compound of claim 1, wherein n is 1.
3. The compound of claim 2, wherein X is -CHR8- and R8 and R9 are both hydrogen, having the Formula II:
Figure imgf000106_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, provided that when Hy is a pyridin-2-yl ring, then R1 is is other than optionally substituted 2- aminophenylaminocarbonyl or 2-hydroxyphenylaminocarbonyl.
4. The compound of claim 2, wherein X is -CHR8-, R8 and R9 together form a bridge -(CH2)P-, and p is 2, 3, or 4, having the Formula III:
Figure imgf000107_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
5. The compound of claim 4, wherein p is 2, having the Formula IV:
Figure imgf000107_0002
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
6. The compound of claim 2, wherein X is -C(=O)- and R9 is hydrogen, having the Formula V:
Figure imgf000107_0003
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
7. The compound of claim 1, wherein n is 0.
8. The compound of claim 7, wherein X is -CHR8- and R8 and R9 are both hydrogen, having the Formula VI:
Figure imgf000108_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, provided that when Hy is a pyridin-2-yl ring, then R1 is other than optionally substituted 2- aminophenylaminocarbonyl or 2-hydroxyphenylaminocarbonyl.
9. The compound of claim 7, wherein X is -CHR8-, R8 and R9 together form a bridge -(CH2)p-, and p is 2, 3, or 4, having the Formula VII:
Figure imgf000108_0002
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
10. The compound of claim 9, wherein p is 2, having the Formula VIII:
Figure imgf000109_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
11. The compound of claim 7, wherein X is -C(=O)- and R9 is hydrogen, having the Formula IX:
Figure imgf000109_0002
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
12. The compound of any one of claims 1-11, wherein Hy is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, and 1,2,4-oxadiazolyl.
13. The compound of claim 12, wherein Hy is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, imidazol-2-yl, imidazol-4-yl, and oxazol-2-yl.
14. The compound of claim 13, wherein Hy is pyridin-2-yl, pyridin-3-yl, pyrimidin- 2-yl, or oxazol-2-yl.
15. The compound of any one of claims 1-14, wherein R1 is attached to a carbon atom adjacent to a nitrogen atom of said Hy ring.
16. The compound of any one of claims 1 and 4-6, having the Formula X:
Figure imgf000110_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein one of Q , Q , or Q is N and the remaining two are each CH; or Q1, Q2, and Q3 each are CH; and X, Z, R1, R2, R9 and m are as defined in claim 1.
17. The compound of claim 16, having the Formula XI:
Figure imgf000110_0002
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
18. The compound of claim 1 , having the Formula XII:
Figure imgf000111_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X, R1, R2, and R9 and m are as defined in claim 1.
19. The compound of any one of claims 16-18, wherein X is -CHR8- and R8 and R9 both are hydrogen.
20. The compound of any one of claims 16-18, wherein X is -CHR8- and R8 and R9 together form a bridge -(CH2)P- and p is 2, 3, or 4.
21. The compound of claim 20, wherein p is 2.
22. The compound of any one of claims 16-18, wherein X is -C(=O)- and R9 is hydrogen.
23. The compound of any one of claims 1-22, wherein R1 is -C(= W)NR3R4, wherein W is O or NR14, R14 is hydrogen or alkyl, and R3 and R4 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
24. The compound of any one of claims 1-23, wherein R14 is hydrogen, R3 is hydrogen or alkyl and R4 is as defined in claim 23.
25. The compound of any one of claims 1-24, wherein R3 is hydrogen and R4 is selected from the group consisting of C]-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo(Ci-6)alkyl, hydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalky^Ci^alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(C1-4)alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered
Figure imgf000112_0001
C6-io aryl, C6-io aryl(C]-4)alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(Ci-4)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl, and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
26. The compound of any one of claims 1-25, wherein R4 is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, halo(C1-6)alkyl, monohydroxy(C1-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7
Figure imgf000112_0002
C3-7 cycloalkenyl, C3-7 cycloalkenyl(C1-4)alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting Of Ci-6 alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(Ci. 6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, di(Ci-6)alkylamino, and hydroxy(Ci-6)alkylamino.
27. The compound of any one of claims 23-26, wherein W is O.
28. The compound of any one of claims 1-23, wherein R1 is -C(=O)-NH-cyclopropyl, -C(=0)-NH2 or -C(=O)-NH-CH2-cyclopropyl.
29. The compound of any one of claims 23-26, wherein W is NH. - I l l -
30. The compound of any one of claims 1-23, wherein R1 is -C(=NH)-NH-CH2- cyclopropyl.
31. The compound of any one of claims 1-22, wherein R1 is -C(=O)OR5, wherein R5 is hydrogen or alkyl.
32. The compound of any one of claims 1-22, wherein R1 is -NR6-C(=O)R7, wherein R6 is hydrogen or alkyl, and R7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
33. The compound of claim 32, wherein R7 is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo(C1-6)alkyl, hydroxy(C]-6)alkyl, C3-7 cycloalkyl, C3-7
Figure imgf000113_0001
C3-7 cycloalkenyl, C3-7 cycloalkenyl(d. 4)alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered heterocyclo(Ci_ 4)alkyl, C6-10 aryl, C6-io aryl(C1-4)alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(C1-4)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl, and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
34. The compound of claim 33, wherein R7 is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, halo(Ct-ό)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci. 6)alkyl, C3-7 cycloalkyl, C3-7 CyClOaUCyI(C1 -4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, and benzyl, wherein said phenyl or phenyl portion of said benzyl is optionally substituted with 1 , 2, or 3 substituents each independently selected from the group consisting of Ci^ alkyl, Ci-6 alkoxy, halogen, halo(Ci-6)alkyl, halo(Ci-6)alkoxy, hydroxy, hydroxy(Ci-6)alkyl, cyano, amino, amino(Ci-6)alkyl, Ci-6 alkylamino, di(Ci-6)alkylamino, and hydroxy(Ci. o)alkylamino.
35. The compound of any one of claims 1-22 and 32-34, wherein R1 is -NH-C(=O)- cyclopropyl.
36. The compound of any one of claims 1-22, wherein R1 is cyano.
37. The compound of any one of claims 1-22, wherein R1 is hydroxyalkyl.
38. The compound of any one of claims 1-22, wherein R1 is a 5-membered, N- containing heteroaryl or a 5-membered, partially unsaturated, N-containing heterocyclo each of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino.
39. The compound of any one of claims 1-22 and 38, wherein R1 is selected from the group consisting of oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, and thiazolyl, any of which is optionally substituted with one or two substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino.
40. The compound of any one of claims 1-22 and 38-39, wherein R1 is selected
from the group consisting of
Figure imgf000114_0001
Figure imgf000114_0002
wherein R101 is selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino, A is O or S, and — is an optional bond forming a double bond.
41. The compound of any one of claims 1-40, wherein R2 is selected from the group consisting of Ci-4 alkyl, halo(Ci-4)alkyl, halogen, hydroxy(Ci-4)alkyl, hydroxy, C1-4 alkoxy, C1-4
Figure imgf000115_0001
4)alkyl, nitro, cyano, amino, Ci-4 alkylamino, and di(Q .^alkylamino.
42. The compound of any one of claims 1-41, wherein m is 0 or 1.
43. The compound of any one of claims 1-42, wherein Z is Z1.
44. The compound of any one of claims 1-43, wherein R10 is C4-8 alkyl, halo(C3- 6)alkyl, C5-I2 cycloalkyl, (C3-I2 cycloalkyl)alkyl, C5-I2 cycloalkenyl, (C3-I2 cycloalkenyl)alkyl, heterocyclo, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylamino, and aryl(alkyl)amino, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
45. The compound of any one of claims 1-44, wherein R10 is selected from the group consisting of C4-6 alkyl, monohalo(C3-6)alkyl, dihalo(C3-6)alkyl, trihalo(C3-6)alkyl, C5-8 cycloalkyl, C3-8 cycloalkyl(Ci-2)alkyl, C5-8 cycloalkenyl, C3-8 cycloalkenyl(Ci-2)alkyl, 5- or 6-membered heterocyclo, 5- or 6-membered heterocyclo(Ci-2)alkyl, C6-I4 aryl, C6-I4 aryl(Ci-2)alkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heteroaryl(Ci-2)alkyl, wherein the cycloalkyl, cycloalkenyl, heterocyclo, aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci_ 4)alkoxy, hydroxy, hydroxy(Ci^)alkyl, cyano, amino, amino(Ci-4)alkyl, CM alkylamino, di(Ci -^alkylamino, and hydroxy(Ci-4)alkylamino.
46. The compound of any one of claims 1-45, wherein R10 is selected from the group consisting of a) cyclohexyl; b) cycloheptyl; c) cyclohexylmethyl; d) cycloheptylmethyl; e) phenyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci
Figure imgf000116_0001
cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci .^alkylamino, and hydroxy(Ci-4)alkylamino, and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group
Figure imgf000116_0002
and cyano; f) benzyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino,
Figure imgf000116_0003
and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, and cyano; g) phenylethyl, unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino,
Figure imgf000116_0004
and preferably substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(C1-4)alkoxy, and cyano; h) pyridin-1-yl, pyridin-2-yl, or pyridin-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, haloCd-^alkyl, halo(C] ^alkoxy, and cyano; i) thiophen-2-yl or thiophen-3-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci. 4)alkyl, halo(Ci ^alkoxy, and cyano; j) isoxazol-3-yl, isoxazol-4-yl, or isoxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(C1-4)alkyl, halo(Ci .^alkoxy, and cyano; k) oxazol-2-yl, oxazol-4-yl, or oxazol-5-yl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci .^alkoxy, and cyano; and
1) isoxazol-3-ylmethyl, isoxazol-4-ylmethyl, or isoxazol-5-ylmethyl, unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, halo(Ci-4)alkyl, halo(Ci -^alkoxy, and cyano.
47. The compound of claim 46, wherein R10 is e) phenyl, unsubstituted or substituted with 1, 2, or 3 substituents each independently selected from the group consisting of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(C1-4)alkyl, halo(Ci. 4)alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(C i-^alkyl, C 1-4 alkylamino, di(Ci-4)alkylamino, and hydroxy(Ci-4)alkylamino, and preferably substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen,
Figure imgf000117_0001
and cyano.
48. The compound of any one of claims 1-42, wherein Z is Z2.
49. The compound of any one of claims 1-42 and 48, wherein R11 and R12 are both hydrogen, and R13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino, provided that when X is -CHR8- and R8 is hydrogen, and R13 is aryl or arylalkyl, then the aryl portions are substituted by at least one of trifluoromethyl or trifluoromethoxy.
50. The compound of any one of claims 1-42 and 48-49, wherein R13 is phenyl, benzyl, phenylethyl, pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, thienyl, pyrrolyl(Ci-2)alkyl, pyridyl(Ci-2)alkyl, pyrimidyl(Ci-2)alkyl, isoxazolyl(C]. 2)alkyl, oxazolyl(Ci-2)alkyl, or thienyl(Ci-2)alkyl, and preferably phenyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, halogen, halo(C1-4)alkyl, halo(Ci .^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(C1-4)alkyl, C1-4 alkylamino, di(Ci_ 4)alkylamino, and hydroxyCd-^alkylamino.
51. The compound of claim 48, wherein R11 is hydrogen, R12 is selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
52. The compound of claim 51, wherein R12 is selected from the group consisting of Cj-4 alkyl, halo(Ci-4)alkyl, hydroxy(Ci-4)alkyl, halogen, hydroxy, halo(Ci- 4)alkoxy, and halo(C1-4)alkoxy(C1-4)alkyl, and R13 is phenyl, benzyl, phenylethyl, pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, thienyl, PyTToIyI(C1 -2)alkyl, pyridyl(Ci-2)alkyl, pyrimidyl(C1-2)alkyl, isoxazolyl(Ci- 2)alkyl, oxazolyl(Ci-2)alkyl, or thienyl(C)-2)alkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting Of C1-4 alkyl, Ci-4 alkoxy, halogen, halo(C1-4)alkyl, halo(Ci ^alkoxy, hydroxy, hydroxy(Ci-4)alkyl, cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(d .^alkylamino, and hydroxy(d. 4)alkylamino.
53. The compound of claim 48, wherein R11 and R12 are each independently selected from the group consisting of alkyl, haloalkyl, hydroxyalkyl, halogen, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, cyano, amino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, and R13 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with one or more substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino.
54. The compound of claim 53, wherein R1 1 and R12 are each independently selected from the group consisting of Ci-4 alkyl, halo(Ci-4)alkyl, hydroxy(Ci- 4)alkyl, halogen, hydroxy, halo(Cj
Figure imgf000119_0001
and R13 is phenyl, benzyl, phenyl ethyl, pyrrolyl, pyridyl, pyrimidyl, isoxazolyl, oxazolyl, thienyl, pyrrolyl(Ci-2)alkyl, pyridyl(C1-2)alkyl, pyrimidyl(Ci-2)alkyl, isoxazolyl(Ci-2)alkyl, oxazolyl(Ci-2)alkyl, or thienyl(C1-2)alkyl, wherein the aryl and heteroaryl portions thereof are optionally substituted with 1 , 2, or 3 substituents each independently selected from the group consisting Of Ci-4 alkyl, Ci-4 alkoxy, halogen,
Figure imgf000119_0002
hydroxy, hydroxy(Ci_ 4)alkyl, cyano, amino,
Figure imgf000119_0003
and hydroxy(Ci-4)alkylamino.
55. The compound of claim 17 or 18, wherein
R1 is -C(=W)NR3R4, wherein
W is O;
R3 is hydrogen; and
R4 is C i-6 alkyl, C2-6 alkenyl, halo(Ci-6)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(Ci-4)alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
R2 is fluoro, chloro or bromo; m is 0 or 1 ;
X is -CHR8-;
R8 and R9 are both hydrogen or together form a bridge -(CH2)P-, wherein p is 2, 3, or 4; and R10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting Of Ci-4 alkyl, Ci-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci
Figure imgf000120_0001
CM alkylamino, di(Ci -^alkylamino, and hydroxy(Ci-4)alkylamino.
56. The compound of claim 55, wherein R8 and R9 are both hydrogen.
57. The compound of claim 55, wherein R8 and R9 together form a bridge -(CH2)P-.
58. The compound of claim 17 or 18, wherein
R1 is -C(=W)NR3R4, wherein
W is O;
R3 is hydrogen; and
R4 is Ci-6 alkyl, C2-6 alkenyl, halo(Ci-6)alkyl, monohydroxy(Ci-6)alkyl, dihydroxy(Ci-6)alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Ci-4)alkyl, C3-7 cycloalkenyl, C3-7 cycloalkenyl(C1-4)alkyl, phenyl, or benzyl, wherein the cycloalkyl, cycloalkenyl, and phenyl portions thereof are optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkylamino;
R2 is fluoro, chloro or bromo; m is 0 or 1 ;
X is -C(=O)- ;
R9 is hydrogen; and
R10 is phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting Of Ci-4 alkyl, Cj-4 alkoxy, halogen, halo(Ci-4)alkyl, halo(Ci
Figure imgf000120_0002
cyano, amino, amino(Ci-4)alkyl, Ci-4 alkylamino, di(Ci
Figure imgf000120_0003
59. The compound of claim 1, wherein said compound is
r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6l-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; l^-chlorobenzenesulfonyO-l^^^'-tetrahydro-^^'Jbipyridinyl-ό-carboxylic acid cyclopropylamide; l'-CZ-trifluoromethylbenzenesulfony^-l'^'.S'.ό'-tetrahydro-tl^^bipyridinyl-ό- carboxylic acid cyclopropylamide; r-(4-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4l]bipyridinyl-6- carboxylic acid cyclopropylamide;
1 '-(4-fluorobenzenesulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(3-cyanobenzenesulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-dimethylsulfamoyl-r,2',3',6l-tetrahydro-[2,4l]bipyridinyl-6-carboxylic acid cyclopropylamide; r-(3,3,3-trifluoropropylsulfonyl)-lI,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-cyclohexylsulfonyl-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(2,4-dichlorobenzenesulfonyl)- 1 l,2l,3l,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3-cyano-4-fluorobenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; r-(pyridin-2-ylsulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-(pyridin-3-ylsulfonyl)-r,2l,3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-(3-trifluoromethylbenzylsulfonyl)- 1 ',2',3',6'-tetrahydro-[2,41]bipyridinyl-6- carboxylic acid cyclopropylamide; r-(3,5-dichlorobenzenesulfonyl)-r,2I,3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide; l'-(2,4,6-trifluorobenzenesulfonyl)-l',21,3',6'-tetrahydro-[2,4I]bipyridinyl-6- carboxylic acid cyclopropylamide; l'-(2-methylprop-l-ylsulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylamide;
1 '-cyclopentylsulfonyl- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; r-(thiophen-3-ylsulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; l'-(4-trifluoromethoxybenzyl)-lI,2',3',6'-tetrahydro-[2,4l]bipyridinyl-6- carboxylic acid cyclopropylamide;
2- [ 1 -(4-trifluoromethoxybenzenesulfonyl)- 1 ,2,3 ,6-tetrahydropyridin-4-yl] - pyrimidine-4-carboxylic acid amide;
2-[ 1 -(3-trifluoromethylbenzenesulfonyl)- 1 ,2,3,6-tetrahydropyridin-4-yl]- pyrimidine-4-carboxylic acid amide; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid methyl ester; r-(3-trifluoromethylbenzenesulfonyl)-r,2l,3l,6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid cyclopropylmethylamide; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 2,2,2-trifluoroethylamide; r-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[3,4I]bipyridinyl-2- carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 2,2,2-trifluoroethylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[3,4']bipyridinyl-2- carboxylic acid cyclopropylmethylamide; r-(3-trifluoromethylbenzenesulfonyl)-l',2l,3t,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid cyclopropylmethylamide; r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4l]-bipyridinyl-6- carboxylic acid 2,2,2-trifluoroethylamide; 1 '-(3-trifluoromethylbenzenesulfonyl)- 11,2',3',6'-tetrahydro-[2,41]-bipyridinyl-6- carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']-bipyridinyl- 6-carboxylic acid 2,2,2-trifluoroethylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']-bipyridinyl- 6-carboxylic acid 3,3,3-trifluoropropylamide; r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']-bipyridinyl- 6-carboxylic acid 4-fluorophenylamide; ll-(3-trifluoromethylbenzenesulfonyl)-l',2',3I,6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid amide; r-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6l-tetrahydro-[2,4l]bipyridinyl-6- carboxylic acid 2-hydroxyethylamide; r-(3-trifluoromethylberizenesulfonyl)-r,2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid l,3-dihydroxyprop-2-ylamide; l'-(3-trifluoromethylbenzenesulfonyl)-l',21,3',6'-tetrahydro-[2,4']bipyridinyl-6- carbonitrile;
N-cyclopropylmethyl- 1 '-(4-trifluoromethoxybenzenesulfonyl)- r,2',3',6'- tetrahydro-[2,4']bipyridinyl-6-carboxamidine;
2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide;
2-[l-(3-trifluoromethylbenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylmethylamide;
2-[l-(4-trifluoromethoxybenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]pyrimidine-4-carboxylic acid cyclopropylamide;
5-chloro-r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
5-chloro-r-(4-trifluoromethoxybenzenesulfonyl)-r,2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
6'-oxo-r-(3-trifluoromethylbenzenesulfonyl)-r,2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
6-[8-(3-trifluoromethylbenzenesulfonyl)-8-aza-bicyclo[3.2.1]oct-2-en-3- yl]pyridine-2-carboxylic acid cyclopropylamide; 2-[l-(4-trifluoromethoxybenzenesulfonyl)-l,2,3,6-tetrahydropyridin-4- yl]oxazole-4-carboxylic acid cyclopropylamide;
1 '-[2,2,2-trifluoro- 1 -(4-trifluoromethoxyphenyl)-ethyl]-l ',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
1 '-[2,2,2-trifluoro- 1 -(4-hydroxymethylphenyl)-ethyl]- 1 '^'.S'.ό'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide;
N-cyclopropyl-6-{l-[(3-trifluoromethylisoxazol-5-yl)methyl]- 1,2,3,6- tetrahydropyridin-4-yl}picolinamide;
1 '-(3-trifluoromethylbenzenesulfonyl)- 1 ',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid methyl ester; l'-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6'-tetrahydro-[2,4']bipyridinyl-6- carboxylic acid; lI-(3-trifluoromethylbenzenesulfonyl)-l',2',3',6I-tetrahydro-[2,4t]bipyridinyl-6- yl]methanol ; r-(3-trifluoromethylbenzenesulfonyl)-l',2l,3',6l-tetrahydro[2,4']bipyridinyl-6- cyclopropanoylamine;
1 '-[(3-trifluoromethylbenzene)aminosulfonyl]- 1 ',2',3',6'-tetrahydro- [2,4']bipyridinyl-6-carboxylic acid cyclopropylamide; or a pharmaceutically acceptable salt, prodrug or solvate thereof.
60. A pharmaceutical composition, comprising the compound of any one of claims claims 1-59 and a pharmaceutically acceptable carrier.
61. A method of treating a disorder responsive to the blockade of calcium channels in a mammal suffering from said disorder, comprising administering to a mammal in need of such treatment an effective amount of a compound as claimed in any one of claims 1-59 or a pharmaceutically acceptable salt, prodrug or solvate thereof.
62. The method of claim 61, wherein a disorder responsive to the blockade of N- type calcium channels is treated.
63. A method for treating stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal, comprising administering an effective amount of a compound as claimed in any one of claims 1-59 or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a mammal in need of such treatment.
64. The method of claim 63, wherein the method is for treating pain.
65. The method of claim 64, wherein the method is for preemptive or palliative treatment of pain.
66. The method of claim 64, wherein said pain is selected from the group consisting of chronic pain, neuropathic pain, acute pain, and surgical pain.
67. A method of modulating calcium channels in a mammal, comprising administering to the mammal at least one compound as claimed in any one of claims 1-59 or a pharmaceutically acceptable salt, prodrug or solvate thereof.
68. The method of claim 67, wherein the N-type calcium channel is modulated.
69. A compound having the Formula I as claimed in any one of claims 1-59, wherein the compound is 3H, 11C, or 14C radiolabeled, or a pharmaceutically acceptable salt, prodrug or solvate thereof.
70. A method of screening a candidate compound for the ability to bind to a binding site on a protein using a radiolabeled compound of claim 69, comprising a) introducing a fixed concentration of the radiolabeled compound to a soluble or membrane-associated protein or fragment thereof to form a mixture; b) titrating the mixture with a candidate compound; and c) determining the binding of the candidate compound to said binding site.
71. Use of a compound as claimed in any one of claims 1-59 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal.
72. Use of a compound as claimed in any one of claims 1-59 or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament for treating pain selected from chronic pain, neuropathic pain, acute pain, and surgical pain.
73. A method of preparing a pharmaceutical composition, comprising admixing a therapeutically effective amount of a compound of any one of claims 1-59, or a pharmaceutically acceptable salt, prodrug or solvate thereof, with a pharmaceutically acceptable carrier.
PCT/US2009/004437 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof WO2010014257A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2011521130A JP5421368B2 (en) 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and their use
US13/056,839 US8324249B2 (en) 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
EP09802045.6A EP2331522B1 (en) 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
ES09802045.6T ES2439767T3 (en) 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and use thereof
US13/675,166 US20130150377A1 (en) 2008-08-01 2012-11-13 Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12995608P 2008-08-01 2008-08-01
US61/129,956 2008-08-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/675,166 Division US20130150377A1 (en) 2008-08-01 2012-11-13 Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof

Publications (2)

Publication Number Publication Date
WO2010014257A2 true WO2010014257A2 (en) 2010-02-04
WO2010014257A3 WO2010014257A3 (en) 2010-06-03

Family

ID=41610901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004437 WO2010014257A2 (en) 2008-08-01 2009-08-03 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof

Country Status (5)

Country Link
US (2) US8324249B2 (en)
EP (2) EP2331522B1 (en)
JP (1) JP5421368B2 (en)
ES (1) ES2439767T3 (en)
WO (1) WO2010014257A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000651A1 (en) 2011-06-27 2013-01-03 Newron Pharmaceuticals S.P.A. Fluorinated arylalkylaminocarboxamide derivatives
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
JP2013538227A (en) * 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ Pyridine compounds and their use
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
WO2014028803A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
US8895551B2 (en) 2009-04-02 2014-11-25 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
US9434693B2 (en) 2012-08-16 2016-09-06 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
JPWO2015182724A1 (en) * 2014-05-28 2017-04-20 トーアエイヨー株式会社 Substituted tropane derivatives
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164326A4 (en) * 2007-05-31 2012-05-09 Euro Celtique Sa Amide compounds and the use thereof
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3703435A1 (en) 1987-02-05 1988-08-18 Thomae Gmbh Dr K NEW THIAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
JP4447663B2 (en) 1997-05-30 2010-04-07 ニューロサーチ、アクティーゼルスカブ 8-Azabicyclo (3.2.1) oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors
DE69811070T2 (en) 1997-05-30 2003-10-02 Neurosearch A/S, Ballerup 9-AZABICYCLO (3.3.1) NON-2-ENE AND NONANDERIVATES AS LIGANDS OF NICOTINERGEN RECEPTORS
US6251919B1 (en) * 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
ATE288415T1 (en) 1999-04-05 2005-02-15 Emisphere Tech Inc SODIUM SALTS, MONOHYDRATES AND ETHANOL SOLVATES
BR0009650A (en) 1999-04-09 2002-01-02 Meiji Seika Kaisha Compound, pharmaceutical composition, processes to inhibit the secretion of a lipoprotein containing apolipoprotein b, to inhibit triglyceride biosynthesis and to prevent or treat hyperlipidemia, arteriosclerotic diseases and pancreatitis, and, use of the compound
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7632950B2 (en) 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
EP1664010A1 (en) 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
US20070167507A1 (en) * 2004-03-26 2007-07-19 Glaxo Group Limited 4-Carbox pyrazole derivatives useful as anti-viral agents
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
AU2006214164B2 (en) * 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
PE20071159A1 (en) * 2005-10-31 2007-11-30 Schering Corp DERIVATIVES OF TROPANE 3-MONOSUSTITUTED AS LIGANDS OF NOCICEPTIN RECEPTORS
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
EP1948187A4 (en) 2005-11-18 2010-11-03 Glaxosmithkline Llc Chemical compounds
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2164326A4 (en) 2007-05-31 2012-05-09 Euro Celtique Sa Amide compounds and the use thereof
JP2010535812A (en) * 2007-08-09 2010-11-25 アボット・ラボラトリーズ Tetrahydropyridine carboxamide derivatives as TRPV1 antagonists
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009151152A1 (en) 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
BRPI1016130A2 (en) 2009-04-02 2017-03-28 Shionogi & Co compound, pharmaceutical composition, and methods for treating or preventing a disorder and condition.
CN102498100A (en) * 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 Antiviral Heterocyclic Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
US8895551B2 (en) 2009-04-02 2014-11-25 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
JP2013538227A (en) * 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ Pyridine compounds and their use
WO2013000651A1 (en) 2011-06-27 2013-01-03 Newron Pharmaceuticals S.P.A. Fluorinated arylalkylaminocarboxamide derivatives
US9434693B2 (en) 2012-08-16 2016-09-06 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
US8901314B2 (en) 2012-08-16 2014-12-02 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
CN104903316A (en) * 2012-08-16 2015-09-09 詹森药业有限公司 Substituted pyrazoles as N-type calcium channel blockers
WO2014028803A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
AU2013302471B2 (en) * 2012-08-16 2017-08-17 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
CN104903316B (en) * 2012-08-16 2017-11-28 詹森药业有限公司 Substituted pyrazoles as N-type calcium channel blocker
CN107857757A (en) * 2012-08-16 2018-03-30 詹森药业有限公司 Substituted pyrazoles as N-type calcium channel blocker
AU2017261551B2 (en) * 2012-08-16 2019-07-04 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US10653673B2 (en) 2013-08-16 2020-05-19 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
JPWO2015182724A1 (en) * 2014-05-28 2017-04-20 トーアエイヨー株式会社 Substituted tropane derivatives

Also Published As

Publication number Publication date
WO2010014257A3 (en) 2010-06-03
EP2331522A2 (en) 2011-06-15
US20130150377A1 (en) 2013-06-13
US8324249B2 (en) 2012-12-04
EP2331522B1 (en) 2013-09-18
EP2676956A1 (en) 2013-12-25
JP2011529884A (en) 2011-12-15
JP5421368B2 (en) 2014-02-19
ES2439767T3 (en) 2014-01-24
US20110136833A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
EP2331522B1 (en) Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US8765736B2 (en) Benzenesulfonamide compounds and the use thereof
US8883816B2 (en) Fused and spirocycle compounds and the use thereof
US8399486B2 (en) Benzenesulfonyl compounds and the use thereof
US8937181B2 (en) Benzenesulfonamide compounds and the use thereof
US8247442B2 (en) Benzenesulfonamide compounds and their use
EP2040698A2 (en) Oxime compounds and the use thereof
EP2164325B1 (en) Oxyimino compounds and the use thereof
EP2164326A1 (en) Amide compounds and the use thereof
US20120322830A1 (en) Cyclourea Compounds as Calcium Channel Blockers
EP2414332B1 (en) Acrylamide compounds and the use thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2011521130

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13056839

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009802045

Country of ref document: EP